Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides

ABSTRACT

The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/307,914 filed Oct. 31, 2016, now U.S. Pat. No. 11,046,984 issued on Jun. 29, 2021, which is a national stage application, filed under 35 U.S.C. § 371, of PCT International Patent Application No. PCT/US2015/030823, filed on May 14, 2015, and claims benefit of priority to U.S. Provisional Patent Application No. 61/993,742, filed on May 15, 2014, both of which, including their contents, are incorporated herein by reference in their entireties.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted via EFS-Web. The content of the text file named “37847-517001US_ST25.txt”, which was created on Oct. 20, 2017 and is 791 KB in size, is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The invention provides compositions and methods for producing purified oligosaccharides, in particular certain fucosylated oligosaccharides that are typically found in human milk.

BACKGROUND OF THE INVENTION

Human milk contains a diverse and abundant set of neutral and acidic oligosaccharides. More than 130 different complex oligosaccharides have been identified in human milk, and their structural diversity and abundance is unique to humans. Although these molecules may not be utilized directly by infants for nutrition, they nevertheless serve critical roles in the establishment of a healthy gut microbiome, in the prevention of disease, and in immune function. Prior to the invention described herein, the ability to produce human milk oligosaccharides (HMOS) inexpensively was problematic. For example, their production through chemical synthesis was limited by stereo-specificity issues, precursor availability, product impurities, and high overall cost. As such, there is a pressing need for new strategies to inexpensively manufacture large quantities of HMOS.

SUMMARY OF THE INVENTION

The invention features an efficient and economical method for producing fucosylated oligosaccharides. Such production of a fucosylated oligosaccharide is accomplished using an isolated nucleic acid comprising a sequence encoding a lactose-utilizing α (1,2) fucosyltransferase gene product (e.g., polypeptide or protein), which is operably linked to one or more heterologous control sequences that direct the production of the recombinant fucosyltransferase gene product in a host production bacterium such as Escherichia coli (E. coli).

The present disclosure provides novel α (1,2) fucosyltransferases (also referred to herein as α(1,2) FTs) that utilize lactose and catalyzes the transfer of an L-fucose sugar from a GDP-fucose donor substrate to an acceptor substrate in an alpha-1,2-linkage. In a preferred embodiment, the acceptor substrate is an oligosaccharide. The α(1,2) fucosyltransferases identified and described herein are useful for expressing in host bacterium for the production of human milk oligosaccharides (HMOS), such as fucosylated oligosaccharides. Exemplary fucosylated oligosaccharides produced by the methods described herein include 2′-fucosyllactose (2′FL), lactodifucotetraose (LDFT), lacto-N-fucopentaose I (LNF I), or lacto-N-difucohexaose I (LDFH I). The “α(1,2) fucosyltransferases” disclosed herein encompasses the amino acid sequences of the α(1,2) fucosyltransferases and the nucleic acid sequences that encode the α(1,2) fucosyltransferases, as well as variants and fragments thereof that exhibit α(1,2) fucosyltransferase activity. Also within the invention is a nucleic acid construct comprising an isolated nucleic acid encoding a lactose-accepting α (1,2) fucosyltransferase enzyme, said nucleic acid being optionally operably linked to one or more heterologous control sequences that direct the production of the enzyme in a host bacteria production strain.

The amino acid sequence of the lactose-accepting α(1,2) fucosyltransferases described herein is at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identity to Helicobacter pylori 26695 alpha-(1,2) fucosyltransferase (futC or SEQ ID NO: 1). Preferably, the lactose-accepting α(1,2) fucosyltransferases described herein is at least 22% identical to H. pylori FutC, or SEQ ID NO: 1.

In another aspect, the amino acid sequence of the lactose-accepting α(1,2) fucosyltransferases described herein is at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identity to Bacteroides vulgatus alpha-(1,2) fucosyltransferase (FutN or SEQ ID NO: 3). Preferably, the lactose-accepting α(1,2) fucosyltransferases described herein is at least 25% identical to B. vlugatos FutN, or SEQ ID NO: 3.

Alternatively, the exogenous α (1,2) fucosyltransferase preferably comprises at least at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identity to any one of the novel α (1,2) fucosyltransferases disclosed herein, for example, to the amino acid sequences in Table 1.

Exemplary α(1,2) fucosyltransferases include, but are not limited to, Prevotella melaninogenica FutO, Clostridium bolteae FutP, Clostridium bolteae+13 FutP, Lachnospiraceae sp. FutQ, Methanosphaerula palustris FutR, Tannerella sp. FutS, Bacteroides caccae FutU, Butyrivibrio FutV, Prevotella sp. FutW, Parabacteroides johnsonii FutX, Akkermansia muciniphilia FutY, Salmonella enterica FutZ, Bacteroides sp. FutZA. For example, the α(1,2) fucosyltransferases comprise the amino acid sequences comprising any one of the following: Prevotella melaninogenica FutO (SEQ ID NO: 10), Clostridium bolteae FutP (SEQ ID NO: 11), Clostridium bolteae+13 FutP (SEQ ID NO: 292), Lachnospiraceae sp. FutQ (SEQ ID NO: 12), Methanosphaerula palustris FutR (SEQ ID NO: 13), Tannerella sp. FutS (SEQ ID NO: 14), Bacteroides caccae FutU (SEQ ID NO: 15), Butyrivibrio FutV (SEQ ID NO: 16), Prevotella sp. FutW (SEQ ID NO: 17), Parabacteroides johnsonii FutX (SEQ ID NO: 18), Akkermansia muciniphilia FutY (SEQ ID NO: 19), Salmonella enterica FutZ (SEQ ID NO: 20), and Bacteroides sp. FutZA (SEQ ID NO: 21), or a functional variant or fragment thereof. Other exemplary α(1,2) fucosyltransferases include any of the enzymes listed in Table 1, or functional variants or fragments thereof.

The present invention features a method for producing a fucosylated oligosaccharide in a bacterium by providing bacterium that express at least one exogenous lactose-utilizing α(1,2) fucosyltransferase. The amino acid sequence of the exogenous lactose-utilizing α(1,2) fucosyltransferase is preferably at least 22% identical to H. pylori FutC or at least 25% identical to B. vulgatus FutN. In one aspect, the bacterium also expresses one or more exogenous lactose-utilizing α(1,3) fucosyltransferase enzymes and/or one or more exogenous lactose-utilizing α(1,4) fucosyltransferase enzymes. The combination of fucosyltransferases expressed in the production bacterium is dependent upon the desired fucosylated oligosaccharide product. The method disclosed herein further includes retrieving the fucosylated oligosaccharide from said bacterium or from a culture supernatant of said bacterium.

Examples of suitable a(1,3) fucosyltransferase enzymes include, but are not limited to Helicobacter pylori 26695 futA gene (GenBank Accession Number HV532291 (GI:365791177), incorporated herein by reference), H. hepaticus Hh0072, H. pylori 11639 FucT, and H. pylori UA948 FucTa (e.g., GenBank Accession Number AF194963 (GI:28436396), incorporated herein by reference)(Rasko, D. A., Wang, G., Palcic, M. M. & Taylor, D. E. J Biol Chem 275, 4988-4994 (2000)). Examples of suitable a(1,4) fucosyltransferase enzymes include, but are not limited to H. pylori UA948 FucTa (which has has relaxed acceptor specificity and is able to generate both a(1,3)- and a(1,4)-fucosyl linkages). An example of an enzyme possessing only a(1,4) fucosyltransferase activity is given by the FucT III enzyme from Helicobacter pylori strain DMS6709 (e.g., GenBank Accession Number AY450598.1 (GI:40646733), incorporated herein by reference) (S. Rabbani, V. Miksa, B. Wipf, B. Ernst, Glycobiology 15, 1076-83 (2005).)

The invention also features a nucleic acid construct or a vector comprising a nucleic acid enconding at least one a (1,2) fucosyltransferase or variant, or fragment thereof, as described herein. The vector can further include one or more regulatory elements, e.g., a heterologous promoter. By “heterologous” is meant that the control sequence and protein-encoding sequence originate from different bacterial strains. The regulatory elements can be operably linked to a gene encoding a protein, a gene construct encoding a fusion protein gene, or a series of genes linked in an operon in order to express the fusion protein. In yet another aspect, the invention comprises an isolated recombinant cell, e.g., a bacterial cell containing an aforementioned nucleic acid molecule or vector. The nucleic acid is optionally integrated into the genome of the host bacterium. In some embodiments, the nucleic acid construct also further comprises one or more a(1,3) fucosyltransferases and/or a(1,4) fucosyltransferases. Alternatively, the α (1,2) fucosyltransferase also exhibits a(1,3) fucosyltransferase and/or a(1,4) fucosyltransferase activity.

The bacterium utilized in the production methods described herein is genetically engineered to increase the efficiency and yield of fucosylated oligosaccharide products. For example, the host production bacterium is characterized as having a reduced level of (3-galactosidase activity, a defective colanic acid synthesis pathway, an inactivated ATP-dependent intracellular protease, an inactivated lacA, or a combination thereof. In one embodiment, the bacterium is characterized as having a reduced level of β-galactosidase activity, a defective colanic acid synthesis pathway, an inactivated ATP-dependent intracellular protease, and an inactivated lacA.

As used herein, an “inactivated” or “inactivation of a” gene, encoded gene product (i.e., polypeptide), or pathway refers to reducing or eliminating the expression (i.e., transcription or translation), protein level (i.e., translation, rate of degradation), or enzymatic activity of the gene, gene product, or pathway. In the instance where a pathway is inactivated, preferably one enzyme or polypeptide in the pathway exhibits reduced or negligible activity. For example, the enzyme in the pathway is altered, deleted or mutated such that the product of the pathway is produced at low levels compared to a wild-type bacterium or an intact pathway. Alternatively, the product of the pathway is not produced. Inactivation of a gene is achieved by deletion or mutation of the gene or regulatory elements of the gene such that the gene is no longer transcribed or translated. Inactivation of a polypeptide can be achieved by deletion or mutation of the gene that encodes the gene product or mutation of the polypeptide to disrupt its activity. Inactivating mutations include additions, deletions or substitutions of one or more nucleotides or amino acids of a nucleic acid or amino acid sequence that results in the reduction or elimination of the expression or activity of the gene or polypeptide. In other embodiments, inactivation of a polypeptide is achieved through the addition of exogenous sequences (i.e., tags) to the N or C-terminus of the polypeptide such that the activity of the polypeptide is reduced or eliminated (i.e., by steric hindrance).

A host bacterium suitable for the production systems described herein exhibits an enhanced or increased cytoplasmic or intracellular pool of lactose and/or GDP-fucose. For example, the bacterium is E. coli and endogenous E. coli metabolic pathways and genes are manipulated in ways that result in the generation of increased cytoplasmic concentrations of lactose and/or GDP-fucose, as compared to levels found in wild type E. coli. Preferably, the bacterium accumulates an increased intracellular lactose pool and an increased intracellular GDP-fucose pool. For example, the bacteria contain at least 10%, 20%, 50%, or 2×, 5×, 10× or more of the levels of intracellular lactose and/or intracellular GDP-fucose compared to a corresponding wild type bacteria that lacks the genetic modifications described herein.

Increased intracellular concentration of lactose in the host bacterium compared to wild-type bacterium is achieved by manipulation of genes and pathways involved in lactose import, export and catabolism. In particular, described herein are methods of increasing intracellular lactose levels in E. coli genetically engineered to produce a human milk oligosaccharide by simultaneous deletion of the endogenous β-galactosidase gene (lacZ) and the lactose operon repressor gene (lad). During construction of this deletion, the lacIq promoter is placed immediately upstream of (contiguous with) the lactose permease gene, lacY, i.e., the sequence of the lacIq promoter is directly upstream and adjacent to the start of the sequence encoding the lacY gene, such that the lacY gene is under transcriptional regulation by the lacIq promoter. The modified strain maintains its ability to transport lactose from the culture medium (via LacY), but is deleted for the wild-type chromosomal copy of the lacZ (encoding β-galactosidase) gene responsible for lactose catabolism. Thus, an intracellular lactose pool is created when the modified strain is cultured in the presence of exogenous lactose.

Another method for increasing the intracellular concentration of lactose in E. coli involves inactivation of the lacA gene. A inactivating mutation, null mutation, or deletion of lacA prevents the formation of intracellular acetyl-lactose, which not only removes this molecule as a contaminant from subsequent purifications, but also eliminates E. coli's ability to export excess lactose from its cytoplasm (Danchin A. Cells need safety valves. Bioessays 2009, July;31(7):769-73.), thus greatly facilitating purposeful manipulations of the E. coli intracellular lactose pool.

The invention also provides methods for increasing intracellular levels of GDP-fucose in a bacterium by manipulating the organism's endogenous colanic acid biosynthesis pathway. This increase is achieved through a number of genetic modifications of endogenous E. coli genes involved either directly in colanic acid precursor biosynthesis, or in overall control of the colanic acid synthetic regulon. Particularly preferred is inactivation of the genes or encoded polypeptides that act in the colanic acid synthesis pathway after the production of GDP-fucose (the donor substrate) and before the generation of colanic acid. Exemplary colanic acid synthesis genes include, but are not limited to: a wcaJ gene, (e.g., GenBank Accession Number (amino acid) BAA15900 (GI:1736749), incorporated herein by reference), a wcaA gene (e.g., GenBank Accession Number (amino acid) BAA15912.1 (GI:1736762), incorporated herein by reference), a wcaC gene (e.g., GenBank Accession Number (amino acid) BAE76574.1 (GI:85675203), incorporated herein by reference), a wcaE gene (e.g., GenBank Accession Number (amino acid) BAE76572.1 (GI:85675201), incorporated herein by reference), a weal gene (e.g., GenBank Accession Number (amino acid) BAA15906.1 (GI:1736756), incorporated herein by reference), a wcaL gene (e.g., GenBank Accession Number (amino acid) BAA15898.1 (GI:1736747), incorporated herein by reference), a wcaB gene (e.g., GenBank Accession Number (amino acid) BAA15911.1 (GI:1736761), incorporated herein by reference), a wcaF gene (e.g., GenBank Accession Number (amino acid) BAA15910.1 (GI:1736760), incorporated herein by reference), a wzxE gene (e.g., GenBank Accession Number (amino acid) BAE77506.1 (GI:85676256), incorporated herein by reference), a wzxC gene, (e.g., GenBank Accession Number (amino acid) BAA15899 (GI:1736748), incorporated herein by reference), a wcaD gene, (e.g., GenBank Accession Number (amino acid) BAE76573 (GI:85675202), incorporated herein by reference), a wza gene (e.g., GenBank Accession Number (amino acid) BAE76576 (GI:85675205), incorporated herein by reference), a wzb gene (e.g., GenBank Accession Number (amino acid) BAE76575 (GI:85675204), incorporated herein by reference), and a wzc gene (e.g., GenBank Accession Number (amino acid) BAA15913 (GI:1736763), incorporated herein by reference).

Preferably, a host bacterium, such as E. coli, is genetically engineered to produce a human milk oligosaccharide by the inactivation of the wcaJ gene, which encoding the UDP-glucose lipid carrier transferase. The inactivation of the wcaJ gene can be by deletion of the gene, a null mutation, or inactivating mutation of the wcaJ gene, such that the activity of the encoded wcaJ is reduced or eliminated compared to wild-type E. coli. In a wcaJ null background, GDP-fucose accumulates in the E. coli cytoplasm.

Over-expression of a positive regulator protein, RcsA (e.g., GenBank Accession Number M58003 (GI:1103316), incorporated herein by reference), in the colanic acid synthesis pathway results in an increase in intracellular GDP-fucose levels. Over-expression of an additional positive regulator of colanic acid biosynthesis, namely RcsB (e.g., GenBank Accession Number E04821 (GI:2173017), incorporated herein by reference), is also utilized, either instead of or in addition to over-expression of RcsA, to increase intracellular GDP-fucose levels.

Alternatively, colanic acid biosynthesis is increased following the introduction of a mutation into the E. coli ion gene (e.g., GenBank Accession Number L20572 (GI:304907), incorporated herein by reference). Lon is an adenosine-5′-triphosphate (ATP)-dependant intracellular protease that is responsible for degrading RcsA, mentioned above as a positive transcriptional regulator of colanic acid biosynthesis in E. coli. In a ion null background, RcsA is stabilized, RcsA levels increase, the genes responsible for GDP-fucose synthesis in E. coli are up-regulated, and intracellular GDP-fucose concentrations are enhanced. Mutations in ion suitable for use with the methods presented herein include null mutations or insertions that disrupt the expression or function of ion.

A functional lactose permease gene is also present in the bacterium. The lactose permease gene is an endogenous lactose permease gene or an exogenous lactose permease gene. For example, the lactose permease gene comprises an E. coli lacY gene (e.g., GenBank Accession Number V00295 (GI:41897), incorporated herein by reference). Many bacteria possess the inherent ability to transport lactose from the growth medium into the cell, by utilizing a transport protein that is either a homolog of the E. coli lactose permease (e.g., as found in Bacillus licheniformis), or a transporter that is a member of the ubiquitous PTS sugar transport family (e.g., as found in Lactobacillus casei and Lactobacillus rhamnosus). For bacteria lacking an inherent ability to transport extracellular lactose into the cell cytoplasm, this ability is conferred by an exogenous lactose transporter gene (e.g., E. coli lacY) provided on recombinant DNA constructs, and supplied either on a plasmid expression vector or as exogenous genes integrated into the host chromosome.

As described herein, in some embodiments, the host bacterium preferably has a reduced level of β-galactosidase activity. In the embodiment in which the bacterium is characterized by the deletion of the endogenous β-galactosidase gene, an exogenous β-galactosidase gene is introduced to the bacterium. For example, a plasmid expressing an exogenous β-galactosidase gene is introduced to the bacterium, or recombined or integrated into the host genome. For example, the exogenous β-galactosidase gene is inserted into a gene that is inactivated in the host bacterium, such as the ion gene.

The exogenous b-galactosidase gene is a functional b-galactosidase gene characterized by a reduced or low leve of b-galactosidase activity compared to β-galactosidase activity in wild-type bacteria lacking any genetic manipulation. Exemplary β-galactosidase genes include E. coli lacZ and β-galactosidase genes from any of a number of other organisms (e.g., the lac4 gene of Kluyveromyces lactis (e.g., GenBank Accession Number M84410 (GI:173304), incorporated herein by reference) that catalyzes the hydrolysis of b-galactosides into monosaccharides. The level of β-galactosidase activity in wild-type E. coli bacteria is, for example, 6,000 units. Thus, the reduced β-galactosidase activity level encompassed by engineered host bacterium of the present invention includes less than 6,000 units, less than 5,000 units, less than 4,000 units, less than 3,000 units, less than 2,000 units, less than 1,000 units, less than 900 units, less than 800 units, less than 700 units, less than 600 units, less than 500 units, less than 400 units, less than 300 units, less than 200 units, less than 100 units, or less than 50 units. Low, functional levels of β-galactosidase include β-galactosidase activity levels of between 0.05 and 1,000 units, e.g., between 0.05 and 750 units, between 0.05 and 500 units, between 0.05 and 400 units, between 0.05 and 300 units, between 0.05 and 200 units, between 0.05 and 100 units, between 0.05 and 50 units, between 0.05 and 10 units, between 0.05 and 5 units, between 0.05 and 4 units, between 0.05 and 3 units, or between 0.05 and 2 units of β-galactosidase activity. For unit definition and assays for determining β-galactosidase activity, see Miller J H, Laboratory CSH. Experiments in molecular genetics. Cold Spring Harbor Laboratory Cold Spring Harbor, N.Y.; 1972; (incorporated herein by reference). This low level of cytoplasmic β-galactosidase activity is not high enough to significantly diminish the intracellular lactose pool. The low level of β-galactosidase activity is very useful for the facile removal of undesired residual lactose at the end of fermentations.

Optionally, the bacterium has an inactivated thyA gene. Preferably, a mutation in a thyA gene in the host bacterium allows for the maintenance of plasmids that carry thyA as a selectable marker gene. Exemplary alternative selectable markers include antibiotic resistance genes such as BLA (beta-lactamase), or proBA genes (to complement a proAB host strain proline auxotropy) or purA (to complement a purA host strain adenine auxotrophy).

In one aspect, the E. coli bacterium comprises the genotype ΔampC::P_(trp) ^(B)cI, Δ(lacI-lacZ)::FRT, P_(lacIq)lacY⁺, ΔwcaJ::FRT, thyA::Tn10, Δlon:(npt3, lacZ⁺), ΔlacA, and also comprises any one of the exogenous α(1,2) fucosyltransferases described herein.

The bacterium comprising these characteristics is cultured in the presence of lactose. In some cases, the method further comprises culturing the bacterium in the presence of tryptophan and in the absence of thymidine. The fucosylated oligosaccharide is retrieved from the bacterium (i.e., a cell lysate) or from a culture supernatant of the bacterium.

The invention provides a purified fucosylated oligosaccharide produced by the methods described herein. The fucosylated oligosaccharide is purified for use in therapeutic or nutritional products, or the bacterium is used directly in such products. The fucosylated oligosaccharide produced by the engineered bacterium is 2′-fucosyllactose (2′-FL) or lactodifucotetraose (LDFT). The new alpha 1,2-fucosyltransferases are also useful to synthesize HMOS of larger molecular weight bearing alpha 1,2 fucose moieties, e.g., lacto-N-fucopentaose (LNF I) and lacto-N-difucohexaose (LDFH I). For example, to produce LDFT, the host bacterium is engineered to express an exogenous α (1,2) fucosyltransferase that also possesses a (1,3) fucosyltransferase activity, or an exogenous α (1,2) fucosyltransferase and an exogenous α (1,3) fucosyltransferase. For the production of LNF I and LDFH I, the host bacterium is engineered to express an exogenous α (1,2) fucosyltransferase that also possesses a (1,3) fucosyltransferase activity and/or a (1,4) fucosyltransferase activity, or an exogenous α (1,2) fucosyltransferase, an exogenous α (1,3) fucosyltransferas, and an exogenous α (1,4) fucosyltransferase.

A purified fucosylated oligosaccharide produced by the methods described above is also within the invention. The purified oligosaccharide (2′-FL) obtained at the end of the process is a white/slightly off-white, crystalline, sweet powder. For example, an engineered bacterium, bacterial culture supernatant, or bacterial cell lysate according to the invention comprises 2′-FL, LDFT, LNF I or LDFH I produced by the methods described herein, and does not substantially comprise a other fucosylated oligosaccharides prior to purification of the fucosylated oligosaccharide products from the cell, culture supernatant, or lysate. As a general matter, the fucosylated oligosaccharide produced by the methods contains a negligible amount of 3-FL in a 2′-FL-containing cell, cell lysate or culture, or supernatant, e.g., less than 1% of the level of 2′-FL or 0.5% of the level of 2′-FL. Moreover, the fucosylated oligosaccharide produced by the methods described herein also have a minimal amount of contaminating lactose, which can often be co-purified with the fucosylated oligosaccharide product, such as 2′FL. This reduction in contaminating lactose results from the reduced level of β-galactosidase activity present in the engineered host bacterium.

A purified oligosaccharide, e.g., 2′-FL, LDFT, LNF I, or LDFH I, is one that is at least 90%, 95%, 98%, 99%, or 100% (w/w) of the desired oligosaccharide by weight. Purity is assessed by any known method, e.g., thin layer chromatography or other chromatographic techniques known in the art. The invention includes a method of purifying a fucosylated oligosaccharide produced by the genetically engineered bacterium described above, which method comprises separating the desired fucosylated oligosaccharide (e.g., 2′-FL) from contaminants in a bacterial cell lysate or bacterial cell culture supernatant of the bacterium.

The oligosaccharides are purified and used in a number of products for consumption by humans as well as animals, such as companion animals (dogs, cats) as well as livestock (bovine, equine, ovine, caprine, or porcine animals, as well as poultry). For example, a pharmaceutical composition comprises purified 2′-FL and a pharmaceutically-acceptable excipient that is suitable for oral administration. Large quantities of 2′-FL are produced in bacterial hosts, e.g., an E. coli bacterium comprising an exogenous α (1,2) fucosyltransferase gene.

A method of producing a pharmaceutical composition comprising a purified human milk oligosaccharide (HMOS) is carried out by culturing the bacterium described above, purifying the HMOS produced by the bacterium, and combining the HMOS with an excipient or carrier to yield a dietary supplement for oral administration. These compositions are useful in methods of preventing or treating enteric and/or respiratory diseases in infants and adults. Accordingly, the compositions are administered to a subject suffering from or at risk of developing such a disease.

The invention also provides methods of identifying an α (1,2) fucosyltransferase gene capable of synthesizing fucosylated oligosaccharides in a host bacterium, i.e., 2′-fucosyllactose (2′-FL) in E. coli. The method of identifying novel lactose-utilizing, α(1,2)fucosyltransferase enzyme comprises the following steps:

1) performing a computational search of sequence databases to define a broad group of simple sequence homologs of any known, lactose-utilizing α(1,2)fucosyltransferase;

2) using the list from step (1), deriving a search profile containing common sequence and/or structural motifs shared by the members of the list;

3) searching sequence databases, using a derived search profile based on the common sequence or structural motif from step (2) as query, and identifying a candidate sequences, wherein a sequence homology to a reference lactose-utilizing α(1,2)fucosyltransferase is a predetermined percentage threshold;

4) compiling a list of candidate organisms, said organisms being characterized as expressing α(1,2)fucosyl-glycans in a naturally-occurring state;

5) selecting candidate sequences that are derived from candidate organisms to generate a list of candidate lactose-utilizing enzymes;

6) expressing the candidate lactose-utilizing enzyme in a host organism; and

7) testing for lactose-utilizing α(1,2)fucosyltransferase activity, wherein detection of the desired fucosylated oligosaccharide product in said organism indicates that the candidate sequence comprises a novel lactose-utilizing α(1,2)fucosyltransferase. In another embodiment, the search profile is generated from a multiple sequence alignment of the amino acid sequences of more than one enzyme with known α(1,2)fucosyltransferase activity. The database search can then be designed to refine and iteratively search for novel α(1,2)fucosyltransferases with significant sequence similarity to the multiple sequence alignment query.

The invention provides a method of treating, preventing, or reducing the risk of infection in a subject comprising administering to said subject a composition comprising a purified recombinant human milk oligosaccharide, wherein the HMOS binds to a pathogen and wherein the subject is infected with or at risk of infection with the pathogen. In one aspect, the infection is caused by a Norwalk-like virus or Campylobacter jejuni. The subject is preferably a mammal in need of such treatment. The mammal is, e.g., any mammal, e.g., a human, a primate, a mouse, a rat, a dog, a cat, a cow, a horse, or a pig. In a preferred embodiment, the mammal is a human. For example, the compositions are formulated into animal feed (e.g., pellets, kibble, mash) or animal food supplements for companion animals, e.g., dogs or cats, as well as livestock or animals grown for food consumption, e.g., cattle, sheep, pigs, chickens, and goats. Preferably, the purified HMOS is formulated into a powder (e.g., infant formula powder or adult nutritional supplement powder, each of which is mixed with a liquid such as water or juice prior to consumption) or in the form of tablets, capsules or pastes or is incorporated as a component in dairy products such as milk, cream, cheese, yogurt or kefir, or as a component in any beverage, or combined in a preparation containing live microbial cultures intended to serve as probiotics, or in prebiotic preparations to enhance the growth of beneficial microorganisms either in vitro or in vivo.

Polynucleotides, polypeptides, and oligosaccharides of the invention are purified and/or isolated. Purified defines a degree of sterility that is safe for administration to a human subject, e.g., lacking infectious or toxic agents. Specifically, as used herein, an “isolated” or “purified” nucleic acid molecule, polynucleotide, polypeptide, protein or oligosaccharide, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. For example, purified HMOS compositions are at least 60% by weight (dry weight) the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. Purity is measured by any appropriate standard method, for example, by column chromatography, thin layer chromatography, or high-performance liquid chromatography (HPLC) analysis. For example, a “purified protein” refers to a protein that has been separated from other proteins, lipids, and nucleic acids with which it is naturally associated. Preferably, the protein constitutes at least 10, 20, 50, 70, 80, 90, 95, 99-100% by dry weight of the purified preparation.

Similarly, by “substantially pure” is meant an oligosaccharide that has been separated from the components that naturally accompany it. Typically, the oligosaccharide is substantially pure when it is at least 60%, 70%, 80%, 90%, 95%, or even 99%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated.

By “isolated nucleic acid” is meant a nucleic acid that is free of the genes which, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term covers, for example: (a) a DNA which is part of a naturally occurring genomic DNA molecule, but is not flanked by both of the nucleic acid sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner, such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. Isolated nucleic acid molecules according to the present invention further include molecules produced synthetically, as well as any nucleic acids that have been altered chemically and/or that have modified backbones.

A “heterologous promoter” is a promoter which is different from the promoter to which a gene or nucleic acid sequence is operably linked in nature.

The term “overexpress” or “overexpression” refers to a situation in which more factor is expressed by a genetically-altered cell than would be, under the same conditions, by a wild type cell. Similarly, if an unaltered cell does not express a factor that it is genetically altered to produce, the term “express” (as distinguished from “overexpress”) is used indicating the wild type cell did not express the factor at all prior to genetic manipulation.

The terms “treating” and “treatment” as used herein refer to the administration of an agent or formulation to a clinically symptomatic individual afflicted with an adverse condition, disorder, or disease, so as to effect a reduction in severity and/or frequency of symptoms, eliminate the symptoms and/or their underlying cause, and/or facilitate improvement or remediation of damage. The terms “preventing” and “prevention” refer to the administration of an agent or composition to a clinically asymptomatic individual who is susceptible to a particular adverse condition, disorder, or disease, and thus relates to the prevention of the occurrence of symptoms and/or their underlying cause.

By the terms “effective amount” and “therapeutically effective amount” of a formulation or formulation component is meant a nontoxic but sufficient amount of the formulation or component to provide the desired effect.

The transitional term “comprising,” which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. By contrast, the transitional phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The transitional phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention.

The host organism used to express the lactose-accepting fucosyltransferase gene is typically the enterobacterium Escherichia coli K12 (E. coli). E. coli K-12 is not considered a human or animal pathogen nor is it toxicogenic. E. coli K-12 is a standard production strain of bacteria and is noted for its safety due to its poor ability to colonize the colon and establish infections (see, e.g., epa.gov/oppt/biotech/pubs/fra/fra004.htm). However, a variety of bacterial species may be used in the oligosaccharide biosynthesis methods, e.g., Erwinia herbicola (Pantoea agglomerans), Citrobacter freundii, Pantoea citrea, Pectobacterium carotovorum, or Xanthomonas campestris. Bacteria of the genus Bacillus may also be used, including Bacillus subtilis, Bacillus licheniformis, Bacillus coagulans, Bacillus thermophilus, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, and Bacillus circulans. Similarly, bacteria of the genera Lactobacillus and Lactococcus may be modified using the methods of this invention, including but not limited to Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus jensenii, and Lactococcus lactis. Streptococcus thermophiles and Proprionibacterium freudenreichii are also suitable bacterial species for the invention described herein. Also included as part of this invention are strains, modified as described here, from the genera Enterococcus (e.g., Enterococcus faecium and Enterococcus thermophiles), Bifidobacterium (e.g., Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum), Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas (e.g., Pseudomonas fluorescens and Pseudomonas aeruginosa). Bacteria comprising the characteristics described herein are cultured in the presence of lactose, and a fucosylated oligosaccharide is retrieved, either from the bacterium itself or from a culture supernatant of the bacterium. The fucosylated oligosaccharide is purified for use in therapeutic or nutritional products, or the bacteria are used directly in such products. A suitable production host bacterial strain is one that is not the same bacterial strain as the source bacterial strain from which the fucosyltransferase-encoding nucleic acid sequence was identified.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All published foreign patents and patent applications cited herein are incorporated herein by reference. Genbank and NCBI submissions indicated by accession number cited herein are incorporated herein by reference. All other published references, documents, manuscripts and scientific literature cited herein are incorporated herein by reference. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic illustration showing the synthetic pathway of the major neutral fucosyl-oligosaccharides found in human milk.

FIG. 2 is a schematic demonstrating metabolic pathways and the changes introduced into them to engineer 2′-fucosyllactose (2′-FL) synthesis in Escherichia coli (E. coli). Specifically, the lactose synthesis pathway and the GDP-fucose synthesis pathway are illustrated. In the GDP-fucose synthesis pathway: manA=phosphomannose isomerase (PMI), manB=phosphomannomutase (PMM), manC=mannose-1-phosphate guanylyltransferase (GMP), gmd=GDP-mannose-4,6-dehydratase,fcl=GDP-fucose synthase (GFS), and Awcaf=mutated UDP-glucose lipid carrier transferase.

FIG. 3A and FIG. 3B show the sequence identity and a multiple sequence alignment of 4 previously known lactose-utilizing α(1,2)-fucosyltransferase protein sequences. FIG. 3A is a table showing the sequence identity between the 4 known lactose-utilizing α(1,2)-fucosyltransferases: H. pylori futC (SEQ ID NO: 1), H. mustelae FutL (SEQ ID NO: 2), Bacteroides vulgatus futN (SEQ ID NO: 3), and E. coli 0126 wbgL (SEQ ID NO: 4). FIG. 3B shows multiple sequence alignment of the 4 known α(1,2)-fucosyltransferases. The ovals highlight regions of particularly high sequence conservation between the four enzymes in the alignment.

FIG. 4A through FIG. 4F show the sequence alignment of the 12 identified α(1,2)-fucosyltransferase syngenes identified, along with the 4 previously known lactose-utilizing α(1,2)-fucosyltransferase protein sequences. The 4 known lactose-utilizing α(1,2)-fucosyltransferases are boxed and include H. pylori futC (SEQ ID NO: 1), H. mustelae FutL (SEQ ID NO: 2), Bacteroides vulgatus futN (SEQ ID NO: 3), and E. coli 0126 wbgL (SEQ ID NO: 4). The 12 identified α(1,2)-fucosyltransferase are as follows: Prevotella melaninogenica FutO (SEQ ID NO: 10), Clostridium bolteae+13 FutP (SEQ ID NO: 292), Lachnospiraceae sp. FutQ (SEQ ID NO: 12), Methanosphaerula palustris FutR (SEQ ID NO: 13), Tannerella sp. FutS (SEQ ID NO: 14), Bacteroides caccae FutU (SEQ ID NO: 15), Butyrivibrio FutV (SEQ ID NO: 16), Prevotella sp. FutW (SEQ ID NO: 17), Parabacteroides johnsonii FutX (SEQ ID NO: 18), Akkermansia muciniphilia FutY (SEQ ID NO: 19), Salmonella enterica FutZ (SEQ ID NO: 20), Bacteroides sp. FutZA (SEQ ID NO: 21). The sequence for Clostridium bolteae FutP (without the 13 additional amino acids in the N-terminus) (SEQ ID NO: 11) is also shown in the alignment.

FIG. 5A and FIG. 5B are two pictures of gels showing the construction of the syngenes for each of the 12 novel α(1,2)-fucosyltransferases. FIG. 5A shows post-Gibson assembly PCR. FIG. 5B shows gel-purified RI/Xho1 syngene fragments.

FIG. 6A and FIG. 6B are two photographs showing thin layer chromatograms of fucosylated oligosaccharide products produced in E. coli cultures using the 12 novel α(1,2)-fucosyltransferase syngenes. FIG. 6A shows fucosylated oligosaccharide products from 2 μl of culture supernatant. FIG. 6B shows fucosylated oligosaccharide products from 0.2 OD₆₀₀ cell equivalents of whole cell heat extracts.

FIG. 7 is a graph showing the growth curve of the host bacterium expressing plasmids containing the α(1,2) fucosyltransferase genes WbgL, FutN, FutO, FutQ, and FutX after tryptophan induction in the presence of lactose in the culture medium (i.e. lac+trp).

FIG. 8 is a photograph of a SDS-PAGE gel showing the proteins produced from host bacterium expressing α(1,2) fucosyltransferase genes WbgL, FutN, FutO, FutQ, and FutX after induction.

FIG. 9A and FIG. 9B are two photographs of thin layer chromatograms showing the production of fucosylated oligosaccharide products from in E. coli cultures expressing select α(1,2)-fucosyltransferase syngenes WbgL, FutN, FutO, FutQ, and FutX at 7 hours or 24 hours after induction. FIG. 9A shows fucosylated oligosaccharide products from 2 μl of culture supernatant. FIG. 9B shows fucosylated oligosaccharide products from 0.2 OD₆₀₀ cell equivalents of whole cell heat extracts.

FIG. 10A and FIG. 10B are two photographs of thin layer chromatograms showing the fucosylated oligosaccharide products after two different 1.5 L fermentation runs from E. coli expressing FutN: FIG. 10A) 36B and FIG. 10B) 37A. The culture yield for run 36B was 33 g/L while the yield for run 37A was 36.3 g/L.

FIG. 11 is a plasmid map of pG217 carrying the B. vulgatus FutN gene.

FIG. 12 is a schematic diagram showing the insertion of the LacIq promoter, the functional lacY gene, and the deletion of lacA.

FIG. 13 is a schematic diagram showing the deletion of the endogenous wcaJ gene using FRT recombination.

FIG. 14 is a schematic diagram of the E. coli W3110 chromosome, showing the insertion of a DNA fragment carrying kanamycin resistance gene (derived from transposon Tn5) and wild-type lacZ into the ion gene.

DETAILED DESCRIPTION OF THE INVENTION

While some studies suggest that human milk glycans could be used as antimicrobial anti-adhesion agents, the difficulty and expense of producing adequate quantities of these agents of a quality suitable for human consumption has limited their full-scale testing and perceived utility. What has been needed is a suitable method for producing the appropriate glycans in sufficient quantities at reasonable cost. Prior to the invention described herein, there were attempts to use several distinct synthetic approaches for glycan synthesis. Some chemical approaches can synthesize oligosaccharides (Flowers, H. M. Methods Enzymol 50, 93-121 (1978); Seeberger, P. H. Chem Commun (Camb) 1115-1121 (2003)), but reactants for these methods are expensive and potentially toxic (Koeller, K. M. & Wong, C. H. Chem Rev 100, 4465-4494 (2000)). Enzymes expressed from engineered organisms (Albermann, C., Piepersberg, W. & Wehmeier, U. F. Carbohydr Res 334, 97-103 (2001); Bettler, E., Samain, E., Chazalet, V., Bosso, C., et al. Glycoconj J 16, 205-212 (1999); Johnson, K. F. Glycoconj J 16, 141-146 (1999); Palcic, M. M. Curr Opin Biotechnol 10, 616-624 (1999); Wymer, N. & Toone, E. J. Curr Opin Chem Biol 4, 110-119 (2000)) provide a precise and efficient synthesis (Palcic, M. M. Curr Opin Biotechnol 10, 616-624 (1999)); Crout, D. H. & Vic, G. Curr Opin Chem Biol 2, 98-111 (1998)), but the high cost of the reactants, especially the sugar nucleotides, limits their utility for low-cost, large-scale production. Microbes have been genetically engineered to express the glycosyltransferases needed to synthesize oligosaccharides from the bacteria's innate pool of nucleotide sugars (Endo, T., Koizumi, S., Tabata, K., Kakita, S. & Ozaki, A. Carbohydr Res 330, 439-443 (2001); Endo, T., Koizumi, S., Tabata, K. & Ozaki, A. Appl Microbiol Biotechnol 53, 257-261 (2000); Endo, T. & Koizumi, S. Curr Opin Struct Biol 10, 536-541 (2000); Endo, T., Koizumi, S., Tabata, K., Kakita, S. & Ozaki, A. Carbohydr Res 316, 179-183 (1999); Koizumi, S., Endo, T., Tabata, K. & Ozaki, A. Nat Biotechnol 16, 847-850 (1998)). However, prior to the invention described herein, there was a growing need to identify and characterize additional glycosyltransferases that are useful for the synthesis of HMOS in metabolically engineered bacterial hosts.

Human Milk Glycans

Human milk contains a diverse and abundant set of neutral and acidic oligosaccharides (Kunz, C., Rudloff, S., Baier, W., Klein, N., and Strobel, S. (2000). Annu Rev Nutr 20, 699-722; Bode, L. (2006). J Nutr 136, 2127-130). More than 130 different complex oligosaccharides have been identified in human milk, and their structural diversity and abundance is unique to humans. Although these molecules may not be utilized directly by infants for nutrition, they nevertheless serve critical roles in the establishment of a healthy gut microbiome (Marcobal, A., Barboza, M., Froehlich, J. W., Block, D. E., et al. J Agric Food Chem 58, 5334-5340 (2010)), in the prevention of disease (Newburg, D. S., Ruiz-Palacios, G. M. & Morrow, A. L. Annu Rev Nutr 25, 37-58 (2005)), and in immune function (Newburg, D. S. & Walker, W. A. Pediatr Res 61, 2-8 (2007)). Despite millions of years of exposure to human milk oligosaccharides (HMOS), pathogens have yet to develop ways to circumvent the ability of HMOS to prevent adhesion to target cells and to inhibit infection. The ability to utilize HMOS as pathogen adherence inhibitors promises to address the current crisis of burgeoning antibiotic resistance. Human milk oligosaccharides produced by biosynthesis represent the lead compounds of a novel class of therapeutics against some of the most intractable scourges of society.

One alternative strategy for efficient, industrial-scale synthesis of HMOS is the metabolic engineering of bacteria. This approach involves the construction of microbial strains overexpressing heterologous glycosyltransferases, membrane transporters for the import of precursor sugars into the bacterial cytosol, and possessing enhanced pools of regenerating nucleotide sugars for use as biosynthetic precursors (Dumon, C., Samain, E., and Priem, B. (2004). Biotechnol Prog 20, 412-19; Ruffing, A., and Chen, R.R. (2006). Microb Cell Fact 5, 25). A key aspect of this approach is the heterologous glycosyltransferase selected for overexpression in the microbial host. The choice of glycosyltransferase can significantly affect the final yield of the desired synthesized oligosaccharide, given that enzymes can vary greatly in terms of kinetics, substrate specificity, affinity for donor and acceptor molecules, stability and solubility. A few glycosyltransferases derived from different bacterial species have been identified and characterized in terms of their ability to catalyze the biosynthesis of HMOS in E. coli host strains (Dumon, C., Bosso, C., Utille, J.P., Heyraud, A., and Samain, E. (2006). Chembiochem 7, 359-365; Dumon, C., Samain, E., and Priem, B. (2004). Biotechnol Prog 20, 412-19; Li, M., Liu, X. W., Shao, J., Shen, J., Jia, Q., Yi, W., Song, J. K., Woodward, R., Chow, C. S., and Wang, P. G. (2008). Biochemistry 47, 378-387). The identification of additional glycosyltransferases with faster kinetics, greater affinity for nucleotide sugar donors and/or acceptor molecules, or greater stability within the bacterial host significantly improves the yields of therapeutically useful HMOS. Prior to the invention described herein, chemical syntheses of HMOS were possible, but were limited by stereo-specificity issues, precursor availability, product impurities, and high overall cost (Flowers, H. M. Methods Enzymol 50, 93-121 (1978); Seeberger, P. H. Chem Commun (Camb) 1115-1121 (2003); Koeller, K. M. & Wong, C. H. Chem Rev 100, 4465-4494 (2000)). The invention overcomes the shortcomings of these previous attempts by providing new strategies to inexpensively manufacture large quantities of human milk oligosaccharides (HMOS) for use as dietary supplements. Advantages include efficient expression of the enzyme, improved stability and/or solubility of the fucosylated oligosaccharide product (2′-FL, LDFT, LNF I, and LDFH I) and reduced toxicity to the host organism. The present invention features novel α(1,2) FTs suitable for expression in production strains for increased efficacy and yield of fucosylated HMOS compared to α(1,2) FTs currently utilized in the field.

As described in detail below, E. coli (or other bacteria) is engineered to produce selected fucosylated oligosaccharides (i.e., 2′-FL, LDFT, LDHF I, or LNF I) in commercially viable levels. For example, yields are >5 grams/liter in a bacterial fermentation process. In other embodiments, the yields are greater than 10 grams/liter, greater than 15 grams/liter, greater than 20 grams/liter, greater than 25 grams/liter, greater than 30 grams/liter, greater than 35 grams/liter, greater than 40 grams/liter, greater than 45 grams/liter, greater than 50 grams/liter, greater than 55 grams/liter, greater than 60 grams/liter, greater than 65 grams/liter, greater than 70 grams/liter, or greater than 75 grams/liter of fucosylated oligosaccharide products, such as 2′-FL, LDFT, LDHF I, and LNF I.

Role of Human Milk Glycans in Infectious Disease

Human milk glycans, which comprise both unbound oligosaccharides and their glycoconjugates, play a significant role in the protection and development of the infant gastrointestinal (GI) tract. Neutral fucosylated oligosaccharides, including 2′-fucosyllactose (2′-FL), protect infants against several important pathogens. Milk oligosaccharides found in various mammals differ greatly, and the composition in humans is unique (Hamosh M., 2001 Pediatr Clin North Am, 48:69-86; Newburg D. S., 2001 Adv Exp Med Biol, 501:3-10). Moreover, glycan levels in human milk change throughout lactation and also vary widely among individuals (Morrow A. L. et al., 2004 J Pediatr, 145:297-303; Chaturvedi P et al., 2001 Glycobiology, 11:365-372). Approximately 200 distinct human milk oligosaccharides have been identified and combinations of simple epitopes are responsible for this diversity (Newburg D.S., 1999 Curr Med Chem, 6:117-127; Ninonuevo M. et al., 2006 J Agric Food Chem, 54:7471-74801).

Human milk oligosaccharides are composed of 5 monosaccharides: D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-fucose (Fuc), and sialic acid (N-acetyl neuraminic acid, NeuSAc, NANA). Human milk oligosaccharides are usually divided into two groups according to their chemical structures: neutral compounds containing Glc, Gal, GlcNAc, and Fuc, linked to a lactose (Galβ1-4G1c) core, and acidic compounds including the same sugars, and often the same core structures, plus NANA (Charlwood J. et al., 1999 Anal Biochem, 273:261-277; Martin-Sosa et al., 2003 J Dairy Sci, 86:52-59; Parkkinen J. and Finne J., 1987 Methods Enzymol, 138:289-300; Shen Z. et al., 2001 J Chromatogr A, 921:315-321).

Approximately 70-80% of oligosaccharides in human milk are fucosylated, and their synthetic pathways are believed to proceed as shown in FIG. 1. A smaller proportion of the oligosaccharides are sialylated or both fucosylated and sialylated, but their synthetic pathways are not fully defined. Understanding of the acidic (sialylated) oligosaccharides is limited in part by the ability to measure these compounds. Sensitive and reproducible methods for the analysis of both neutral and acidic oligosaccharides have been designed. Human milk oligosaccharides as a class survive transit through the intestine of infants very efficiently, being essentially indigestible (Chaturvedi, P., Warren, C. D., Buescher, C. R., Pickering, L. K. & Newburg, D. S. Adv Exp Med Biol 501, 315-323 (2001)).

Human Milk Glycans Inhibit Binding of Enteropathogens to their Receptors

Human milk glycans have structural homology to cell receptors for enteropathogens and function as receptor decoys. For example, pathogenic strains of Campylobacter bind specifically to glycans containing H-2, i.e., 2′-fucosyl-N-acetyllactosamine or 2′-fucosyllactose (2′FL); Campylobacter binding and infectivity are inhibited by 2′-FL and other glycans containing this H-2 epitope. Similarly, some diarrheagenic E. coli pathogens are strongly inhibited in vivo by human milk oligosaccharides containing 2-linked fucose moieties. Several major strains of human caliciviruses, especially the noroviruses, also bind to 2-linked fucosylated glycans, and this binding is inhibited by human milk 2-linked fucosylated glycans. Consumption of human milk that has high levels of these 2-linked fucosyloligosaccharides was associated with lower risk of norovirus, Campylobacter, ST of E. coli-associated diarrhea, and moderate-to-severe diarrhea of all causes in a Mexican cohort of breastfeeding children (Newburg D.S. et al., 2004 Glycobiology, 14:253-263; Newburg D. S. et al., 1998 Lancet, 351:1160-1164). Several pathogens utilize sialylated glycans as their host receptors, such as influenza (Couceiro, J. N., Paulson, J. C. & Baum, L. G. Virus Res 29, 155-165 (1993)), parainfluenza (Amonsen, M., Smith, D. F., Cummings, R. D. & Air, G. M. J Virol 81, 8341-8345 (2007), and rotoviruses (Kuhlenschmidt, T. B., Hanafin, W. P., Gelberg, H. B. & Kuhlenschmidt, M. S. Adv Exp Med Biol 473, 309-317 (1999)). The sialyl-Lewis X epitope is used by Helicobacter pylori (Mandavi, J., Sondén, B., Hurtig, M., Olfat, F. O., et al. Science 297, 573-578 (2002)), Pseudomonas aeruginosa (Scharfman, A., Delmotte, P., Beau, J., Lamblin, G., et al. Glycoconj J 17, 735-740 (2000)), and some strains of noroviruses (Rydell, G. E., Nilsson, J., Rodriguez-Diaz, J., Ruvoen-Clouet, N., et al. Glycobiology 19, 309-320 (2009)).

Identification of Novel α(1,2) Fucosyltransferases

The present invention provides novel α(1,2) fucosyltransferase enzymes. The present invention also provides nucleic acid constructs (i.e., a plasmid or vector) carrying the nucleic acid sequence of a novel α(1,2) fucosyltransferases for the expression of the novel α(1,2) fucosyltransferases in host bacterium. The present invention also provides methods for producing fucosylated oligosaccharides by expressing the novel α(1,2) fucosyltransferases in suitable host production bacterium, as further described herein.

Not all α(1,2)fucosyltransferases can utilize lactose as an acceptor substrate. An acceptor substrate includes, for example, a carbohydrate, an oligosaccharide, a protein or glycoprotein, a lipid or glycolipid, e.g., N-acetylglucosamine, N-acetyllactosamine, galactose, fucose, sialic acid, glucose, lactose, or any combination thereof. A preferred alpha (1,2) fucosyltransferase of the present invention utilizes GDP-fucose as a donor, and lactose is the acceptor for that donor.

A method of identifying novel α(1,2)fucosyltransferase enzymes capable of utilizing lactose as an acceptor was previously carried out (as described in PCT/US2013/051777, hereby incorporated by reference in its entirety) using the following steps: 1) performing a computational search of sequence databases to define a broad group of simple sequence homologs of any known, lactose-utilizing α(1,2)fucosyltransferase; 2) using the list of homologs from step 1 to derive a search profile containing common sequence and/or structural motifs shared by the members of the broad group, e.g. by using computer programs such as MEME (Multiple Em for Motif Elicitation available at http://meme.sdsc.edu/meme/cgi-bin/meme.cgi) or PSI-BLAST (Position-Specific Iterated BLAST available at ncbi.nlm.nih.gov/blast with additional information at cnx.org/content/m11040/latest/); 3) searching sequence databases (e.g., using computer programs such as PSI-BLAST, or MAST (Motif Alignment Search Tool available at http://meme.sdsc.edu/meme/cgi-bin/mast.cgi);, using this derived search profile as query, and identifying “candidate sequences” whose simple sequence homology to the original lactose-accepting α(1,2)fucosyltransferase is 40% or less; 4) scanning the scientific literature and developing a list of “candidate organisms” known to express α(1,2)fucosyl-glycans; 5) selecting only those “candidate sequences” that are derived from “candidate organisms” to generate a list of “candidate lactose-utilizing enzymes”; and 6) expressing each “candidate lactose-utilizing enzyme” and testing for lactose-utilizing α(1,2)fucosyltransferase activity.

The MEME suite of sequence analysis tools (meme.sdsc.edu/meme/cgi-bin/meme.cgi) can also be used as an alternative to PSI-BLAST. Sequence motifs are discovered using the program “MEME”. These motifs can then be used to search sequence databases using the program “MAST”. The BLAST and PSI-BLAST search algorithms are other well known alternatives.

To identify additional novel α(1,2)fucosyltransferases, a multiple sequence alignment query was generated using four previously identified lactose-utilizing α(1,2)fucosyltransferase protein sequences: H. pylori futC (SEQ ID NO: 1), H. mustelae FutL (SEQ ID NO: 2), Bacteroides vulgatus futN (SEQ ID NO: 3), and E. coli 0126 wbgL (SEQ ID NO: 4). These sequence alignment and percentage of sequence identity is shown in FIG. 3. An iterative PSI-BLAST was performed, using the FASTA-formatted multiple sequence alignment as the query, and the NCBI PSI-BLAST program run on a local copy of NCBI BLAST+version 2.2.29. An initial position-specific scoring matrix file (.pssm) was generated by PSI-BLAST, which the program then used to adjust the score of iterative homology search runs. The process is iterated to generate an even larger group of candidates, and the results of each run were used to further refine the matrix.

This PSI-BLAST search resulted in an initial 2515 hits. There were 787 hits with greater than 22% sequence identity to FutC. 396 hits were of greater than 275 amino acids in length. Additional analysis of the hits was performed, including sorting by percentage identity to FutC, comparing the sequences by BLAST to existing α(1,2) fucosyltransferase inventory (of known α(1,2) fucosyltransferases), and manual annotation of hit sequences to identify those originating from bacteria that naturally exist in the gastrointestinal tract. An annotated list of the novel α(1,2) fucosyltransferases identified by this screen are listed in Table 1. Table 1 provides the bacterial species from which the candidate enzyme is found, the GenBank Accession Number, GI Identification Number, amino acid sequence, and % sequence identity to FutC.

Of the identified hits, 12 novel α(1,2) fucosyltransferases were further analyzed for their functional capacity: Prevotella melaninogenica FutO, Clostridium bolteae FutP, Clostridium bolteae+13 FutP, Lachnospiraceae sp. FutQ, Methanosphaerula palustries FutR, Tannerella sp. FutS, Bacteroides caccae FutU, Butyrivibrio FutV, Prevotellaa sp. FutW, Parabacteroides johnsonii FutX, Akkermansia muciniphilia FutY, Salmonella enterica FutZ, and Bacteroides sp. FutZA. For Clostridium bolteae FutP, the annotation named the wrong initiation methionine codon. Thus, the present invention includes FutP with an additional 13 amino acids at the N-terminus of the annotated FutP (derived in-frame from the natural upstream DNA sequence), which is designated herein as Clostridium bolteae+13 FutP. The sequence identity between the 12 novel α(1,2) fucosyltransferases identified and the 4 previously identified α(1,2) fucosyltransferases is shown in Table 2 below.

TABLE 2 Sequence Identity 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 H.pylori futC 1 70.10 21.99 20.82 27.68 27.36 23.56 23.28 23.62 25.75 23.72 24.05 22.29 24.19 22.92 22.29 H.mustelae futL 2 70.10 23.87 19.88 26.38 28.21 24.30 23.38 24.62 25.31 25.31 24.47 23.56 25.15 23.55 23.26 Bacteroides vulgatus 3 21.99 23.87 25.16 32.05 28.71 28.94 25.79 37.46 32.27 26.11 61.27 71.63 27.67 25.15 84.75 futN E. coli 0126 wbgL 4 20.82 19.88 25.16 24.25 22.73 22.32 26.04 25.45 24.77 21.49 23.29 26.71 24.63 21.45 25.16 Prevotella 5 27.68 26.38 32.05 24.25 36.96 31.63 35.74 35.16 55.74 30.28 30.03 32.80 30.09 26.28 31.83 melaninogenica Fut0 YP_003814512.1 Clostridium bolteae + 6 27.36 28.21 28.71 22.73 36.96 37.87 35.10 33.77 36.91 35.74 29.58 31.39 27.67 26.33 29.13 13 FutP WP_002570768.1 Lachnospiraceae sp. 7 23.56 24.30 28.94 22.32 31.63 37.87 29.87 29.17 32.90 51.02 28.53 30.00 27.69 24.00 27.74 FutQ WP_009251343.1 Methanosphaerula 8 23.28 23.38 25.79 26.04 35.74 35.10 29.87 28.71 38.24 31.41 25.39 28.08 30.65 23.93 25.55 palustris FutR YP_002467213.1 Tannerella sp. FutS 9 23.62 24.62 37.46 25.45 35.16 33.77 29.17 28.71 34.41 30.03 35.71 36.27 26.48 21.75 36.60 WP_021929367.1 Bacteroides caccae 10 25.75 25.31 32.27 24.77 55.74 36.91 32.90 38.24 34.41 31.21 29.94 33.33 29.28 24.46 33.01 FutU WP_005675707.1 Butyrivibrio FutV 11 23.72 25.31 26.11 21.49 30.28 35.74 51.02 31.41 30.03 31.21 27.62 26.20 26.46 22.15 26.52 WP_022772718.1 Prevotella sp. FutW 12 24.05 24.47 61.27 23.29 30.03 29.58 28.53 25.39 35.71 29.94 27.62 57.60 25.79 22.15 59.01 WP_022481266.1 Parabacteroides 13 22.29 23.56 71.63 26.71 32.80 31.39 30.00 28.08 36.27 33.33 26.20 57.60 28.71 24.00 74.02 johnsonii FutX WP_008155883.1 Akkermansia 14 24.19 25.15 27.67 24.63 30.09 27.67 27.69 30.65 26.48 29.28 26.46 25.79 28.71 21.45 28.08 muciniphilia FutY YP_001877555 Salmonella enterica 15 22.92 23.55 25.15 21.45 26.28 26.33 24.00 23.93 21.75 24.46 22.15 22.15 24.00 21.45 24.62 FutZ WP_023214330 Bacteroides sp. 16 22.29 23.26 84.75 25.16 31.83 29.13 27.74 25.55 36.60 33.01 26.52 59.01 74.02 28.08 24.62 FutZA WP_022161880.1

Based on the amino acid sequences of the identified α(1,2) fucosyltransferases (i.e., in Table 1), syngenes can be readily designed and constructed by the skilled artisan using standard methods known in the art. For example, the syngenes include a ribosomal binding site, are codon-optimized for expression in a host bacterial production strain (i.e., E. coli), and have common 6-cutter restriction sites or sites recognized by endogenous restriction enzymes present in the host strain (i.e., EcoK restriction sites) removed to ease cloning and expression in the E. coli host strain. In a preferred embodiment, the syngenes are constructed with the following configuration: EcoRI site-T7g10 RBS-α(1,2) FT syngene-XhoI site. The nucleic acid sequences of sample syngenes for the 12 identified α(1,2) fucosyltransferases are shown in Table 3. (the initiating methionine ATG codon is bolded)

TABLE 3 Nucleic acid sequences of 12 novel α(1,2) fucosyltransferase syngenes Bacteria/ SEQ Gene name Sequence ID NO: FutO CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGAAAATCGTCAAAATCCTGGGCGGT 276 CTGGGCAATCAGATGTTCCAGTATGCTCTGTACCTGAGCCTGCAAGAAAGTTTTCCAAAA GAACGTGTGGCCCTGGACCTGTCCTCCTTCCACGGCTATCACCTGCATAATGGCTTTGAG CTGGAGAACATTTTCTCCGTTACCGCTCAGAAAGCATCCGCCGCAGATATCATGCGTATT GCTTATTACTACCCGAACTATCTGCTGTGGCGCATTGGCAAACGTTTTCTGCCGCGTCGT AAAGGTATGTGCCTGGAATCTAGCTCCCTGCGTTTCGATGAAAGCGTTCTGCGTCAGGAA GGTAACCGTTATTTTGACGGTTACTGGCAAGACGAACGCTACTTCGCAGCCTATCGTGAA AAAGTGCTGAAGGCTTTCACCTTTCCTGCATTCAAACGCGCAGAAAACCTGAGCCTGCTG GAAAAACTGGACGAAAACAGCATTGCTCTGCATGTTCGTCGCGGTGATTACGTAGGTAAT AACCTGTACCAAGGCATCTGTGACCTGGACTACTACCGTACCGCTATCGAGAAAATGTGT GCACACGTTACTCCGTCTCTGTTTTGTATCTTTTCCAACGACATCACGTGGTGCCAGCAG CACCTGCAACCGTACCTGAAGGCCCCTGTGGTGTACGTTACTTGGAACACCGGTGTTGAA TCCTACCGCGATATGCAGCTGATGTCCTGCTGCGCACATAACATCATCGCGAATAGCTCC TTCTCTTGGTGGGGTGCTTGGCTGAATCAGAACCGTGAAAAAGTTGTTATCGCCCCGAAA AAATGGCTGAACATGGAAGAATGTCACTTCACGCTGCCGGCAAGCTGGATCAAAATTTAG CTCGAGTGACTGACTG FutP CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGGTGATTATCAAAATGATGGGTGGT 277 CTGGGCAACCAGATGTTCCAGTACGCACTGTACAAAGCATTCGAGCAGAAGCACATCGAT GTGTATGCAGACCTGGCATGGTACAAAAACAAATCCGTGAAATTTGAACTGTACAACTTC GGCATTAAAATCAACGTAGCATCCGAGAAAGACATCAACCGTCTGAGCGATTGCCAGGCG GACTTTGTTTCCCGCATCCGCCGTAAAATCTTTGGTAAAAAAAAGAGCTTCGTATCTGAA AAAAATGACTCCTGCTATGAAAACGACATCCTGCGTATGGACAACGTTTATCTGAGCGGT TATTGGCAGACCGAAAAATACTTCTCTAACACGCGTGAGAAGCTGCTGGAGGATTATTCC TTCGCTCTGGTAAACTCTCAGGTGTCCGAATGGGAAGACTCCATTCGCAACAAAAACAGC GTTAGCATCCATATCCGTCGTGGTGATTATCTACAGGGCGAACTGTATGGTGGTATTTGC ACCTCTCTGTACTACGCCGAAGCAATCGAGTACATTAAAATGCGTGTTCCGAACGCAAAA TTCTTCGTTTTCTCTGATGACGTTGAATGGGTTAAACAGCAAGAAGACTTCAAAGGCTTC GTAATCGTTGATCGCAACGAGTATTCTAGCGCTCTGTCCGATATGTACCTGATGTCCCTG TGCAAGCATAACATTATTGCTAACTCCTCTTTCAGCTGGTGGGCAGCTTGGCTGAACCGT AACGAAGAAAAAATTGTAATCGCGCCGCGCCGTTGGCTGAACGGCAAGTGCACCCCAGAT ATCTGGTGTAAAAAATGGATTCGTATCTAGCTCGAGTGACTGACTG FutQ CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGGTGATCGTACAGCTGAGCGGCGGT 278 CTGGGCAACCAGATGTTCGAATACGCGCTGTACCTGAGCCTGAAAGCAAAAGGCAAAGAA GTGAAAATTGACGATGTTACGTGTTACGAGGGCCCTGGCACCCGTCCGCGTCAACTGGAT GTTTTTGGTATCACGTACGATCGCGCGTCTCGTGAGGAGCTGACTGAGATGACGGACGCG AGCATGGATGCGCTGTCTCGTGTTCGTCGCAAACTGACCGGTCGCCGCACTAAAGCGTAC CGCGAACGCGACATCAACTTCGATCCACTGGTTATGGAAAAAGACCCGGCACTGCTGGAA GGCTGTTTCCAGTCTGACAAATACTTTCGTGATTGCGAAGGCCGCGTGCGCGAAGCGTAT CGTTTCCGCGGCATTGAATCCGGCGCGTTCCCGCTGCCGGAAGACTATCTGCGCCTGGAA AAGCAGATCGAAGATTGTCAGTCCGTATCCGTACACATCCGTCGTGGCGACTACCTGGAC GAATCTCATGGTGGTCTGTACACCGGCATTTGTACTGAGGCGTACTATAAAGAGGCTTTT GCTCGCATGGAACGTCTGGTTCCGGGCGCACGTTTCTTCCTGTTCTCTAACGATCCAGAA TGGACTCGTGAGCACTTTGAGAGCAAGAACTGCGTTCTGGTTGAAGGTAGCACCGAAGAC ACGGGTTACATGGACCTGTACCTGATGAGCCGCTGCCGCCACAATATTATTGCCAACTCT TCTTTCAGCTGGTGGGGCGCTTGGCTGAATGAGAACCCTGAGAAAAAAGTCATCGCACCG GCTAAATGGCTGAACGGTCGTGAGTGCCGTGATATCTATACCGAACGCATGATTCGTCTG TAGCTCGAGTGACTGACTG FutR CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGATCATTGTTCGTCTGAAAGGCGGT 279 CTGGGCAACCAACTGTCTCAGTATGCACTGGGCCGTAAGATCGCGCATCTGCACAATACC GAACTGAAACTGGACACCACTTGGTTCACCACTATCTCCTCCGACACTCCACGTACCTAC CGTCTGAACAATTATAACATCATCGGCACTATTGCATCCGCAAAGGAAATCCAGCTGATC GAACGTGGTCGCGCGCAAGGCCGTGGCTACCTGCTGTCTAAAATTTCTGATCTGCTGACT CCGATGTACCGTCGTACCTACGTCCGTGAACGTATGCATACCTTCGATAAAGCTATCCTG ACCGTTCCGGACAACGTGTACCTGGATGGTTACTGGCAGACCGAAAAGTACTTCAAAGAC ATCGAAGAAATCCTGCGCCGTGAGGTTACGCTGAAAGATGAACCGGATAGCATCAACCTG GAAATGGCTGAACGTATTCAGGCTTGCCACAGCGTTTCCCTGCACGTGCGTCGTGGCGAC TACGTTTCCAACCCGACCACTCAACAATTCCACGGCTGTTGCTCCATTGACTACTACAAC CGCGCTATCTCTCTGATTGAAGAAAAAGTGGATGACCCGTCTTTCTTTATTTTTTCTGAC GATCTGCCGTGGGCTAAAGAAAACCTGGACATCCCTGGCGAAAAAACCTTCGTTGCGCAT AACGGCCCGGAAAAAGAGTATTGCGATCTGTGGCTGATGTCTCTGTGCCAGCACCATATC ATCGCAAACTCTTCTTTCAGCTGGTGGGGTGCCTGGCTGGGTCAAGACGCCGAAAAGATG GTGATCGCGCCGCGTCGCTGGGCCCTGTCCGAGAGCTTTGACACTTCTGACATCATTCCG GACTCTTGGATTACTATCTAGCTCGAGTGACTGACTG FutS CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGGTACGCATTGTGGAAATCATCGGC 280 GGTCTGGGTAACCAGATGTTCCAGTACGCATTCTCCCTGTACCTGAAAAACAAATCTCAC ATCTGGGACCGTCTGTATGTGGACATCGAGGCGATGAAAACCTACGATCGTCACTATGGT CTGGAACTGGAGAAAGTTTTCAATCTGAGCCTGTGTCCAATCTCTAACCGTCTGCACCGC AACCTGCAAAAACGCTCCTTCGCAAAACACTTTGTAAAGAGCCTGTACGAGCACTCTGAA TGCGAGTTCGACGAACCGGTGTACCGTGGCCTGCGTCCTTATCGCTATTATCGCGGCTAC TGGCAAAACGAAGGTTACTTCGTTGATATTGAACCGATGATCCGTGAGGCTTTTCAGTTC AACGTTAACATCCTGAGCAAAAAGACTAAAGCGATCGCATCCAAAATGCGCCGTGAACTG TCCGTATCTATCCATGTTCGCCGTGGTGATTACGAAAACCTGCCGGAAGCGAAAGCGATG CATGGCGGTATTTGTTCTCTGGACTATTACCACAAAGCGATCGACTTCATCCGCCAGCGT CTGGATAATAACATCTGTTTCTATCTGTTCTCCGACGATATCAATTGGGTAGAAGAAAAC CTGCAACTGGAAAACCGTTGCATCATCGACTGGAACCAGGGCGAAGATAGCTGGCAGGAC ATGTACCTGATGAGCTGCTGCCGCCACCACATTATCGCAAACAGCTCTTTCTCCTGGTGG GCGGCATGGCTGAATCCAAACAAGAACAAAATCGTACTGACCCCGAACAAATGGTTCAAC CATACTGACGCAGTGGGTATCGTCCCAAAGTCCTGGATTAAAATTCCTGTGTTTTAGCTC GAGTGACTGACTG FutU CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGAAAATCGTTAAAATCCTGGGCGGC 281 CTGGGTAACCAGATGTTTCAGTACGCCCTGTTCCTGTCTCTGAAAGAACGCTTCCCGCAT GAACAGGTGATGATTGACACCAGCTGCTTCCGCAATTACCCACTGCACAACGGTTTCGAA GTGGATCGTATCTTCGCCCAGAAAGCACCGGTTGCCTCTTGGCGTAACATCCTGAAGGTT GCCTACCCGTACCCGAACTACCGTTTCTGGAAAATCGGTAAATACATCCTGCCTAAACGT AAAACCATGTGTGTAGAGCGTAAAAACTTCAGCTTTGACGCCGCAGTCCTGACCCGTAAA GGCGATTGCTACTATGATGGCTACTGGCAGCATGAGGAATATTTCTGTGATATGAAAGAA ACGATTTGGGAGGCTTTCTCCTTCCCTGAGCCGGTTGATGGTCGTAACAAGGAGATCGGT GCCCTGCTACAGGCATCTGATAGCGCTTCCCTGCACGTTCGTCGCGGTGACTACGTGAAC CACCCACTGTTTCGTGGTATTTGTGACCTGGACTATTATAAACGTGCCATCCACTACATG GAAGAACGCGTCAACCCACAGCTGTACTGCGTTTTCAGCAACGATATGGCCTGGTGCGAG TCCCACCTGCGTGCACTGCTGCCAGGCAAAGAAGTAGTTTATGTTGACTGGAACAAGGGT GCGGAATCTTACGTTGATATGCGTCTGATGAGCCTGTGCCGTCACAACATCATCGCTAAC TCTTCTTTCAGCTGGTGGGGCGCATGGCTGAACCGTAACCCGCAGAAAGTGGTGGTAGCG CCGGAACGTTGGATGAACAGCCCGATTGAAGACCCAGTGAGCGACAAATGGATTAAACTG TAGCTCGAGTGACTGACTG FutV CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGATCATCATCCAGCTGAAAGGTGGC 282 CTGGGCAACCAAATGTTCCAGTACGCGCTGTACAAATCCCTGAAAAAACGTGGTAAAGAA GTTAAAATTGATGACAAAACTGGCTTCGTGAACGACAAACTGCGTATCCCGGTACTGTCC CGTTGGGGTGTTGAGTACGATCGTGCAACCGACGAAGAGATTATTAACCTGACCGACTCC AAAATGGACCTGTTCTCTCGCATCCGCCGTAAACTGACTGGCCGCAAAACGTTCCGTATC GACGAAGAATCCGGTAAATTCAACCCGGAAATCCTGGAAAAAGAGAACGCTTATCTGGTG GGTTATTGGCAGTGCGACAAGTACTTCGACGACAAAGATGTGGTTCGCGAAATTCGTGAA GCGTTCGAGAAAAAACCGCAGGAGCTGATGACCGACGCCAGCTCTTGGTCTACTCTACAG CAGATTGAATGCTGCGAGTCCGTATCCCTGCACGTACGTCGTACTGATTACGTGGACGAG GAACATATTCATATCCATAACATCTGTACGGAAAAATACTATAAAAACGCCATTGATCGT GTGCGTAAACAGTACCCGAGCGCAGTGTTCTTCATCTTCACCGATGATAAAGAATGGTGC CGCGACCACTTTAAAGGTCCGAACTTCATCGTAGTCGAACTGGAAGAAGGCGACGGTACC GACATCGCTGAAATGACTCTGATGTCCCGCTGTAAACATCACATCATCGCTAATTCTAGC TTTAGCTGGTGGGCGGCGTGGCTGAACGACTCCCCGGAAAAAATCGTGATCGCTCCTCAG AAATGGATTAACAACCGCGACATGGACGATATTTACACCGAGCGTATGACTAAAATCGCA CTGTAGCTCGAGTGACTGACTG FutW CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGCGCCTGGTTAAAATGATCGGCGGT 283 CTGGGTAATCAGATGTTCATCTACGCGTTTTACCTACAGATGCGTAAGCGTTTCTCCAAC GTTCGTATCGACCTGACCGATATGATGCACTACAACGTACACTATGGCTACGAACTGCAC AAAGTTTTCGGTCTGCCGCGCACCGAGTTCTGTATGAACCAGCCTCTGAAAAAGGTTCTG GAGTTCCTGTTCTTCCGTACCATTGTTGAACGTAAACAGCACGGTCGTATGGAGCCGTAT ACTTGCCAGTATGTTTGGCCGCTGGTTTACTTTAAGGGCTTCTATCAGTCCGAACGTTAC TTCTCCGAAGTTAAGGACGAAGTTCGTGAGTGTTTCACCTTCAATCCGGCACTGGCGAAT CGTTCTTCCCAACAGATGATGGAACAGATCCAGAATGATCCTCAGGCTGTCTCTATCCAC ATCCGTCGTGGCGACTATCTGAATCCGAAGCACTACGACACTATCGGTTGTATCTGTCAG CTGCCGTATTACAAGCACGCCGTTTCCGAAATTAAAAAGTACGTTTCTAACCCTCACTTT TACGTTTTCTCCGAAGACCTGGATTGGGTCAAAGCAAACCTGCCGCTGGAAAACGCACAG TACATCGATTGGAACAAAGGCGCAGATAGCTGGCAGGATATGATGCTGATGAGCTGTTGC AAACACCACATTATCTGTAACTCCACCTTTAGCTGGTGGGCGGCGTGGCTGAACCCATCT GTCGAAAAAACCGTGATCATGCCGGAACAGTGGACGTCTCGTCAAGATTCCGTGGACTTT GTGGCTAGCTGTGGCCGTTGGGTCCGTGTTAAAACGGAGTAGCTCGAGTGACTGACTG FutX CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGCGTCTGATCAAGATGATCGGCGGC 284 CTGGGTAACCAGATGTTTATCTACGCGTTCTACCTGAAAATGAAACACCATTACCCGGAT ACGAACATCGATCTGTCTGACATGGTTCATTATAAAGTTCACAACGGTTATGAGATGAAC CGTATCTTTGACCTGAGCCAGACTGAATTTTGCATCAACCGTACCCTGAAAAAAATCCTG GAGTTCCTGTTCTTCAAAAAAATCTACGAACGTCGCCAGGACCCGTCTACTCTGTATCCA TACGAAAAACGTTATTTTTGGCCGCTGCTGTACTTTAAAGGTTTCTACCAGTCTGAACGC TTCTTCTTCGATATCAAAGACGACGTTCGTAAAGCCTTCTCTTTTAACCTGAACATCGCT AACCCGGAAAGCCTGGAACTGCTGAAACAGATCGAAGTTGACGACCAAGCTGTTTCTATC CACATCCGCCGTGGTGACTACCTGCTGCCGCGTCACTGGGCAAACACGGGTTCCGTGTGC CAGCTGCCGTATTACAAGAACGCGATCGCGGAAATGGAGAACCGTATTACTGGCCCGAGC TACTACGTGTTCTCTGATGATATCTCTTGGGTTAAAGAAAACATCCCGCTGAAGAAAGCG GTCTACGTGACGTGGAACAAGGGCGAAGACAGCTGGCAGGATATGATGCTGATGAGCCAC TGTCGTCACCACATTATCTGTAATTCTACGTTCTCCTGGTGGGGTGCTTGGCTGAACCCA CGTAAAGAGAAAATCGTCATCGCGCCGTGTCGCTGGTTCCAGCATAAAGAAACCCCGGAC ATGTACCCGAAAGAATGGATCAAAGTACCGATTAACTAGCTCGAGTGACTGACTG FutZ CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGTATTCTTGCCTGTCTGGTGGCCTG 285 GGTAACCAAATGTTTCAATACGCAGCAGCGTATATCCTGAAGCAGTATTTTCAGTCTACC ACTCTGGTCCTGGATGATAGCTATTACTATTCCCAGCCGAAACGTGATACCGTTCGTAGC CTGGAACTGAATCAGTTCAACATCTCTTATGATCGTTTTAGCTTCGCGGATGAAAAAGAG AAGATCAAACTGCTGCGCAAATTCAAACGTAACCCGTTCCCTAAACAGATTTCCGAGATC CTGTCTATTGCGCTGTTCGGCAAATACGCGCTGTCCGACCGTGCATTTTACACCTTCGAA ACTATCAAAAACATCGACAAAGCGTGCCTGTTCTCCTTTTACCAGGACGCCGATCTGCTG AATAAATATAAGCAGCTGATCCTGCCGCTGTTCGAACTGCGCGATGACCTGCTGGATATC TGCAAGAACCTGGAACTGTATTCCCTGATCCAACGCAGCAACAATACCACTGCACTGCAT ATCCGCCGTGGCGACTACGTGACCAACCAGCACGCCGCGAAATACCACGGCGTGCTGGAC ATCAGCTACTATAACCACGCAATGGAATACGTGGAACGTGAACGCGGCAAACAGAACTTC ATTATCTTCAGCGATGATGTACGTTGGGCACAGAAAGCGTTTCTGGAGAACGATAATTGC TACGTGATTAACAACTCCGACTACGATTTCTCTGCGATCGATATGTATCTGATGTCTCTG TGCAAAAACAACATCATCGCAAATTCCACCTACTCCTGGTGGGGTGCGTGGCTGAACAAA TACGAGGACAAACTGGTTATCTCTCCGAAACAATGGTTTCTGGGTAACAACGAAACCTCT CTGCGTAACGCGTCTTGGATCACCCTGTAGCTCGAGTGACTGACTG FutZA CAGTCAGTCAGAATTCAAGAAGGAGATATACATATGCGTCTGATCAAGATGACCGGTGGC 286 CTGGGTAACCAGATGTTCATCTACGCGTTTTATCTGCGTATGAAAAAACGTTATCCGAAA GTTCGTATTGATCTGTCTGATATGGTTCATTATCACGTTCACCACGGCTATGAAATGCAC CGTGTTTTCAATCTGCCGCACACCGAATTTTGCATCAACCAGCCGCTGAAAAAAGTGATC GAGTTCCTGTTTTTCAAAAAGATTTACGAACGTAAACAGGACCCTAATTCTCTGCGTGCA TTCGAGAAGAAGTATCTGTGGCCGCTGCTGTACTTCAAAGGTTTCTATCAATCTGAGCGC TTCTTTGCTGACATCAAAGACGAGGTTCGTAAAGCATTCACCTTTGACTCTTCTAAAGTG AACGCTCGCTCTGCCGAACTGCTGCGTCGCCTGGATGCCGATGCTAACGCGGTTAGCCTG CACATTCGTCGCGGTGACTATCTACAGCCGCAGCATTGGGCTACCACTGGTTCTGTCTGC CAGCTGCCGTACTACCAGAACGCGATCGCTGAAATGAACCGTCGCGTTGCTGCCCCGAGC TACTACGTTTTCAGCGATGACATCGCGTGGGTGAAGGAAAACATCCCTCTACAGAACGCA GTGTACATCGACTGGAATAAAGGCGAAGAAAGCTGGCAGGATATGATGCTGATGAGCCAC TGCCGCCACCACATTATCTGTAACAGCACCTTCTCTTGGTGGGGCGCGTGGCTGGACCCG CACGAGGACAAAATTGTAATCGTTCCGAATCGTTGGTTCCAGCATTGCGAAACTCCTAAC ATCTATCCGGCAGGCTGGGTGAAAGTTGCGATTAATTAGCTCGAGTGACTGACTG

In any of the methods described herein, the α(1,2) fucosyltransferase genes or gene products may be variants or functional fragments thereof. A variant of any of genes or gene products disclosed herein may have 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleic acid or amino acid sequences described herein.

Variants as disclosed herein also include homolog, orthologs, or paralogs of the genes or gene products described herein that retain the same biological function as the genes or gene products specified herein. These variants can be used interchangeably with the genes recited in these methods. Such variants may demonstrate a percentage of homology or identity, for example, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity conserved domains important for biological function, preferably in a functional domain, e.g. catalytic domain.

The term “% identity,” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. For example, % identity is relative to the entire length of the coding regions of the sequences being compared, or the length of a particular fragment or functional domain thereof.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Percent identity is determined using search algorithms such as BLAST and PSI-BLAST (Altschul et al., 1990, J Mol Biol 215:3, 403-410; Altschul et al., 1997, Nucleic Acids Res 25:17, 3389-402). For the PSI-BLAST search, the following exemplary parameters are employed: (1) Expect threshold was 10; (2) Gap cost was Existence:11 and Extension:1; (3) The Matrix employed was BLOSUM62; (4) The filter for low complexity regions was “on”.

Changes can be introduced by mutation into the nucleic acid sequence or amino acid sequence of any of the genes or gene products described herein, leading to changes in the amino acid sequence of the encoded protein or enzyme, without altering the functional ability of the protein or enzyme. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of any of sequences expressly disclosed herein. A “non-essential” amino acid residue is a residue at a position in the sequence that can be altered from the wild-type sequence of the polypeptide without altering the biological activity, whereas an “essential” amino acid residue is a residue at a position that is required for biological activity. For example, amino acid residues that are conserved among members of a family of proteins are not likely to be amenable to mutation. Other amino acid residues, however, (e.g., those that are poorly conserved among members of the protein family) may not be as essential for activity and thus are more likely to be amenable to alteration. Thus, another aspect of the invention pertains to nucleic acid molecules encoding the proteins or enzymes disclosed herein that contain changes in amino acid residues relative to the amino acid sequences disclosed herein that are not essential for activity (i.e., fucosyltransferase activity).

An isolated nucleic acid molecule encoding a protein essentially retaining the functional capability compared to any of the genes described herein can be created by introducing one or more nucleotide substitutions, additions or deletions into the corresponding nucleotide sequence, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into a nucleic acid sequence by standard techniques such that the encoded amino acid sequence is altered, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. Certain amino acids have side chains with more than one classifiable characteristic. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, tryptophan, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tyrosine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a given polypeptide is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a given coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for given polypeptide biological activity to identify mutants that retain activity. Conversely, the invention also provides for variants with mutations that enhance or increase the endogenous biological activity. Following mutagenesis of the nucleic acid sequence, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined. An increase, decrease, or elimination of a given biological activity of the variants disclosed herein can be readily measured by the ordinary person skilled in the art, i.e., by measuring the capability for mediating oligosaccharide modification, synthesis, or degradation (via detection of the products).

The present invention also provides for functional fragments of the genes or gene products described herein. A fragment, in the case of these sequences and all others provided herein, is defined as a part of the whole that is less than the whole. Moreover, a fragment ranges in size from a single nucleotide or amino acid within a polynucleotide or polypeptide sequence to one fewer nucleotide or amino acid than the entire polynucleotide or polypeptide sequence. Finally, a fragment is defined as any portion of a complete polynucleotide or polypeptide sequence that is intermediate between the extremes defined above.

For example, fragments of any of the proteins or enzymes disclosed herein or encoded by any of the genes disclosed herein can be 10 to 20 amino acids, 10 to 30 amino acids, 10 to 40 amino acids, 10 to 50 amino acids, 10 to 60 amino acids, 10 to 70 amino acids, 10 to 80 amino acids, 10 to 90 amino acids, 10 to 100 amino acids, 50 to 100 amino acids, 75 to 125 amino acids, 100 to 150 amino acids, 150 to 200 amino acids, 200 to 250 amino acids, 250 to 300 amino acids, 300 to 350 amino acids, 350 to 400 amino acids, 400 to 450 amino acids, or 450 to 500 amino acids. The fragments encompassed in the present invention comprise fragments that retain functional fragments. As such, the fragments preferably retain the catalytic domains that are required or are important for functional activity. Fragments can be determined or generated by using the sequence information herein, and the fragments can be tested for functional activity using standard methods known in the art. For example, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined. The biological function of said fragment can be measured by measuring ability to synthesize or modify a substrate oligosaccharide, or conversely, to catabolize an oligosaccharide substrate.

Within the context of the invention, “functionally equivalent”, as used herein, refers to a gene or the resulting encoded protein variant or fragment thereof capable of exhibiting a substantially similar activity as the wild-type fucosyltransferase. Specifically, the fucosyltransferase activity refers to the ability to transfer a fucose sugar to an acceptor substrate via an alpha-(1,2)-linkage. As used herein, “substantially similar activity” refers to an activity level within 5%, 10%, 20%, 30%, 40%, or 50% of the wild-type fucosyltransferase.

To test for lactose-utilizing fucosylatransferase activity, the production of fucosylated oligossacharides (i.e., 2′-FL) is evaluated in a host organism that expresses the candidate enzyme (or syngene) and which contains both cytoplasmic GDP-fucose and lactose pools. The production of fucosylated oligosaccharides indicates that the candidate enzyme-encoding sequence functions as a lactose-utilizing α(1,2)fucosyltransferase.

Engineering of E. coli to Produce Human Milk Oligosaccharide 2′-FL

Described herein is a gene screening approach, which was used to validate the novel α (1,2) fucosyltransferases (a (1,2) FTs) for the synthesis of fucosyl-linked oligosaccharides in metabolically engineered E. coli. Of particular interest are a (1,2) FTs that are capable of the synthesis of the HMOS 2′-fucosyllactose (2′-FL). 2′-FL is the most abundant fucosylated oligosaccharide present in human milk, and this oligosaccharide provides protection to newborn infants against infectious diarrhea caused by bacterial pathogens such as Campylobacter jejuni (Ruiz-Palacios, G. M., et al. (2003). J Biol Chem 278, 14112-120; Morrow, A. L. et al. (2004). J Pediatr 145, 297-303; Newburg, D. S. et al. (2004). Glycobiology 14, 253-263). Other a (1,2) FTs of interest are those capable of synthesis of HMOS lactodifucotetraose (LDFT), laco-N-fucopentaose I (LNFI), or lacto-N-difucohexaose I (LDFH I).

The synthetic pathway of fucosyl oligosaccharides of human milk is illustrated in FIG. 1. Structurally, 2′-FL consists of a fucose molecule a 1,2 linked to the galactose portion of lactose (Fucα1-2Galβ1-4G1c). An α (1,2) FT from H. pylori strain 26695 termed FutC has been utilized to catalyze the synthesis of 2′-FL in metabolically engineered E. coli (Drouillard, S. et al. (2006). Angew Chem Int Ed Engl 45, 1778-780).

Candidate α(1,2) FTs (i.e., syngenes) were cloned by standard molecular biological techniques into an expression plasmid. This plasmid utilizes the strong leftwards promoter of bacteriophage λ (termed P_(L)) to direct expression of the candidate genes (Sanger, F. et al. (1982). J Mol Biol 162, 729-773). The promoter is controllable, e.g., a trp-cI construct is stably integrated the into the E. coli host's genome (at the ampC locus), and control is implemented by adding tryptophan to the growth media. Gradual induction of protein expression is accomplished using a temperature sensitive cI repressor. Another similar control strategy (temperature independent expression system) has been described (Mieschendahl et al., 1986, Bio/Technology 4:802-808). The plasmid also carries the E. coli rcsA gene to up-regulate GDP-fucose synthesis, a critical precursor for the synthesis of fucosyl-linked oligosaccharides. In addition, the plasmid carries a β-lactamase (bla) gene for maintaining the plasmid in host strains by ampicillin selection (for convenience in the laboratory) and a native thyA (thymidylate synthase) gene as an alternative means of selection in thyA⁻ hosts. Alternative selectable markers include the proBA genes to complement proline auxotrophy (Stein et al., (1984), J Bacteriol 158:2, 696-700 (1984) or purA to complement adenine auxotrophy (S. A. Wolfe, J. M. Smith, J Biol Chem 263, 19147-53 (1988)). To act as plasmid selectable markers each of these genes are first inactivated in the host cell chromosome, then wild type copies of the genes are provided on the plasmid. Alternatively a drug resistance gene may be used on the plasmid, e.g. beta-lactamase (this gene is already on the expression plasmid described above, thereby permitting selection with ampicillin). Ampicillin selection is well known in the art and described in standard manuals such as Maniatis et al., (1982) Molecular cloning, a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring, N.Y.

The nucleic acid sequence of such an expression plasmid, pEC2-(T7)FutX-rcsA-thyA (pG401) is provided below. The underlined sequence represents the FutX syngene, which can be readily replaced with any of the novel α(1,2) FTs described herein using standard recombinant DNA techniques.

(SEQ ID NO: 287) TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGT CTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGG CTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACC GCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCCTCCTCAACCTGTATATTCGTAAACCACGCC CAATGGGAGCTGTCTCAGGTTTGTTCCTGATTGGTTACGGCGCGTTTCGCATCATTGTTGAGTTTTTC CGCCAGCCCGACGCGCAGTTTACCGGTGCCTGGGTGCAGTACATCAGCATGGGGCAAATTCTTTCCAT CCCGATGATTGTCGCGGGTGTGATCATGATGGTCTGGGCATATCGTCGCAGCCCACAGCAACACGTTT CCTGAGGAACCATGAAACAGTATTTAGAACTGATGCAAAAAGTGCTCGACGAAGGCACACAGAAAAAC GACCGTACCGGAACCGGAACGCTTTCCATTTTTGGTCATCAGATGCGTTTTAACCTGCAAGATGGATT CCCGCTGGTGACAACTAAACGTTGCCACCTGCGTTCCATCATCCATGAACTGCTGTGGTTTCTGCAGG GCGACACTAACATTGCTTATCTACACGAAAACAATGTCACCATCTGGGACGAATGGGCCGATGAAAAC GGCGACCTCGGGCCAGTGTATGGTAAACAGTGGCGCGCCTGGCCAACGCCAGATGGTCGTCATATTGA CCAGATCACTACGGTACTGAACCAGCTGAAAAACGACCCGGATTCGCGCCGCATTATTGTTTCAGCGT GGAACGTAGGCGAACTGGATAAAATGGCGCTGGCACCGTGCCATGCATTCTTCCAGTTCTATGTGGCA GACGGCAAACTCTCTTGCCAGCTTTATCAGCGCTCCTGTGACGTCTTCCTCGGCCTGCCGTTCAACAT TGCCAGCTACGCGTTATTGGTGCATATGATGGCGCAGCAGTGCGATCTGGAAGTGGGTGATTTTGTCT GGACCGGTGGCGACACGCATCTGTACAGCAACCATATGGATCAAACTCATCTGCAATTAAGCCGCGAA CCGCGTCCGCTGCCGAAGTTGATTATCAAACGTAAACCCGAATCCATCTTCGACTACCGTTTCGAAGA CTTTGAGATTGAAGGCTACGATCCGCATCCGGGCATTAAAGCGCCGGTGGCTATCTAATTACGAAACA TCCTGCCAGAGCCGACGCCAGTGTGCGTCGGTTTTTTTACCCTCCGTTAAATTCTTCGAGACGCCTTC CCGAAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGC TATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCC CAGTCACGACGTTGTAAAACGACGGCCAGTGCCAAGCTTTCTTTAATGAAGCAGGGCATCAGGACGGT ATCTTTGTGGAGAAAGCAGAGTAATCTTATTCAGCCTGACTGGTGGGAAACCACCAGTCAGAATGTGT TAGCGCATGTTGACAAAAATACCATTAGTCACATTATCCGTCAGTCGGACGACATGGTAGATAACCTG TTTATTATGCGTTTTGATCTTACGTTTAATATTACCTTTATGCGATGAAACGGTCTTGGCTTTGATAT TCATTTGGTCAGAGATTTGAATGGTTCCCTGACCTGCCATCCACATTCGCAACATACTCGATTCGGTT CGGCTCAATGATAACGTCGGCATATTTAAAAACGAGGTTATCGTTGTCTCTTTTTTCAGAATATCGCC AAGGATATCGTCGAGAGATTCCGGTTTAATCGATTTAGAACTGATCAATAAATTTTTTCTGACCAATA GATATTCATCAAAATGAACATTGGCAATTGCCATAAAAACGATAAATAACGTATTGGGATGTTGATTA ATGATGAGCTTGATACGCTGACTGTTAGAAGCATCGTGGATGAAACAGTCCTCATTAATAAACACCAC TGAAGGGCGCTGTGAATCACAAGCTATGGCAAGGTCATCAACGGTTTCAATGTCGTTGATTTCTCTTT TTTTAACCCCTCTACTCAACAGATACCCGGTTAAACCTAGTCGGGTGTAACTACATAAATCCATAATA ATCGTTGACATGGCATACCCTCACTCAATGCGTAACGATAATTCCCCTTACCTGAATATTTCATCATG ACTAAACGGAACAACATGGGTCACCTAATGCGCCACTCTCGCGATTTTTCAGGCGGACTTACTATCCC GTAAAGTGTTGTATAATTTGCCTGGAATTGTCTTAAAGTAAAGTAAATGTTGCGATATGTGAGTGAGC TTAAAACAAATATTTCGCTGCAGGAGTATCCTGGAAGATGTTCGTAGAAGCTTACTGCTCACAAGAAA AAAGGCACGTCATCTGACGTGCCTTTTTTATTTGTACTACCCTGTACGATTACTGCAGCTCGAGCTAG TTAATCGGTACTTTGATCCATTCTTTCGGGTACATGTCCGGGGTTTCTTTATGCTGGAACCAGCGACA CGGCGCGATGACGATTTTCTCTTTACGTGGGTTCAGCCAAGCACCCCACCAGGAGAACGTAGAATTAC AGATAATGTGGTGACGACAGTGGCTCATCAGCATCATATCCTGCCAGCTGTCTTCGCCCTTGTTCCAC GTCACGTAGACCGCTTTCTTCAGCGGGATGTTTTCTTTAACCCAAGAGATATCATCAGAGAACACGTA GTAGCTCGGGCCAGTAATACGGTTCTCCATTTCCGCGATCGCGTTCTTGTAATACGGCAGCTGGCACA CGGAACCCGTGTTTGCCCAGTGACGCGGCAGCAGGTAGTCACCACGGCGGATGTGGATAGAAACAGCT TGGTCGTCAACTTCGATCTGTTTCAGCAGTTCCAGGCTTTCCGGGTTAGCGATGTTCAGGTTAAAAGA GAAGGCTTTACGAACGTCGTCTTTGATATCGAAGAAGAAGCGTTCAGACTGGTAGAAACCTTTAAAGT ACAGCAGCGGCCAAAAATAACGTTTTTCGTATGGATACAGAGTAGACGGGTCCTGGCGACGTTCGTAG ATTTTTTTGAAGAACAGGAACTCCAGGATTTTTTTCAGGGTACGGTTGATGCAAAATTCAGTCTGGCT CAGGTCAAAGATACGGTTCATCTCATAACCGTTGTGAACTTTATAATGAACCATGTCAGACAGATCGA TGTTCGTATCCGGGTAATGGTGTTTCATTTTCAGGTAGAACGCGTAGATAAACATCTGGTTACCCAGG CCGCCGATCATCTTGATCAGACGCATATGTATATCTCCTTCTTGAATTCTAAAAATTGATTGAATGTA TGCAAATAAATGCATACACCATAGGTGTGGTTTAATTTGATGCCCTTTTTCAGGGCTGGAATGTGTAA GAGCGGGGTTATTTATGCTGTTGTTTTTTTGTTACTCGGGAAGGGCTTTACCTCTTCCGCATAAACGC TTCCATCAGCGTTTATAGTTAAAAAAATCTTTCGGAACTGGTTTTGCGCTTACCCCAACCAACAGGGG ATTTGCTGCTTTCCATTGAGCCTGTTTCTCTGCGCGACGTTCGCGGCGGCGTGTTTGTGCATCCATCT GGATTCTCCTGTCAGTTAGCTTTGGTGGTGTGTGGCAGTTGTAGTCCTGAACGAAAACCCCCCGCGAT TGGCACATTGGCAGCTAATCCGGAATCGCACTTACGGCCAATGCTTCGTTTCGTATCACACACCCCAA AGCCTTCTGCTTTGAATGCTGCCCTTCTTCAGGGCTTAATTTTTAAGAGCGTCACCTTCATGGTGGTC AGTGCGTCCTGCTGATGTGCTCAGTATCACCGCCAGTGGTATTTATGTCAACACCGCCAGAGATAATT TATCACCGCAGATGGTTATCTGTATGTTTTTTATATGAATTTATTTTTTGCAGGGGGGCATTGTTTGG TAGGTGAGAGATCAATTCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGG CGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGC TCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAA AAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCC CCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATA CCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACC TGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCG GTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTT ATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTG GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTAC GGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGT TGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGA TTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGG AACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT AAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAAT GCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCC GTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTG GTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCG CCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGG TATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAA AAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATG GTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGA GTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATAC GGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGA AAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATC TTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAA AGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATT TATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGT TCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCT ATAAAAATAGGCGTATCACGAGGCCCTTTCGTC

The expression constructs were transformed into a host strain useful for the production of 2′-FL. Biosynthesis of 2′-FL requires the generation of an enhanced cellular pool of both lactose and GDP-fucose (FIG. 2). The wild-type Escherichia coli K12 prototrophic strain W3110 was selected as the parent background to test the ability of the candidates to catalyze 2′-FL production (Bachmann, B J (1972). Bacteriol Rev 36, 525-557). The particular W3110 derivative employed was one that previously had been modified by the introduction (at the ampC locus) of a tryptophan-inducible P_(trpB) cI+ repressor cassette, generating an E. coli strain known as GI724 (LaVallie, E. R. et al. (2000). Methods Enzymol 326, 322-340). Other features of GI724 include lacIq and lacPL8 promoter mutations. E. coli strain GI724 affords economical production of recombinant proteins from the phage λ P_(L) promoter following induction with low levels of exogenous tryptophan (LaVallie, E. R. et al. (1993). Biotechnology (N Y) 11, 187-193; Mieschendahl, et al. (1986). Bio/Technology 4, 802-08). Additional genetic alterations were made to this strain to promote the biosynthesis of 2′-FL. This was achieved in strain GI724 through several manipulations of the chromosome using λ Red recombineering (Court, D. L. et al. (2002). Annu Rev Genet 36, 361-388) and generalized P1 phage transduction.

First, the ability of the E. coli host strain to accumulate intracellular lactose was engineered by simultaneous deletion of the endogenous β-galactosidase gene (lacZ) and the lactose operon repressor gene (lad). During construction of this deletion, the lacIq promoter was placed immediately upstream of the lactose permease gene, lacY. The modified strain maintains its ability to transport lactose from the culture medium (via LacY), but is deleted for the wild-type copy of the lacZ (β-galactosidase) gene responsible for lactose catabolism. Therefore, an intracellular lactose pool is created when the modified strain is cultured in the presence of exogenous lactose. A schematic of the P_(lacIq) lacY⁺ chromosomal construct is shown in FIG. 12.

Genomic DNA sequence of the P _(lacIq) lacY⁺ chromosomal construct is set forth below (SEQ ID NO: 288):

CACCATCGAATGGCGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCG GAAGAGAGTCAAGTGTAGGCTGGAGCTGCTTCGAAGTTCCTATACTTTC TAGAGAATAGGAACTTCGGAATAGGAACTTCGGAATAGGAACTAAGGAG GATATTCATATGTACTATTTAAAAAACACAAACTTTTGGATGTTCGGTT TATTCTTTTTCTTTTACTTTTTTATCATGGGAGCCTACTTCCCGTTTTT CCCGATTTGGCTACATGACATCAACCATATCAGCAAAAGTGATACGGGT ATTATTTTTGCCGCTATTTCTCTGTTCTCGCTATTATTCCAACCGCTGT TTGGTCTGCTTTCTGACAAACTCGGGCTGCGCAAATACCTGCTGTGGAT TATTACCGGCATGTTAGTGATGTTTGCGCCGTTCTTTATTTTTATCTTC GGGCCACTGTTACAATACAACATTTTAGTAGGATCGATTGTTGGTGGTA TTTATCTAGGCTTTTGTTTTAACGCCGGTGCGCCAGCAGTAGAGGCATT TATTGAGAAAGTCAGCCGTCGCAGTAATTTCGAATTTGGTCGCGCGCGG ATGTTTGGCTGTGTTGGCTGGGCGCTGTGTGCCTCGATTGTCGGCATCA TGTTCACCATCAATAATCAGTTTGTTTTCTGGCTGGGCTCTGGCTGTGC ACTCATCCTCGCCGTTTTACTCTTTTTCGCCAAAACGGATGCGCCCTCT TCTGCCACGGTTGCCAATGCGGTAGGTGCCAACCATTCGGCATTTAGCC TTAAGCTGGCACTGGAACTGTTCAGACAGCCAAAACTGTGGTTTTTGTC ACTGTATGTTATTGGCGTTTCCTGCACCTACGATGTTTTTGACCAACAG TTTGCTAATTTCTTTACTTCGTTCTTTGCTACCGGTGAACAGGGTACGC GGGTATTTGGCTACGTAACGACAATGGGCGAATTACTTAACGCCTCGAT TATGTTCTTTGCGCCACTGATCATTAATCGCATCGGTGGGAAAAACGCC CTGCTGCTGGCTGGCACTATTATGTCTGTACGTATTATTGGCTCATCGT TCGCCACCTCAGCGCTGGAAGTGGTTATTCTGAAAACGCTGCATATGTT TGAAGTACCGTTCCTGCTGGTGGGCTGCTTTAAATATATTACCAGCCAG TTTGAAGTGCGTTTTTCAGCGACGATTTATCTGGTCTGTTTCTGCTTCT TTAAGCAACTGGCGATGATTTTTATGTCTGTACTGGCGGGCAATATGTA TGAAAGCATCGGTTTCCAGGGCGCTTATCTGGTGCTGGGTCTGGTGGCG CTGGGCTTCACCTTAATTTCCGTGTTCACGCTTAGCGGCCCCGGCCCGC TTTCCCTGCTGCGTCGTCAGGTGAATGAAGTCGCTTAAGCAATCAATGT CGGATGCGGCGCGAGCGCCTTATCCGACCAACATATCATAACGGAGTGA TCGCATTGTAAATTATAAAAATTGCCTGATACGCTGCGCTTATCAGGCC TACAAGTTCAGCGATCTACATTAGCCGCATCCGGCATGAACAAAGCGCA GGAACAAGCGTCGCA

Second, the ability of the host E. coli strain to synthesize colanic acid, an extracellular capsular polysaccharide, was eliminated by the deletion of the wcaJ gene, encoding the UDP-glucose lipid carrier transferase (Stevenson, G. et al. (1996). J Bacteriol 178, 4885-893). In a wcaJ null background GDP-fucose accumulates in the E. coli cytoplasm (Dumon, C. et al. (2001). Glycoconj J 18, 465-474). A schematic of the chromosomal deletion of wcaJ is shown in FIG. 13.

The sequence of the chromosomal region of E. coli bearing the ΔwcaJ::FRT mutation is set forth below (SEQ ID NO: 289):

GTTCGGTTATATCAATGTCAAAAACCTCACGCCGCTCAAGCTGGTGATC AACTCCGGGAACGGCGCAGCGGGTCCGGTGGTGGACGCCATTGAAGCCC GCTTTAAAGCCCTCGGCGCGCCCGTGGAATTAATCAAAGTGCACAACAC GCCGGACGGCAATTTCCCCAACGGTATTCCTAACCCACTACTGCCGGAA TGCCGCGACGACACCCGCAATGCGGTCATCAAACACGGCGCGGATATGG GCATTGCTTTTGATGGCGATTTTGACCGCTGTTTCCTGTTTGACGAAAA AGGGCAGTTTATTGAGGGCTACTACATTGTCGGCCTGTTGGCAGAAGCA TTCCTCGAAAAAAATCCCGGCGCGAAGATCATCCACGATCCACGTCTCT CCTGGAACACCGTTGATGTGGTGACTGCCGCAGGTGGCACGCCGGTAAT GTCGAAAACCGGACACGCCTTTATTAAAGAACGTATGCGCAAGGAAGAC GCCATCTATGGTGGCGAAATGAGCGCCCACCATTACTTCCGTGATTTCG CTTACTGCGACAGCGGCATGATCCCGTGGCTGCTGGTCGCCGAACTGGT GTGCCTGAAAGATAAAACGCTGGGCGAACTGGTACGCGACCGGATGGCG GCGTTTCCGGCAAGCGGTGAGATCAACAGCAAACTGGCGCAACCCGTTG AGGCGATTAACCGCGTGGAACAGCATTTTAGCCGTGAGGCGCTGGCGGT GGATCGCACCGATGGCATCAGCATGACCTTTGCCGACTGGCGCTTTAAC CTGCGCACCTCCAATACCGAACCGGTGGTGCGCCTGAATGTGGAATCGC GCGGTGATGTGCCGCTGATGGAAGCGCGAACGCGAACTCTGCTGACGTT GCTGAACGAGTAATGTCGGATCTTCCCTTACCCCACTGCGGGTAAGGGG CTAATAACAGGAACAACGATGATTCCGGGGATCCGTCGACCTGCAGTTC GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCGAAGCAGCTCCAGCC TACAGTTAACAAAGCGGCATATTGATATGAGCTTACGTGAAAAAACCAT CAGCGGCGCGAAGTGGTCGGCGATTGCCACGGTGATCATCATCGGCCTC GGGCTGGTGCAGATGACCGTGCTGGCGCGGATTATCGACAACCACCAGT TCGGCCTGCTTACCGTGTCGCTGGTGATTATCGCGCTGGCAGATACGCT TTCTGACTTCGGTATCGCTAACTCGATTATTCAGCGAAAAGAAATCAGT CACCTTGAACTCACCACGTTGTACTGGCTGAACGTCGGGCTGGGGATCG TGGTGTGCGTGGCGGTGTTTTTGTTGAGTGATCTCATCGGCGACGTGCT GAATAACCCGGACCTGGCACCGTTGATTAAAACATTATCGCTGGCGTTT GTGGTAATCCCCCACGGGCAACAGTTCCGCGCGTTGATGCAAAAAGAGC TGGAGTTCAACAAAATCGGCATGATCGAAACCAGCGCGGTGCTGGCGGG CTTCACTTGTACGGTGGTTAGCGCCCATTTCTGGCCGCTGGCGATGACC GCGATCCTCGGTTATCTGGTCAATAGTGCGGTGAGAACGCTGCTGTTTG GCTACTTTGGCCGCAAAATTTATCGCCCCGGTCTGCATTTCTCGCTGGC GTCGGTGGCACCGAACTTACGCTTTGGTGCCTGGCTGACGGCGGACAGC ATCATCAACTATCTCAATACCAACCTTTCAACGCTCGTGCTGGCGCGTA TTCTCGGCGCGGGCGTGGCAGGGGGATACAACCTGGCGTACAACGTGGC CGTTGTGCCACCGATGAAGCTGAACCCAATCATCACCCGCGTGTTGTTT CCGGCATTCGCCAAAATTCAGGACGATACCGAAAAGCTGCGTGTTAACT TCTACAAGCTGCTGTCGGTAGTGGGGATTATCAACTTTCCGGCGCTGCT CGGGCTAATGGTGGTGTCGAATAACTTTGTACCGCTGGTCTTTGGTGAG AAGTGGAACAGCATTATTCCGGTGCTGCAATTGCTGTGTGTGGTGGGTC TGCTGCGCTCCG

Third, the magnitude of the cytoplasmic GDP-fucose pool was enhanced by the introduction of a null mutation into the ion gene. Lon is an ATP-dependant intracellular protease that is responsible for degrading RcsA, which is a positive transcriptional regulator of colanic acid biosynthesis in E. coli (Gottesman, S. & Stout, V. Mol Microbiol 5, 1599-1606 (1991)). In a ion null background, RcsA is stabilized, RcsA levels increase, the genes responsible for GDP-fucose synthesis in E. coli are up-regulated, and intracellular GDP-fucose concentrations are enhanced. The lon gene was almost entirely deleted and replaced by an inserted functional, wild-type, but promoter-less E. coli lacZ⁺ gene (Δlon::(kan, lacZ⁺). λ Red recombineering was used to perform the construction. A schematic of the kan, lacZ⁺ insertion into the ion locus is shown in FIG. 14.

Genomic DNA sequence surrounding the lacZ+ insertion into the ion region in the. E. coli strain is set forth below (SEQ ID NO: 290):

GTGGATGGAAGAGGTGGAAAAAGTGGTTATGGAGGAGTGGGTAATTGAT GGTGAAAGGAAAGGGTTGGTGATTTATGGGAAGGGGGAAGGGGAAGAGG GATGTGGTGAATAATTAAGGATTGGGATAGAATTAGTTAAGGAAAAAGG GGGGATTTTATGTGGGGTTTAATTTTTGGTGTATTGTGGGGGTTGAATG TGGGGGAAAGATGGGGATATAGTGAGGTAGATGTTAATAGATGGGGTGA AGGAGAGTGGTGTGATGTGATTAGGTGGGGGAAATTAAAGTAAGAGAGA GGTGTATGATTGGGGGGATGGGTGGAGGTGGAGTTGGAAGTTGGTATTG TGTAGAAAGTATAGGAAGTTGAGAGGGGTTTTGAAGGTGAGGGTGGGGG AAGGAGTGAGGGGGGAAGGGGTGGTAAAGGAAGGGGAAGAGGTAGAAAG GGAGTGGGGAGAAAGGGTGGTGAGGGGGGATGAATGTGAGGTAGTGGGG TATGTGGAGAAGGGAAAAGGGAAGGGGAAAGAGAAAGGAGGTAGGTTGG AGTGGGGTTAGATGGGGATAGGTAGAGTGGGGGGTTTTATGGAGAGGAA GGGAAGGGGAATTGGGAGGTGGGGGGGGGTGTGGTAAGGTTGGGAAGGG GTGGAAAGTAAAGTGGATGGGTTTGTTGGGGGGAAGGATGTGATGGGGG AGGGGATGAAGATGTGATGAAGAGAGAGGATGAGGATGGTTTGGGATGA TTGAAGAAGATGGATTGGAGGGAGGTTGTGGGGGGGGTTGGGTGGAGAG GGTATTGGGGTATGAGTGGGGAGAAGAGAGAATGGGGTGGTGTGATGGG GGGGTGTTGGGGGTGTGAGGGGAGGGGGGGGGGGTTGTTTTTGTGAAGA GGGAGGTGTGGGGTGGGGTGAATGAAGTGGAGGAGGAGGGAGGGGGGGT ATGGTGGGTGGGGAGGAGGGGGGTTGGTTGGGGAGGTGTGGTGGAGGTT GTGAGTGAAGGGGGAAGGGAGTGGGTGGTATTGGGGGAAGTGGGGGGGG AGGATGTGGTGTGATGTGAGGTTGGTGGTGGGGAGAAAGTATGGATGAT GGGTGATGGAATGGGGGGGGTGGATAGGGTTGATGGGGGTAGGTGGGGA TTGGAGGAGGAAGGGAAAGATGGGATGGAGGGAGGAGGTAGTGGGATGG AAGGGGGTGTTGTGGATGAGGATGATGTGGAGGAAGAGGATGAGGGGGT GGGGGGAGGGGAAGTGTTGGGGAGGGTGAAGGGGGGATGGGGGAGGGGG AGGATGTGGTGGTGAGGGATGGGGATGGGTGGTTGGGGAATATGATGGT GGAAAATGGGGGGTTTTGTGGATTGATGGAGTGTGGGGGGGTGGGTGTG GGGGAGGGGTATGAGGAGATAGGGTTGGGTAGGGGTGATATTGGTGAAG AGGTTGGGGGGGAATGGGGTGAGGGGTTGGTGGTGGTTTAGGGTATGGG GGGTGGGGATTGGGAGGGGATGGGGTTGTATGGGGTTGTTGAGGAGTTG TTGTAATAAGGGGATGTTGAAGTTGGTATTGGGAAGTTGGTATTGTGTA GAAAGTATAGGAAGTTGGAAGGAGGTGGAGGGTAGATAAAGGGGGGGGT TATTTTTGAGAGGAGAGGAAGTGGTAATGGTAGGGAGGGGGGGTGAGGT GGAATTGGGGGGATAGTGAGGGGGTGGAGGAGTGGTGGGGAGGAATGGG GATATGGAAAGGGTGGATATTGAGGGATGTGGGTTGTTGGGGGTGGAGG AGATGGGGATGGGTGGTTTGGATGAGTTGGTGTTGAGTGTAGGGGGTGA TGTTGAAGTGGAAGTGGGGGGGGGAGTGGTGTGGGGGATAATTGAATTG GGGGGTGGGGGAGGGGAGAGGGTTTTGGGTGGGGAAGAGGTAGGGGGTA TAGATGTTGAGAATGGGAGATGGGAGGGGTGAAAAGAGGGGGGAGTAAG GGGGTGGGGATAGTTTTGTTGGGGGGGTAATGGGAGGGAGTTTAGGGGG TGTGGTAGGTGGGGGAGGTGGGAGTTGAGGGGAATGGGGGGGGGATGGG GTGTATGGGTGGGGAGTTGAAGATGAAGGGTAATGGGGATTTGAGGAGT AGGATGAATGGGGTAGGTTTTGGGGGTGATAAATAAGGTTTTGGGGTGA TGGTGGGAGGGGTGAGGGGTGGTAATGAGGAGGGGATGAGGAAGTGTAT GTGGGGTGGAGTGGAAGAAGGGTGGTTGGGGGTGGTAATGGGGGGGGGG GTTGGAGGGTTGGAGGGAGGGGTTAGGGTGAATGGGGGTGGGTTGAGTT AGGGGAATGTGGTTATGGAGGGGTGGAGGGGTGAAGTGATGGGGGAGGG GGGTGAGGAGTTGTTTTTTATGGGGAATGGAGATGTGTGAAAGAAAGGG TGAGTGGGGGTTAAATTGGGAAGGGTTATTAGGGAGGTGGATGGAAAAA TGGATTTGGGTGGTGGTGAGATGGGGGATGGGGTGGGAGGGGGGGGGGA GGGTGAGAGTGAGGTTTTGGGGGAGAGGGGAGTGGTGGGAGGGGGTGAT GTGGGGGGGTTGTGAGGATGGGGTGGGGTTGGGTTGGAGTAGGGGTAGT GTGAGGGAGAGTTGGGGGGGGGTGTGGGGGTGGGGTAGTTGAGGGAGTT GAATGAAGTGTTTAGGTTGTGGAGGGAGATGGAGAGGGAGTTGAGGGGT TGGGAGGGGGTTAGGATGGAGGGGGAGGATGGAGTGGAGGAGGTGGTTA TGGGTATGAGGGAAGAGGTATTGGGTGGTGAGTTGGATGGTTTGGGGGG ATAAAGGGAAGTGGAAAAAGTGGTGGTGGTGTTTTGGTTGGGTGAGGGG TGGATGGGGGGTGGGGTGGGGAAAGAGGAGAGGGTTGATAGAGAAGTGG GGATGGTTGGGGGTATGGGGAAAATGAGGGGGGTAAGGGGAGGAGGGGT TGGGGTTTTGATGATATTTAATGAGGGAGTGATGGAGGGAGTGGGAGAG GAAGGGGGGGTGTAAAGGGGGATAGTGAGGAAAGGGGTGGGAGTATTTA GGGAAAGGGGGAAGAGTGTTAGGGATGGGGTGGGGGTATTGGGAAAGGA TGAGGGGGGGGGTGTGTGGAGGTAGGGAAAGGGATTTTTTGATGGAGGA TTTGGGGAGAGGGGGGAAGGGGTGGTGTTGATGGAGGGGGGGGTAGATG GGGGAAATAATATGGGTGGGGGTGGTGTGGGGTGGGGGGGGTTGATAGT GGAGGGGGGGGGAAGGATGGAGAGATTTGATGGAGGGATAGAGGGGGTG GTGATTAGGGGGGTGGGGTGATTGATTGGGGAGGGAGGAGATGATGAGA GTGGGGTGATTAGGATGGGGGTGGAGGATTGGGGTTAGGGGTTGGGTGA TGGGGGGTAGGGAGGGGGGATGATGGGTGAGAGGATTGATTGGGAGGAT GGGGTGGGTTTGAATATTGGGTTGATGGAGGAGATAGAGGGGGTAGGGG TGGGAGAGGGTGTAGGAGAGGGGATGGTTGGGATAATGGGAAGAGGGGA GGGGGTTAAAGTTGTTGTGGTTGATGAGGAGGATATGGTGGAGGATGGT GTGGTGATGGATGAGGTGAGGATGGAGAGGATGATGGTGGTGAGGGTTA AGGGGTGGAATGAGGAAGGGGTTGGGGTTGAGGAGGAGGAGAGGATTTT GAATGGGGAGGTGGGGGAAAGGGAGATGGGAGGGTTGTGGTTGAATGAG GGTGGGGTGGGGGGTGTGGAGTTGAAGGAGGGGAGGATAGAGATTGGGG ATTTGGGGGGTGGAGAGTTTGGGGTTTTGGAGGTTGAGAGGTAGTGTGA GGGGATGGGGATAAGGAGGAGGGTGATGGATAATTTGAGGGGGGAAAGG GGGGGTGGGGGTGGGGAGGTGGGTTTGAGGGTGGGATAAAGAAAGTGTT AGGGGTAGGTAGTGAGGGAAGTGGGGGGAGATGTGAAGTTGAGGGTGGA GTAGAGGGGGGGTGAAATGATGATTAAAGGGAGTGGGAAGATGGAAATG GGTGATTTGTGTAGTGGGTTTATGGAGGAAGGAGAGGTGAGGGAAAATG GGGGTGATGGGGGAGATATGGTGATGTTGGAGATAAGTGGGGTGAGTGG AGGGGAGGAGGATGAGGGGGAGGGGGTTTTGTGGGGGGGGTAAAAATGG GGTGAGGTGAAATTGAGAGGGGAAAGGAGTGTGGTGGGGGTAAGGGAGG GAGGGGGGGTTGGAGGAGAGATGAAAGGGGGAGTTAAGGGGATGAAAAA TAATTGGGGTGTGGGGTTGGTGTAGGGAGGTTTGATGAAGATTAAATGT GAGGGAGTAAGAAGGGGTGGGATTGTGGGTGGGAAGAAAGGGGGGATTG AGGGTAATGGGATAGGTGAGGTTGGTGTAGATGGGGGGATGGTAAGGGT GGATGTGGGAGTTTGAGGGGAGGAGGAGAGTATGGGGGTGAGGAAGATG GGAGGGAGGGAGGTTTGGGGGAGGGGTTGTGGTGGGGGAAAGGAGGGAA AGGGGGATTGGGGATTGAGGGTGGGGAAGTGTTGGGAAGGGGGATGGGT GGGGGGGTGTTGGGTATTAGGGGAGGTGGGGAAAGGGGGATGTGGTGGA AGGGGATTAAGTTGGGTAAGGGGAGGGTTTTGGGAGTGAGGAGGTTGTA AAAGGAGGGGGAGTGAATGGGTAATGATGGTGATAGTAGGTTTGGTGAG GTTGTGAGTGGAAAATAGTGAGGTGGGGGAAAATGGAGTAATAAAAAGA GGGGTGGGAGGGTAATTGGGGGTTGGGAGGGTTTTTTTGTGTGGGTAAG TTAGATGGGGGATGGGGGTTGGGGTTATTAAGGGGTGTTGTAAGGGGAT GGGTGGGGTGATATAAGTGGTGGGGGTTGGTAGGTTGAAGGATTGAAGT GGGATATAAATTATAAAGAGGAAGAGAAGAGTGAATAAATGTGAATTGA TGGAGAAGATTGGTGGAGGGGGTGATATGTGTAAAGGTGGGGGTGGGGG TGGGTTAGATGGTATTATTGGTTGGGTAAGTGAATGTGTGAAAGAAGG

Fourth, a thyA (thymidylate synthase) mutation was introduced into the strain by P1 transduction. In the absence of exogenous thymidine, thyA strains are unable to make DNA and die. The defect can be complemented in trans by supplying a wild-type thyA gene on a multicopy plasmid (Belfort, M., Maley, G. F., and Maley, F. (1983). Proc Natl Acad Sci USA 80, 1858-861), This complementation was used here as a means of plasmid maintenance.

An additional modification that is useful for increasing the cytoplasmic pool of free lactose (and hence the final yield of 2′-FL) is the incorporation of a lacA mutation. LacA is a lactose acetyltransferase that is only active when high levels of lactose accumulate in the E. coli cytoplasm. High intracellular osmolarity (e.g., caused by a high intracellular lactose pool) can inhibit bacterial growth, and E. coli has evolved a mechanism for protecting itself from high intra cellular osmlarity caused by lactose by “tagging” excess intracellular lactose with an acetyl group using LacA, and then actively expelling the acetyl-lactose from the cell (Danchin, A. Bioessays 31, 769-773 (2009)). Production of acetyl-lactose in E. coli engineered to produce 2′-FL or other human milk oligosaccharides is therefore undesirable: it reduces overall yield. Moreover, acetyl-lactose is a side product that complicates oligosaccharide purification schemes. The incorporation of a lacA mutation resolves these problems. Sub-optimal production of fucosylated oligosaccharides occurs in strains lacking either or both of the mutations in the colanic acid pathway and the lon protease. Diversion of lactose into a side product (acetyl-lactose) occurs in strains that do not contain the lacA mutation. A schematic of the lacA deletion and corresponding genomic sequence is provided above (SEQ ID NO: 288).

The strain used to test the different α(1,2) FT candidates incorporates all the above genetic modifications and has the following genotype: ΔampC::P_(trp) ^(B) cI, A(lacI-lacZ)::FRT, P_(lacIq)lacY⁺, ΔwcaJ::FRT, thyA::Tn10, Δlon:(npt3, lacZ⁺), ΔlacA

The E. coli strains harboring the different α(1,2) FT candidate expression plasmids were analyzed. Strains were grown in selective media (lacking thymidine) to early exponential phase. Lactose was then added to a final concentration of 0.5%, and tryptophan (200 μM) was added to induce expression of each candidate α(1,2) FT from the P_(L) promoter. At the end of the induction period (˜24 h) equivalent OD 600 units of each strain and the culture supernatant was harvested. Lysates were prepared and analyzed for the presence of 2′-FL by thin layer chromatography (TLC).

A map of plasmid pG217 is shown in FIG. 11, which carries the B. vulgatus FutN. The sequence of plasmid pG217 is set forth below (SEQ ID NO: 291):

TCTAGAATTCTAAAAATTGATTGAATGTATGCAAATAAATGCATACAC CATAGGTGTGGTTTAATTTGATGCCCTTTTTCAGGGCTGGAATGTGTA AGAGCGGGGTTATTTATGCTGTTGTTTTTTTGTTACTCGGGAAGGGCT TTACCTCTTCCGCATAAACGCTTCCATCAGCGTTTATAGTTAAAAAAA TCTTTCGGAACTGGTTTTGCGCTTACCCCAACCAACAGGGGATTTGCT GCTTTCCATTGAGCCTGTTTCTCTGCGCGACGTTCGCGGCGGCGTGTT TGTGCATCCATCTGGATTCTCCTGTCAGTTAGCTTTGGTGGTGTGTGG CAGTTGTAGTCCTGAACGAAAACCCCCCGCGATTGGCACATTGGCAGC TAATCCGGAATCGCACTTACGGCCAATGCTTCGTTTCGTATCACACAC CCCAAAGCCTTCTGCTTTGAATGCTGCCCTTCTTCAGGGCTTAATTTT TAAGAGCGTCACCTTCATGGTGGTCAGTGCGTCCTGCTGATGTGCTCA GTATCACCGCCAGTGGTATTTATGTCAACACCGCCAGAGATAATTTAT CACCGCAGATGGTTATCTGTATGTTTTTTATATGAATTTATTTTTTGC AGGGGGGCATTGTTTGGTAGGTGAGAGATCAATTCTGCATTAATGAAT CGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGC TTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGC GGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGG GGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAG GAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCC CCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAA CCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCT CGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGC CTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAG GTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCA CGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCG TCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGA GTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATT TGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG TAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTT TGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTC ACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTA GATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATA TGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC TATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCC CGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAG TGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATC AGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGC AACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAG AGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGC TACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAG CTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTG CAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAA GTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTC TCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTA CTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTC TTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTT AAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAG GATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACC CAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGC AAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACG GAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCAT TTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTA GAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCC ACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAA TAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGG TGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCT GTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGG TGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGAT TGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGC GTAAGGAGAAAATACCGCATCAGGCGCCTCCTCAACCTGTATATTCGT AAACCACGCCCAATGGGAGCTGTCTCAGGTTTGTTCCTGATTGGTTAC GGCGCGTTTCGCATCATTGTTGAGTTTTTCCGCCAGCCCGACGCGCAG TTTACCGGTGCCTGGGTGCAGTACATCAGCATGGGGCAAATTCTTTCC ATCCCGATGATTGTCGCGGGTGTGATCATGATGGTCTGGGCATATCGT CGCAGCCCACAGCAACACGTTTCCTGAGGAACCATGAAACAGTATTTA GAACTGATGCAAAAAGTGCTCGACGAAGGCACACAGAAAAACGACCGT ACCGGAACCGGAACGCTTTCCATTTTTGGTCATCAGATGCGTTTTAAC CTGCAAGATGGATTCCCGCTGGTGACAACTAAACGTTGCCACCTGCGT TCCATCATCCATGAACTGCTGTGGTTTCTGCAGGGCGACACTAACATT GCTTATCTACACGAAAACAATGTCACCATCTGGGACGAATGGGCCGAT GAAAACGGCGACCTCGGGCCAGTGTATGGTAAACAGTGGCGCGCCTGG CCAACGCCAGATGGTCGTCATATTGACCAGATCACTACGGTACTGAAC CAGCTGAAAAACGACCCGGATTCGCGCCGCATTATTGTTTCAGCGTGG AACGTAGGCGAACTGGATAAAATGGCGCTGGCACCGTGCCATGCATTC TTCCAGTTCTATGTGGCAGACGGCAAACTCTCTTGCCAGCTTTATCAG CGCTCCTGTGACGTCTTCCTCGGCCTGCCGTTCAACATTGCCAGCTAC GCGTTATTGGTGCATATGATGGCGCAGCAGTGCGATCTGGAAGTGGGT GATTTTGTCTGGACCGGTGGCGACACGCATCTGTACAGCAACCATATG GATCAAACTCATCTGCAATTAAGCCGCGAACCGCGTCCGCTGCCGAAG TTGATTATCAAACGTAAACCCGAATCCATCTTCGACTACCGTTTCGAA GACTTTGAGATTGAAGGCTACGATCCGCATCCGGGCATTAAAGCGCCG GTGGCTATCTAATTACGAAACATCCTGCCAGAGCCGACGCCAGTGTGC GTCGGTTTTTTTACCCTCCGTTAAATTCTTCGAGACGCCTTCCCGAAG GCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGT GCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGC AAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTG TAAAACGACGGCCAGTGCCAAGCTTTCTTTAATGAAGCAGGGCATCAG GACGGTATCTTTGTGGAGAAAGCAGAGTAATCTTATTCAGCCTGACTG GTGGGAAACCACCAGTCAGAATGTGTTAGCGCATGTTGACAAAAATAC CATTAGTCACATTATCCGTCAGTCGGACGACATGGTAGATAACCTGTT TATTATGCGTTTTGATCTTACGTTTAATATTACCTTTATGCGATGAAA CGGTCTTGGCTTTGATATTCATTTGGTCAGAGATTTGAATGGTTCCCT GACCTGCCATCCACATTCGCAACATACTCGATTCGGTTCGGCTCAATG ATAACGTCGGCATATTTAAAAACGAGGTTATCGTTGTCTCTTTTTTCA GAATATCGCCAAGGATATCGTCGAGAGATTCCGGTTTAATCGATTTAG AACTGATCAATAAATTTTTTCTGACCAATAGATATTCATCAAAATGAA CATTGGCAATTGCCATAAAAACGATAAATAACGTATTGGGATGTTGAT TAATGATGAGCTTGATACGCTGACTGTTAGAAGCATCGTGGATGAAAC AGTCCTCATTAATAAACACCACTGAAGGGCGCTGTGAATCACAAGCTA TGGCAAGGTCATCAACGGTTTCAATGTCGTTGATTTCTCTTTTTTTAA CCCCTCTACTCAACAGATACCCGGTTAAACCTAGTCGGGTGTAACTAC ATAAATCCATAATAATCGTTGACATGGCATACCCTCACTCAATGCGTA ACGATAATTCCCCTTACCTGAATATTTCATCATGACTAAACGGAACAA CATGGGTCACCTAATGCGCCACTCTCGCGATTTTTCAGGCGGACTTAC TATCCCGTAAAGTGTTGTATAATTTGCCTGGAATTGTCTTAAAGTAAA GTAAATGTTGCGATATGTGAGTGAGCTTAAAACAAATATTTCGCTGCA GGAGTATCCTGGAAGATGTTCGTAGAAGCTTACTGCTCACAAGAAAAA AGGCACGTCATCTGACGTGCCTTTTTTATTTGTACTACCCTGTACGAT TACTGCAGCTCGAGTTAGGATACCGGCACTTTGATCCAACCAGTCGGG TAGATATCCGGTGCTTCGGAGTGCTGGAACCAACGGCTCGGCACAATA ACAGTCTTATCCATATTAGGGTTCAGCCAGGCACCCCACCAAGAAAAC GTGCTGTTACAAATGATGTGATGTTTGCAATGAGACATCAGCATCATA TCCTGCCAGGAGTCTTCATCAGTGTTCCAGTCAATATAAACCGCATTC TGCAGTGGCAGATTTTCTTTAACCCACGCGATATCGTCGGAGAAGATA TAGTAAGATGGGCTAGCAACACGACGGGACATTTCCGCGATAGCATTC TGGTAATACGGCAGCTGGCACACGGAACCGGTAGTAGCCCAGTGTTTC GGCTGCAGATAGTCACCACGACGAATGTGCAGGGAAACCGCGTTTTCA TCTTTGTCCAGGATTTCCAGCATGTTCAGGCTGCGGGAATTTGCTTTG TTCTTATCAAAGGTGAAGGATTCACGCACTTCGTCTTTGATATCAGCG AAGAAACGCTCGCTCTGATAGAAACCTTTAAAGTACAGCAGCGGCCAG AAATACTTCTTCTCGAACGCACGCAGAGAGTTCGGCGCCTGCTTGCGT TCGTAGATTTTTTTAAAAAACAGGAATTCGATAACTTTTTTCAGCGGT TGGTTGATGCAGAATTCGGTGTGCGGCAGGTTGAACACGCGGTGCATT TCGTAACCGTAATGGACTTTGTAATGCATCATGTCGCTCAGGTCGATA CGGACCTTCGGGTAATACTTTTTCATACGCAGATAGAAAGCATAGATA AACATCTGGTTGCCCAGACCGCCAGTCACTTTGATCAGACGCATTATA TCTCCTTCTTG

Fucosylated oligosaccharides produced by metabolically engineered E. coli cells are purified from culture broth post-fermentation. An exemplary procedure comprises five steps. (1) Clarification: Fermentation broth is harvested and cells removed by sedimentation in a preparative centrifuge at 6000×g for 30 min. Each bioreactor run yields about 5-7 L of partially clarified supernatant. (2) Product capture on coarse carbon: A column packed with coarse carbon (Calgon 12×40 TR) of ˜4000 ml volume (dimension 5 cm diameter×60 cm length) is equilibrated with 1 column volume (CV) of water and loaded with clarified culture supernatant at a flow rate of 40 ml/min. This column has a total capacity of about 120 g of sugar. Following loading and sugar capture, the column is washed with 1.5 CV of water, then eluted with 2.5 CV of 50% ethanol or 25% isopropanol (lower concentrations of ethanol at this step (25-30%) may be sufficient for product elution.) This solvent elution step releases about 95% of the total bound sugars on the column and a small portion of the color bodies. In this first step capture of the maximal amount of sugar is the primary objective. Resolution of contaminants is not an objective. (3) Evaporation: A volume of 2.5 L of ethanol or isopropanol eluate from the capture column is rotary-evaporated at 56 C.° and a sugar syrup in water is generated. Alternative methods that could be used for this step include lyophilization or spray-drying. (4) Flash chromatography on fine carbon and ion exchange media: A column (GE Healthcare HiScale50/40, 5×40 cm, max pressure 20 bar) connected to a Biotage Isolera One FLASH Chromatography System is packed with 750 ml of a Darco Activated Carbon G60 (100-mesh): Celite 535 (coarse) 1:1 mixture (both column packings were obtained from Sigma). The column is equilibrated with 5 CV of water and loaded with sugar from step 3 (10-50 g, depending on the ratio of 2′-FL to contaminating lactose), using either a celite loading cartridge or direct injection. The column is connected to an evaporative light scattering (ELSD) detector to detect peaks of eluting sugars during the chromatography. A four-step gradient of isopropanol, ethanol or methanol is run in order to separate 2′-FL from monosaccharides (if present), lactose and color bodies. Fractions corresponding to sugar peaks are collected automatically in 120-ml bottles, pooled and directed to step 5. In certain purification runs from longer-than-normal fermentations, passage of the 2′-FL-containing fraction through anion-exchange and cation exchange columns can remove excess protein/DNA/caramel body contaminants. Resins tested successfully for this purpose are Dowex 22.

The gene screening approach described herein was successfully utilized to identify new α(1,2) FTs for the efficient biosynthesis of 2′-FL in metabolically engineered E. coli host strains. The results of the screen are summarized in Table 1.

Production Host Strains

E. coli K-12 is a well-studied bacterium which has been the subject of extensive research in microbial physiology and genetics and commercially exploited for a variety of industrial uses. The natural habitat of the parent species, E. coli, is the large bowel of mammals. E. coli K-12 has a history of safe use, and its derivatives are used in a large number of industrial applications, including the production of chemicals and drugs for human administration and consumption. E. coli K-12 was originally isolated from a convalescent diphtheria patient in 1922. Because it lacks virulence characteristics, grows readily on common laboratory media, and has been used extensively for microbial physiology and genetics research, it has become the standard bacteriological strain used in microbiological research, teaching, and production of products for industry and medicine. E. coli K-12 is now considered an enfeebled organism as a result of being maintained in the laboratory environment for over 70 years. As a result, K-12 strains are unable to colonize the intestines of humans and other animals under normal conditions. Additional information on this well known strain is available at http://epa.gov/oppt/biotech/pubs/fra/fra004.htm. In addition to E. coli K12, other bacterial strains are used as production host strains, e.g., a variety of bacterial species may be used in the oligosaccharide biosynthesis methods, e.g., Erwinia herbicola (Pantoea agglomerans), Citrobacter freundii, Pantoea citrea, Pectobacterium carotovorum, or Xanthomonas campestris. Bacteria of the genus Bacillus may also be used, including Bacillus subtilis, Bacillus licheniformis, Bacillus coagulans, Bacillus thermophilus, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, and Bacillus circulans. Similarly, bacteria of the genera Lactobacillus and Lactococcus may be modified using the methods of this invention, including but not limited to Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus jensenii, and Lactococcus lactis. Streptococcus thermophiles and Proprionibacterium freudenreichii are also suitable bacterial species for the invention described herein. Also included as part of this invention are strains, modified as described here, from the genera Enterococcus (e.g., Enterococcus faecium and Enterococcus thermophiles), Bifidobacterium (e.g., Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum), Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas (e.g., Pseudomonas fluorescens and Pseudomonas aeruginosa).

Suitable host strains are amenable to genetic manipulation, e.g., they maintain expression constructs, accumulate precursors of the desired end product, e.g., they maintain pools of lactose and GDP-fucose, and accumulate endproduct, e.g., 2′-FL. Such strains grow well on defined minimal media that contains simple salts and generally a single carbon source. The strains engineered as described above to produce the desired fucosylated oligosaccharide(s) are grown in a minimal media. An exemplary minimal medium used in a bioreactor, minimal “FERM” medium, is detailed below.

Ferm (10 liters): Minimal medium comprising:

40 g (NH₄)₂HPO₄

100 g KH₂PO₄

10 g MgSO₄.7H₂O

40 g NaOH

1× Trace elements:

1.3 g NTA (nitrilotriacetic acid)

0.5 g FeSO₄.7H₂O

0.09 g MnCl₂.4H₂O

0.09 g ZnSO₄.7H₂O

0.01 g CoCl₂.6H₂O

0.01 g CuCl₂.2H₂O

0.02 g H₃BO₃

0.01 g Na₂MoO₄.2H₂O (pH 6.8)

Water to 10 liters

DF204 antifoam (0.1 ml/L)

150 g glycerol (initial batch growth), followed by fed batch mode with a 90% glycerol-1% MgSO₄-1× trace elements feed, at various rates for various times.

A suitable production host strain is one that is not the same bacterial strain as the source bacterial strain from which the fucosyltransferase-encoding nucleic acid sequence was identified.

Bacteria comprising the characteristics described herein are cultured in the presence of lactose, and a fucosylated oligosaccharide is retrieved, either from the bacterium itself or from a culture supernatant of the bacterium. The fucosylated oligosaccharide is purified for use in therapeutic or nutritional products, or the bacteria are used directly in such products.

EXAMPLES Example 1: Identification of Novel α(1,2) Fucosyltransferases

To identify additional novel α(1,2)fucosyltransferases, a multiple sequence alignment query was generated using the alignment algorithm of the CLCbio Main Workbench package, version 6.9 (CLCbio, 10 Rogers Street #101, Cambridge, Mass. 02142, USA) using four previously identified lactose-utilizing α(1,2)fucosyltransferase protein sequences: H. pylori futC (SEQ ID NO: 1), H. mustelae FutL (SEQ ID NO: 2), Bacteroides vulgatus futN (SEQ ID NO: 3), and E. coli 0126 wbgL (SEQ ID NO: 4). This sequence alignment and percentages of sequence identity between the four previously identified lactose-utilizing α(1,2)fucosyltransferase protein sequences is shown in FIG. 3. An iterative PSI-BLAST was performed, using the FASTA-formatted multiple sequence alignment as the query, and the NCBI PSI-BLAST program run on a local copy of NCBI BLAST+version 2.2.29. An initial position-specific scoring matrix file (.pssm) was generated by PSI-BLAST, which was then used to adjust the score of iterative homology search runs. The process is iterated to generate an even larger group of candidates, and the results of each run were used to further refine the matrix.

A portion of the initial position-specific scoring matrix file used is shown below:

Last position-specific scoring matrix computed A R N

C Q E G H I L K N F P S T W Y V  1 M −1 −1 −2 −3 −2

−2 −3 −2 1 2 −1 6

−3 −2 −1 −2 −1 1  2 A 2 −2

4 −2 −1 1 −1 −1 −2 −3 −1 −2 −3 −1 1 −1 −3 −3 −1  3 F −2 −3 −3 −4 −3 −3 −3 −3 −1

−3

7 −4 −3 −2 1 3 −1  4 K

3

−1 −2 1

−1 −1 −3 −3 3 −2 −3 −1 2

−3 −2 −2  5 V −1 −3 −3 −4 −1 −3 −3 −4 −3 4 2 −3 1

−3 −2 −1 −3 −1 3  6 V −1 −3 −3 −3 −1 −3 −3 −4 −3 4 1 −3 1 −1 −3 −2

−3 −1 3  7

−1 4

−1 −3 4 1 −2

−3 −2 3 −1 −3 −2

−1 −3 −2 −3  8 I −1 −3 −3 −4 −1 −2 −3 −4 −3 3 2 −3 1

−3 −2 −1 −3 −1 3  9 C −1 −1

−1 5 3

−2 4 −2 −2

−1 −2 −2

2 −2 −1 −1 10 G

−3 −1 −1 −3 −2 −2

−2 −4 −4 −2 −3 −3 −2

−2 −3 −3 −3 11 G

−3 −1 −1 −3 −2 −2

−2 −4 −4 −2 −3 −3 −2

−2 −3 −3 −3 12 L −2 −2 −4 −4 −1 −2 −3 −4 −3 2 4 −3 2

−3 −3 −1 −2 −1 1 13 G

−3 −1 −1 −3 −2 −2

−2 −4 −4 −2 −3 −3 −2

−2 −3 −3 −3 14 N −2 −1

1 −3

−1 1 −4 −4

−2 −3 −2 1

−4 −2 −3 15

−1 1

−3

2 −2

−3 −2 1 −1 −3 −1

−1 −2 −2 −2 16 M −1 −2 −3 −4 −2 −1 −2 −3 −2 1 3 −2 5

−3 −2 −1 −2 −1 1 17 F −2 −3 −3 −4 −3 −3 −4 −3 −1

−3

7 −4 −3 −2 1 3 −1 18

−1

−1 −1 −3 5 1 −2

1 −1 1

−2 −2 −1 −1 −2 −2

19 Y −2 −2 −3 −3 −3 −2 −3 −3 1 −1 −1 −2 −1

−2 −2 −2 2

−1 20 A 4 −1 −1 −1 −1 −1 −1

−2 −2 −2 −1 −1 −2 −1 2

−3 −2 −1 21 F −2 −3 −3 −4 −3 −3 −4 −3 −1

−3

7 −4 −3 −2 1 3 −1 22 A 3 −2 −1 −2 −1 −1 −1 4 −2 −2 −2 −1 −2 −3 −1 1 −1 −3 −2 −1 23 K −1

−1 −2 −3

−1 −3 1 −2 −2 3 −1 2 −2 −1 −1 1

−2 24 S 2 −1 −1 −2 −1 −1 −1 −1 −2 −1 1 −1

−1 −1 3

−3 −2

25 L −2 3 −2 −3 −2 −1 −2 −3 −2 1 3

1

−3 −2 −1 −2 −1

26

−1 −2 4 1 −2 −1 −1

3 −2 −2 2

−2 −2 −1 27 K −1 2

−1 −3 1

−2 −1 −2 −2 4 −1 −3 −1

2 −3 −2 −2 28

−1

−2 −3

−2

1 −1 2 −1 −1 −2 −1 −1 −3

29 S −1 −1 3 −1 −2 −1 −1 −2

−1 1 −1

1 −2 1

4 −1 30 N −1 −1 4

−3 −1 −1 3

−3 −3 −1 −2

−3

−1 −1 4 −3 31 T −1 −2 −1 −2 −2 −1 −2 −2 −2 1 −1 −1 −1 −2 5

3 −3 −2

32 P −1

−2 −1 −3

−1 −2 −2 −3 −3 2 −2 −4 7 −1 −1 −4 −3 −3 33 V −1 −3 −3 −4 −1 −2 −3 −4 −3 2 2 −3 1 −1 −3 −2

−3 −1 4 34 L −2 3 −2 −3 −2 −1 −2 −3

2

1 1 −3 −2 −1

4 −1 35 L −2 −3 −4 −4 −2 −3 −3 −4 −3 3 3 −3 1 3 −3 −3 −1 −1 1 1 36

−2 −2 1

−4

1 −2 −1 −4 −4 −1 −3 −4 −2

−1 −5 −3 −4

indicates data missing or illegible when filed

The command line of PSI-BLAST that was used is as follows: psiblast-db<LOCAL NR database name>-max_target_seqs 2500-in_msa<MSA file in FAST format>-out<results output file>-outfmt “7sskingdoms sscinames scomnames sseqid stitle evalue length pident”-out_pssm<PSSM file output>-out_ascii_pssm<PSSM (ascii) output>-num_iterations 6-num_threads 8

This PSI-BLAST search resulted in an initial 2515 hits. There were 787 hits with greater than 22% sequence identity to FutC. 396 hits were of greater than 275 amino acids in length. Additional analysis of the hits was performed, including sorting by percentage identity to FutC, comparing the sequences by BLAST to an existing α(1,2) fucosyltransferase inventory (of known α(1,2) fucosyltransferases, to eliminate known lactose-utilizing enzymes and duplicate hits), and manual annotation of hits to identify those originating from bacteria that naturally exist in the gastrointestinal tract. An annotated list of the novel α(1,2) fucosyltransferases identified by this screen are listed in Table 1. Table 1 provides the bacterial species from which the enzyme is found, the GenBank Accession Number, GI Identification Number, amino acid sequence, and % sequence identity to FutC.

Multiple sequence alignment of the 4 known α(1,2) FTs used for the PSI-BLAST query and 12 newly identified α(1,2) FTs is shown in FIG. 4.

Example 2: Validation of Novel α(1,2) FTs

To test for lactose-utilizing fucosylatransferase activity, the production of fucosylated oligossacharides (i.e., 2′-FL) is evaluated in a host organism that expresses the candidate enzyme (i.e., syngene) and which contains both cytoplasmic GDP-fucose and lactose pools. The production of fucosylated oligosaccharides indicates that the candidate enzyme-encoding sequence functions as a lactose-utilizing α(1,2)fucosyltransferase. Of the identified hits, 12 novel α(1,2) fucosyltransferases were further analyzed for their functional capacity to produce 2′-fucosyllactose: Prevotella melaninogenica FutO, Clostridium bolteae FutP, Clostridium bolteae+13 FutP, Lachnospiraceae sp. FutQ, Methanosphaerula palustries FutR, Tannerella sp. FutS, Bacteroides caccae FutU, Butyrivibrio FutV, Prevotellaa sp. FutW, Parabacteroides johnsonii FutX, Akkermansia muciniphilia FutY, Salmonella enterica FutZ, and Bacteroides sp. FutZA.

Syngenes were constructed comprising the 12 novel α(1,2) FTs in the configuration as follows: EcoRI-T7g10 RBS-syngene-XhoI. FIG. 5A and FIG. 5B show the syngene fragments after PCR assembly and gel-purification.

The candidate α(1,2) FTs (i.e., syngenes) were cloned by standard molecular biological techniques into an exemplary expression plasmid pEC2-(T7)-Fut syngene-rcsA-thyA. This plasmid utilizes the strong leftwards promoter of bacteriophage X (termed PL) to direct expression of the candidate genes (Sanger, F. et al. (1982). J Mol Biol 162, 729-773). The promoter is controllable, e.g., a trp-cI construct is stably integrated the into the E. coli host's genome (at the ampC locus), and control is implemented by adding tryptophan to the growth media. Gradual induction of protein expression is accomplished using a temperature sensitive cI repressor. Another similar control strategy (temperature independent expression system) has been described (Mieschendahl et al., 1986, Bio/Technology 4:802-808). The plasmid also carries the E. coli rcsA gene to up-regulate GDP-fucose synthesis, a critical precursor for the synthesis of fucosyl-linked oligosaccharides. In addition, the plasmid carries a β-lactamase (bla) gene for maintaining the plasmid in host strains by ampicillin selection (for convenience in the laboratory) and a native thyA (thymidylate synthase) gene as an alternative means of selection in thyA⁻ hosts.

The expression constructs were transformed into a host strain useful for the production of 2′-FL. The host strain used to test the different α(1,2) FT candidates incorporates all the above genetic modifications described above and has the following genotype: ΔampC::P_(trp) ^(B) cl, A(lacl-lacZ)::FRT, P_(lacIq)lacY⁺, ΔwcaJ::FRT, thyA::Tn10, Δlon:(npt3, lacZ⁺), ΔlacA

The E. coli strains harboring the different α(1,2) FT candidate expression plasmids were analyzed. Strains were grown in selective media (lacking thymidine) to early exponential phase. Lactose was then added to a final concentration of 0.5%, and tryptophan (200 μM) was added to induce expression of each candidate α(1,2) FT from the P_(L) promoter. At the end of the induction period (˜24 h) the culture supernatants and cells were harvested. Heat extracts were prepared from whole cells and the equivalent of 0.2OD₆₀₀ units of each strain analyzed for the presence of 2′-FL by thin layer chromatography (TLC), along with 2 μl of the corresponding clarified culture supernatant for each strain.

FIG. 6 shows the oligosaccharides produced by the α(1,2) FT-expressing bacteria, as determined by TLC analysis of the culture supernatant and extracts from the bacterial cells. 2′FL was produced by exogenous expression of WbgL (used as control), FutO, FutP, FutQ, FutR, FutS, FutU, FutW, FutX, FutZ, and FutZA.

Table 4 summarizes the fucosyltransferase activity for each candidate syngene as determined by the 2′FL synthesis screen described above. 11 of the 12 candidate α(1,2) FTs were found to have lactose-utilizing fucosyltransferase activity.

TABLE 4 2′FL synthesis screen results 2′FL 2′FL 24 h OD culture cell Syngene (induced) medium extract Escherichia coli WbgL  9.58 5 5 pG204 pEC2-WbgL-rcsA-thyA E640 Prevotella melaninogenica FutO 12.2 3 2 pG393 pEC2-(T7)FutO-rcsA-thyA E985 Clostridium bolteae FutP 10.4 1 2 pG394 pEC2-(T7)FutP-rcsA-thyA E986 Lachnospiraceae sp. FutQ 10.6 3 4 pG395 pEC2-(T7)FutQ-rcsA-thyA E987 Methanosphaerula palustris FutR 11.9 0 1 pG396 pEC2-(T7)FutR-rcsA-thyA E988 Tannerella sp. FutS 11.3 2 3 pG397 pEC2-(T7)FutS-rcsA-thyA E989 Bacteroides caccae FutU 12.1 0 2 pG398 pEC2-(T7)FutU-rcsA-thyA E990 Butyrivibrio FutV 11.3 0 1 pG399 pEC2-(T7)FutV-rcsA-thyA E991 Prevotella sp. FutW 10.5 3 3 pG400 pEC2-(T7)FutW-rc sA-thyA E992 Parabacteroides johnsonii FutX 10.7 3 5 pG401 pEC2-(T7)FutX-rcsA-thyA E993 Akkermansia muciniphilia FutY  9.1 0 0 pG402 pEC2-(T7)FutY-rcsA-thyA E994 Salmonella enterica FutZ 11.0 0 3 pG403 pEC2-(T7)FutZ-rcsA-thyA E995 Bacteroides sp. FutZA  9.9 3 3 pG404 pEC2-(T7)FutZA-rcsA-thyA E996

Example 3: Characterization of Cultures Expressing Novel α(1,2) FTs

Further characterization of the bacterium expressing novel α(1,2) FTs FutO, FutQ, and FutX was performed. Specifically, proliferation rate and exogenous α(1,2) FT expression was examined.

Expression plasmids containing fucosyltransferases WbgL (plasmid pG204), FutN (plasmid pG217), and novel α(1,2) FTs FutO (plasmid pG393), FutQ (plasmid pG395), and FutX (pG401) were introduced into host bacterial strains. For example, the host strains utilized has the following genotype: ΔampC::P_(trp) ^(B)cI, A(lacl-lacZ)::FRT, P_(lacIq)lacY⁺, ΔwcaJ::FRT, thyA::Tn10, Δlon:(npt3, lacZ⁺), ΔlacA

Bacterial cultures expressing each exogenous fucosyltransferase were induced by addition of tryptophan (to induce expression of the exogenous fucosyltransferases) in the presence of lactose. Growth of the cultures was monitored by spectrophotometric readings at A600 at the following timepoints: 4 hours and 1 hour before induction, at the time of induction (time 0), and 3 hours, 7 hours, and 24 hours after induction. The results are shown in FIG. 7, and indicate that expression of the exogenous fucosyltransferase did not prevent cell proliferation. Furthermore, the growth curve for the bacterial cultures expressing the novel α(1,2) fucosyltransferases FutO, FutQ, and FutX is similar to those expressing the known α(1,2)FT enzymes WbgL and FutN.

Protein expression was also assessed for the bacterial cultures expressing each fucosyltransferase after induction. Cultures were induced as described previously, and protein lysates were prepared from the bacterial cultures at the time of induction (0 hours), 3 hours, 7 hours, and 24 hours after induction. The protein lysates were run on an SDS-PAGE gel and stained to examine the distribution of proteins at each time point. As shown in FIG. 8, induction at 7 hours and 24 hours showed increases in a protein band at around 20-28 kDa for bacterial cultures expressing exogenous FutN, FutO, and FutX. These results indicate that induction results in significant expression of the exogenous fucosyltransferases.

Finally, additional TLC analysis to assess the efficiency and yield of 2′FL production in bacterial cultures expressing novel α(1,2) FTs FutO, FutQ, and FutX compared to known fucosyltransferases WbgL and FutN. Cultures were induced at 7 hours and 24 hours, and run out on TLC. FIG. 9A shows the level of 2′FL in the cell supernatant. The level of 2′FL found in the bacterial cells were also examined. As shown in FIG. 9B, 2′FL was produced in cell lysates from bacteria expressing the novel α(1,2) FTs FutO, FutQ, and FutX at 7 hours and 24 hours after induction.

Example 4: FutN Exhibits Increased Efficiency for Production of 2′FL

Fucosylated oligosaccharides produced by metabolically engineered E. coli cells to express B. vulgatus FutN was purified from culture broth post-fermentation.

Fermentation broth was harvested and cells were removed by sedimentation in a preparative centrifuge at 6000×g for 30 min. Each bioreactor run yields about 5-7 L of partially clarified supernatant. A column packed with coarse carbon (Calgon 12×40 TR) of ˜1000 ml volume (dimension 5 cm diameter×60 cm length) was equilibrated with 1 column volume (CV) of water and loaded with clarified culture supernatant at a flow rate of 40 ml/min. This column had a total capacity of about 120 g of sugar. Following loading and sugar capture, the column is washed with 1.5 CV of water, then was eluted with 2.5 CV of 50% ethanol or 25% isopropanol (lower concentrations of ethanol at this step (25-30%) may be sufficient for product elution.) This solvent elution step released about 95% of the total bound sugars on the column and a small portion of color bodies (caramelized sugars). A volume of 2.5 L of ethanol or isopropanol eluate from the capture column was rotary-evaporated at 56 C.° and a sugar syrup in water was generated. A column (GE Healthcare HiScale50/40, 5×40 cm, max pressure 20 bar) connected to a Biotage Isolera One FLASH Chromatography System was packed with 750 ml of a Darco Activated Carbon G60 (100-mesh): Celite 535 (coarse) 1:1 mixture (both column packings were obtained from Sigma). The column was equilibrated with 5 CV of water and loaded with sugar from step 3 (10-50 g, depending on the ratio of 2′-FL to contaminating lactose), using either a celite loading cartridge or direct injection. The column was connected to an evaporative light scattering (ELSD) detector to detect peaks of eluting sugars during the chromatography. A four-step gradient of isopropanol, ethanol or methanol was run in order to separate 2′-FL from monosaccharides (if present), lactose and color bodies. Fractions corresponding to sugar peaks were collected automatically in 120-ml bottles, pooled.

The results from two fermentation runs are shown in FIG. 10A and FIG. 10B. The cultures were grown for 136 (run 36B) or 112 hours (run 37A), and the levels of 2′-FL produced was analyzed by TLC analysis. As shown in both FIG. 10A and FIG. 10B, the 2′-fucosyllactose was produced at 40 hours of culture, and production continued to increase until the end point of the fermentation process. The yield of 2′-FL produced from run 36B was 33 grams per liter. The yield of 2′-FL produced from run 37A was 36.3 grams per liter. These results indicate that expression of exogenous FutN is suitable for high yield of 2′-fucosyllactose product.

TABLE 1 Hits from PSI-BLAST multiple sequence alignment query for novel α(1,2) fucosyltransferases % SEQ Accession Gene name identity ID Bacterium names No. GI No. [bacterium] FutC Alias SEQUENCE NO Helicobacter AAD29869.1 4808599 alpha-1,2- 98 FutC MAFKVVQICGGLGNQMFQYAFAKSLQKHSNTPVLLDITSFDWSDRKMQLELFPINLPY 1 pylori fucosyl- ASAKEIAIAKMQHLPKLVRDALKCMGFDRVSQEIVFEYEPELLKPSRLTYFYGYFQDP transferase RYFDAISPLIKQTFTLPPPPENNKNNNKKEEEYHRKLSLILAAKNSVFVHIRRGDYVG [helicobacter IGCQLGIDYQKKALEYMAKRVPNMELFVFCEDLEFTQNLDLGYPFMDMTTRNKEEEAY pylori] WDMLLMQSCQHGIIANSTYSWWAAYLIENPEKIIIGPKHWLFGHENILCKEWVKIESH FEVKSQKYNA Helicobacter YP_ 291277413 alpha-1,2- 70.85 FutL MDFKIVQVHGGLGNQMFQYAFAKSLOTHLNIPVLLDTTWFDYGNRELGLHLFPIDLQC 2 mustelae; 003517185.1 fucosyl-   ASAQQIAAAHMQNLPRLVRGALRRMGLGRVSKEIVFEYMPELFEPSRIAYFHGYFQDP Helicobacter transferase RYFEDISPLIKQTFTLPHPTEHAEQYSRKLSQILAAKNSVFVHIRRGDYMRLGWQLDI mustelae 12198 [helicobacter SYQLRAIAYMAKRVQNLELFLFCEDLEFVQNLDLGYPFVDMTTRDGAAHWDMMLMQSC mustelae KHGIITNSTYSWWAAYLIKNPEKIIIGPSHWIYGNENILCKDWVKIESQFETKS 12198] Bacteroides; YP_ 150005717 glycosyl 24.83 FutN MRLIKVIGGLGNQMFIYAFYLRMKKYYPKVRIDLSDMMHYKVHYGYEMHRVFNLPHTE 3 Bacteroides 001300461.1 transferase FCINQPLKKVIEFLFFKKIYERKQAPNSLRAFEKKYFWPLLYFKGFYQSERFFADIKD vulgatus ATCC family protein EVRESFTFDKNKANSRSLNMLEILDKDENAVSLHIRRGDYLQPKHWATTGSVCQLPYY 8482; Bacteroides [Bacteroides QNAIAEMSRRVASPSYYIFSDDIAWVKENLPLQNAVYIDWNTDEDSWQDMMLMSHCKH sp. vulgatus ATCC HIICNSTFSWWGAWLNPNMDKTVIVPSRWFQHSEAPDIYPTGWIKVPVS 4_3_47FAA; 8482] Bacteroides sp. 3_1_40A; Bacteroides vulgatus PC510; Bacteroides vulgatus CL09T03C04; Bacteroides vulgatus dnLKV7; Bacteroides vulgatus CAG:6 Escherichia WP_ 545259828 protein 23.13 WbgL MSIIRLQGGLGNQLFQFSFGYALSKINGTPLYFDISHYAENDDHGGYRLNNLQIPEEY 4 coli; 021554465.1 [Escherichia LQYYTPKINNIYKLLVRGSRLYPDIFLFLGFCNEFHAYGYDFEYIAQKWKSKKYIGYW Escherichia coli coli] IQSEHFFHKHILDLKEFFIPKNVSEQANLLAAKLESQSSLSIHIRRGDYIKNKTATLT UMEA 3065-1 HGVCSLEYYKKALNKIRDLAMIRDVFIFSDDIFWCKENIETLLSKKYNIYYSEDLSQE EDLWLMSLANHHIIANSSFSWWGAYLGSSASQIVIYPTPWYDITPKNTYIPIVNHWIN VDKHSSC Helicobacter WP_ 491361813 predicted 36.79 FutD MGDYKIVELTCGLGNQMFQYAFAKALQKHLQVPVLLDKIWYDTQDNSTQFSLDIFNVD 5 bilis; 005219731.1 protein LEYATNTQIEKAKARVSKLPGLLRKMFGLKKHNIAYSQSFDFHDEYLLPNDFTYFSGF Helicobacter [Helicobacter FQNAKYLKGLEQELKSIFYYDSNNFSNFGKQRLELILQAKNSIFIHIRRGDYCKIGWE bilis ATCC 43879 bilis] LGMDYYKRAIQYIMDRVEEPKFFIFGATDMSFTEQFQKNLGLNENNSANLSEKTITQD NQHEDMFLMCYCKHAILANSSYSFWSAYLNNDANNIVIAPTPWLLDNDNIICDDWIKI SSK Escherichia AAO37698.1 37788088 fucosyl- 25.94 WbsJ MEVKIIGGLGNQMFQYATAFAIAKRTHQNLTVDISDAVKYKTHPLRLVELSCSSEFVK 6 coli transferase KAWPFEKYLFSEKIPHEMKKGMFRKHYVEKSLEYDPDIDTKSINKKIVGYFQTEKYFK [Escherichia EFRHELIKEFQPKTKENSYQNELLNLIKENDTCSLHIRRGDYVSSKIANETHGTCSEK coli] YFERAIDYLMNKGVINKKILLFIFSDDIKWCRENIFFNNQICFVQGDAYHVELDMLLM SKCKNNIISNSSFSWWAAWLNENKNKTVIAPSKWFKKDIKHDIIPESWVKL Vibrio cholerae BAA33632.1 3721682 probable beta- 25.94 WblA MIVMKISGGLGNQLFQYAVGRAIAIQYGVPLKLDVSAYKNYKLHNGYRLDQFNINADI 7 D-galactoside ANEDEIFHLKGSSNRLSRILRRLGWLKKNTYYAEKORTIYDVSVFMQAPRYLDGYWQN 2-alpha- EQYFSQIRAVLLQELWPNQPLSINAQAHQIKIQQTHAVSIHVRRGDYLNHPEIGVLDI L-fucosyl DYYKRAVDYIKEKIEAPVFFVFSNDVAWCKDNENFIDSPVFIEDTQTEIDDLMLMCQC transferase QHNIVANSSFSWWAAWLNSNVDKIVIAPKTWMAENPKGYKWVPDSWREI [Vibrio cholerae] Bacteroides YP_ 53713126 alpha-1,2- 24.58 Bft2 MIVSSLRGGLGNQMFIYAMVKAMALRNNVPFAFNLITDFANDEVYKRKLLLSYFALDL 8 fragilis; 099118.1 fucosyl- PENKKLIFDFSYGNYYRRLSRNLGCHILHPSYRYICEERPPHFESRLISSKITNAFLE Bacteroides transferase GYWQSEKYFLDYKQEIKEDNIQKKLEYTSYLELEEIKLLDKNAIMIGVRRYQESDVAP fragilis NCTC [Bacteroides GGVLEDDYYKCAMDIMASKVISPVFFCFSQDLEWVEKHLAGKYPVRLISKKEDDSGTI 9343; Bacteroides fragilis  DDMFLMMHFRNYIISNSSFYWWGAWLSKYDDKLVIAPGNFINKDSVPESWFKLNVR fragilis YCH46] YCH46; Bacteroides fragilis HMW 615 Escherichia WP_ 486356116 protein 24.25 WbgN MSIVVARLAGGLGNQMFQYAKGYAESVERNSYLKLDLRGYKNYTLHGGFRLDKLNIDN 9 coli; 001592236.1 [Escherichia IFVMSKKEMCIFPNFIVRAINKFPKLSLCSKRFESEQYSKKINGSMKGSVEFIGFWQN Escherichia coli coli] ERYFLEHKEKLREIFTPININLDAKELSDVIRCINSVSVHIRRGDYVSNVEALKIHGL KTE84 CTERYYIDSIRYLKERFNNLVFFVFSDDIEWCKKYKNEIFSRSDDVKFIEGNIQEVDM WLMSNAKYHIIANSSFSWWGAWLKNYDLGITIAPTPWFEREELNSFDPCPEKWVRIEK Prevotella YP_ 302346214 glycosyl- 31.1 FutO MKIVKILGGLGNQMFQYALYLSLQESFPKERVALDLSSFHGYHLHNGFELENIFSVTA 10 melaninogenica; 003814512.1 transferase QKASAADIMRIAYYYPNYLLWRIGKRFLPRRKGMCLESSSLRFDESVLRQEGNRYFDG Prevotella family 11 YWQDERYFAAYREKVLKAFTFPAFKRAENLSLLEKLDENSIALHVRRGDYVGNNLYQG melaninogenica  [Prevotella ICDLDYYRTAIEKMCAHVIPSLFCIFSNDITWCQQHLQPYLKAPVVYVTWNTGVESYR ATCC 25845 melaninogenica DMQLMSCCAHNIIANSSFSWWGAWLNQNREKVVIAPKKWLNMEECHFTLPASWIKI ATCC 25845] Clostridium WP_ 488634090 protein 29.86 FutP MFQYALYKAFEQKHIDVYADLAWYKNKSVKFELYNEGIKINVASEKDINRLSDCQADF 11 bolteae; 002570768.1 [Clostridium VSRIRRKIFGKKKSFVSEKNDSCYENDILRMDNVYLSGYWQTEKYFSNTREKLLEDYS Clostridium bolteae] FALVNSQVSEWEDSIRNKNSVSIHIRRGDYLQGELYGGICTSLYYAEAIEYIKMRVPN bolteae AKFFVFSDDVEWVKQQEDFKGFVIVDRNEYSSALSDMYLMSLCKHNIIANSSFSWWAA 90A9; Clostridium WLNRNEEKIVIAPRRWLNGKCTPDIWCKKWIRI bolteae 90133; Clostridium bolteae 90138 Lachnospiraceae WP_ 496545268 protein 29.25 FutQ MVIVQLSGGLGNQMFEYALYLSLKAKGKEVKIDDVTCYEGPGTRPRQLDVEGITYDRA 12 bacterium 009251343.1 [Lachno- SREELTEMTDASMDALSRVRRKLTGRRTKAYRERDINFDPLVMEKDPALLEGCFQSDK 3_1_57FAA_CT1 spiraceae YFRDCEGRVREAYRFRGIESGAFPLPEDYLRLEKQIEDCQSVSVHIRRGDYLDESHGG bacterium LYTGICTEAYYKEAFARMERLVPGARFFLFSNDPEWTREHFESKNCVLVEGSTEDTGY 3_1_57FAA_CT1] MDLYLMSRCRHNIIANSSFSWWGAWLNENPEKKVIAPAKWLNGRECRDIYTERMIRL Methano- YP_ 219852781 glycosyl 28.52 FutR MIIVRLKGGLGNQLSQYALGRKIAHLHNTELKLDTTWFTTISSDTPRTYRLNNYNIIG 13 sphaerula 002467213.1 transferase TIASAKEIQLIERGRAQGRGYLLSKISDLLTPMYRRTYVRERMHTFDKAILTVPDNVY palustris; family protein LDGYWQTEKYFKDIEEILRREVTLKDEPDSINLEMAERIQACHSVSLHVRRGDYVSNP Methano- [Methano- TTQQFHGCCSIDYYNRAISLIEEKVDDPSFFIFSDDLPWAKENLDIPGEKTFVAHNGP sphaerula  sphaerula  EKEYCDLWLMSLCQHHIIANSSFSWWGAWLGQDAEKMVIAPRRWALSESFDTSDIIPD palustris E1-9c palustris E1-9c SWITI Tannerella sp. WP_ 547187521 glycosyl 28.38 FutS MVRIVEIIGGLGNQMFQYAFSLYLKNKSHIWDRLYVDIEAMKTYDRHYGLELEKVFNL 14 CAG:118 021929367.1 transferase SLCPISNRLHRNLQKRSFAKHFVKSLYEHSECEFDEPVYRGLRPYRYYRGYWQNEGYF family 11 VDIEPMIREAFQFNVNILSKKTKAIASKMRRELSVSIHVRRGDYENLPEAKAMHGGIC [Tannerella  SLDYYHKAIDFIRQRLDNNICFYLFSDDINWVEENLQLENRCIIDWNQGEDSWQDMYL sp. CAG:118] MSCCRHHIIANSSFSWWAAWLNPNKNKIVLTPNKWFNHTDAVGIVPKSWIKIPVF Bacteroides WP_ 491925845 protein 28.09 FutU MKIVKILGGLGNQMFQYALFLSLKERFPHEQVMIDTSCFRNYPLHNGFEVDRIFAQKA 15 caccae; 005675707.1 [Bacteroides PVASWRNILKVAYPYPNYRFWKIGKYILPKRKTMCVERKNFSFDAAVLTRKGDCYYDG Bacteroides caccae] YWQHEEYFCDMKETIWEAFSFPEPVDGRNKEIGALLQASDSASLHVRRGDYVNHPLFR caccae ATCC 43185 GICDLDYYKRAIHYMEERVNPQLYCVFSNDMAWCESHLRALLPGKEVVYVDWNKGAES YVDMRLMSLCRHNIIANSSFSWWGAWLNRNPQKVVVAPERWMNSPIEDPVSDKWIKL Butyrivibrio sp. WP_ 551028636 protein 27.8 FutV MIIIQLKGGLGNQMFQYALYKSLKKRGKEVKIDDKTGFVNDKLRIPVLSRWGVEYDRA 16 AE2015 022772718.1 [Butyrivibrio TDEEIINLTDSKMDLFSRIRRKLTGRKTFRIDEESGKENPEILEKENAYLVGYWQCDK sp. YFDDKDVVREIREAFEKKPQELMTDASSWSTLQQIECCESVSLHVRRIDYVDEEHIHI AE2015] HNICTEKYYKNAIDRVRKQYPSAVFFIFTDDKEWCRDHFKGPNFIVVELEEGDGTDIA EMTLMSRCKHHIIANSSFSWWAAWLNDSPEKIVIAPQKWINNRDMDDIYTERMTKIAL Prevotella sp. WP_ 548264264 uncharacterized 27.4 FutW MRLVKMIGGLGNQMFIYAFYLQMRKRFSNVRIDLTDMMHYNVHYGYELHKVFGLPRTE 17 CAG:891 022481266.1 protein FCMNQPLKKVLEFLFFRTIVERKQHGRMEPYTCQYVWPLVYFKGFYQSERYFSEVKDE [Prevotella VRECFTFNPALANRSSQQMMEQIQNDPQAVSIHIRRGDYLNPKHYDTIGCICQLPYYK sp. CAG:891] HAVSEIKKYVSNPHFYVFSEDLDWVKANLPLENAQYIDWNKGADSWQDMMLMSCCKHH IICNSTFSWWAAWLNPSVEKTVIMPEQWTSRQDSVDEVASCGRWVRVKTE Parabacteroides WP_ 495431188 glycosyl 26.69 FutX MRLIKMIGGLGNQMFIYAFYLKMKHHYPDTNIDLSDMVHYKVHNGYEMNRIFDLSQTE 18 johnsonii; 008155883.1 transferase FCINRTLKKILEFLFFKKIYERRQDPSTLYPYEKRYFWPLLYFKGFYQSERFFFDIKD Parabacteroides [Para- DVRKAFSFNLNIANPESLELLKQIEVDDQAVSIHIRRGDYLLPRHWANTGSVCQLPYY johnsonii bacteroides KNAIAEMENRITGPSYYVFSDDISWVKENIPLKKAVYVTWNKGEDSWQDMMLMSHCRH CL02T12C29 johnsonii] HIICNSTFSWWGAWLNPRKEKIVIAPCRWFQHKETPDMYPKEWIKVPIN Akkermansia YP_ 187735443 glycosyl 25.67 FutY MRLFGGLGNQLFQYAFLFALSRQGGKARLETSSYEHDDKRVCELHHFRVSLPIEGGPP 19 muciniphila; 001877555.1 transferase PWAFRKSRIPACLRSLFAAPKYPHFREEKRHGFDPGLAAPPRRHTYFKGYFQTEQYFL Akkermansia family protein HCREQLCREFRLKTPLTPENARILEDIRSCCSISLHIRRIDYLSNPYLSPPPLEYYLR muciniphila [Akkermansia SMAEMEGRLRAAGAPQESLRYFIFSDDIEWARQNLRPALPHVHVDINDGGIGYFDLEL ATCC BAA-835 muciniphila MRNCRHHIIANSTFSWWAAWLNEHAEKIVIAPRIWENREEGDRYHTDDALIPGSWLRI ATCC BAA-835] Salmonella WP_ 555221695 fucosyl- 25.99 FutZ MYSCLSGGLGNQMFQYAAAYILKQYFQSTTLVLDDSYYYSQPKRDTVRSLELNQFNIS enterica; 023214330.1 transferase YDRFSFADEKEKIKLLRKFKRNPFPKQISEILSIALFGKYALSDRAFYTFETIKNIDK 20 Salmonella [Salmonella ACLFSFYQDADLLNKYKQLILPLFELRDDLLDICKNLELYSLIQRSNNTTALHIRRGD enterica subsp. enterica] YVTNQHAAKYHGVLDISYYNHAMEYVERERGKQNFIIFSDDVRWAQKAFLENDNCYVI enterica serovar NNSDYDFSAIDMYLMSLCKNNIIANSTYSWWGAWLNKYEDKLVISPKQWFLGNNETSL Poona str. ATCC  RNASWITL BAA-1673 Bacteroides sp. WP_ 547748823 glycosyl- 26.01 FutZA MRLIKMTGGLGNQFIYAFYLRMKKRYPKVRIDLSDMVHYHVHHGYEMHRVFNLPHTEF 21 CAG:633 022161880.1 transferase CINQPLKKVIEFLFFKKIYERKQDPNSLRAFEKKYLWPLLYFKGFYQSERFFADIKDE family 11 VRKAFTFDSSKVNARSAELLRRLDADANAVSLHIRRGDYLQPQHWATTGSVCQLPYYQ [Bacteroides NAIAEMNRRVAAPSYYVFSDDIAWVKENIPLQNAVYIDWNKGEESWQDMMLMSHCRHH sp. CAG:633] IICNSTFSWWGAWLDPHEDKIVIVPNRWFQHCETPNIYPAGWVKVAIN Clostridium sp. WP_ 547839506 alpha-1 2- 34.28 MEKIKIVKLQGGMGNQMFQYAFGKGLESKFGCKVISDKINYDELQKTIINNTGKNAEG 22 CAG:306 022247142.1 fucosyl- ICVRKYELGIFNLNIDFATAEQIQECIGEKLNKACYLPGFIRKIFNLSKNKTVSNRIF transferase EKKYGEYDEEILKDYSLAYYDGYFQNPKYFEDISDKIKKEFTLPEIKNHDIYNKKLLE [Clostridium KITQFENSVFIHVRRDDYLNINCEIDLDYYQKAVKYILKHIENPKFFVFCAEDPDYIK sp. CAG:306] NHFDIGYDFELVGENNKTQDTYYENMRLMMACKHAIIANSSYSWWAAWLSDYDNKIVI APTPWLPGISNEIICKNWIQIKRGISNE Prevotella WP_ 497004957 protein 32.11 MKIVKILGGLGNQMFQYALYLSLQESFPKERVALDLSCFNGYHLHNGFELERIFSLTA 23 sp. oral taxon  009434595.1 [Prevotella sp. QKASAATIMRIAYYYPNYLLWRIGKRLLPRRKTMCLESSTFRYDESVLTREGNRYFDG 306; Prevotella oral taxon YWQDERYFVACREKVLKAFTFPAFKRTENLSLLRKLDKNSVAIHVRRGDYIGNQLYQG sp. oral taxon  306] ICDLDYYRAAIDKISTYVTPSVFCIFSNDIAWCQTHLQPYLKAPVVYVTWNTGTESYR 306 str. F0472 DMQLMSCCAHNIIANSSFSWWGAWLNQNNEKVVIAPKRWLNMDDCQFPLPASWVKI glycosyl WP_ 547139308 [Brachyspira 30.14 MQLVKLMGGLGNQMFQYAFAKALGDKNILFYGDYKKHSLRKVELNRFKCKAVYIPREL 24 transferase 021917109.1 sp. FKYLKFVFTKFDKIEYMRSGIYVPEYLNRDGNHIYIGFWQTEKYFKQIRPRLLKDFTP family 11 CAG:484] RKKLDRENAGIISKMQQINSVSVHIRRTDYVDESHIYGDINLDYYKRAIEYISSKIEN Brachyspira sp. PEFFFFSDDMAYVKEKFAGLKEPHSFIDINSGNNSYKDLILMKNCKHNIIANSTFSWW CAG:484 GAWLNENEEKIVIAPAKWFVTGENDKDIVPDEWIKL Thalassospira WP_ 496164823 glycosyl 30 MVIVKLLGGLGNQMFQYATGRAVASRLDVELLLDVSAFAHYDLRRYELDDWNITARLA 25 profundimaris; 008889330.1 transferase TSEELARSGVTAAPPSFFDRIARFLRIDLPVNCFREASFTYDPRILEVSSPVYLDGYW Thalassospira family 11 QSERYFLDIEKKLRQEFQLKASIDANNHSFKKKIDGLGKQAVSLHVRRGDYVINPQTA profundimaris [Thalassospira SYHGVCSLDYYRAAVDYIAEHVSDPCFFVFSDDLEWVQTNLNIKQPIVLVDANGPDNG WP0211 profundimaris] AADMALMMACRHHIIANSSFSWWGSWLNPLNDKIIVAPKKWFGRANHDTTDLVPDSWV RL Acetobacter sp. WP_ 547459369 alpha-1 2- 29.9 MAVSPQESKYSAHVSPDKPLRIVRLGGGLGNQMFQYAFGLAAGDVLWDNTSFLINHYR 26 CAG:267 022078656.1 fucosyl- SFDLGLYNISGDFASNEQIKKCKNEIRFKNILPRSIRKKFNLGKFIYLKTNRVCERQI transferase NRYEPELLSKDGDVYYDGVFQTEKYFKPLRERLLHDFILTKPLDAANLDMLAKIRAAD [Acetobacter AVAVHIRRGDYLNPRSPFTYLDKDYFLNAMDYIGKRVDKPHFFIFSSDIDWVRTNIQT sp. CAG:267] AYPQTIVEINDEKHGYFDLELMRNCRHNIIANSTFSWWGAWLNINPDKIVVAPKQWFR PDAAEYSGDIVPNDWIKL Dysgonomonas WP_ 493896281 protein 29.9 MVTVLLSGGLGNQMFQYAAAKSLAIRLNTALSVDLYTFSKKTQATVRPYELGIENIED 27 mossii; 006842165.1 [Dysgonomonas VVETSSLKAKAVIKARPFIQRHRSFFQRFGVFIDTYAILYQPIFEALTGGVIMSGYFQ Dysgonomonas mossii] NESYFKNISELLRKDFSFKYPLIGENKDVAGQISENQSVAVHIRRGDYLNKNSQSNFA mossii DSM 22836 ILEKDYYEKAINYISAHVKNPEFYVFSEDFDWIKDNLNEKEFPVTFIDWNKGKDSYID MQLMSLCKHNIIANSSFSWWSAWLNNSEERKIVAPERWFVDEQKNELLDCFYPQGWIK I Clostridium WP_ 545396671 glycosyl- 29.83 >gi|545396671|ref|WP_021636924.1|glycosyltransferase, 28 sp. KLE 021636924.1 transferase, family11 [Clostridium sp.KLE 1755] 1755 family 11 MIIIEISGGLGNQMFQYALGQKFISMGKEVKYDLSFYNDRVQTLRQFELDIFDLDCPV [Clostridium ASNSELSRFGKGNSLKSRLKQKLGWDKEKIYEENLDLGYQPRIFELDDIYLSGYWQSE sp. LYFKDIREQILRLYTFPIQLDYMNGVFLRKIENSNSVSIHIRRGDYLNENNLKIYGNI KLE 1755] CTLNYYNKALQIIAKKITNPIIFVFINDIEWVRKELEIPNMVIVDCNSGKLSYWDMYL MSKCKANIVANSSFSWWGAWLNKNENRIIISPKRWLNNHEQTSTLCDNWIRCGDD Gillisia WP_ 494045950 alpha-1,2- 29.28 MFISKNIVIIKLVGGLGNQMFQFAIAKIIAEKEKSEVLVDITFYTELTENTKKFPRHF 29 limnaea; 006988068.1 fucosyl- SLGIFNSSFAIASKKEIDYFTKLSNENKFKKKLGLNYPTIFHESSFNFKAQVLELKAP Gillisia limnaea transferase IYLNGYFQSFRYFLGKEYVIRKIFKFPDEALDKDNDNIKRKIIGKTSVSLHIRRGDYV DSM 15749 [Gillisia NNKKTQQFHGNCTIDYYQSAIAYLSSKLTDFNLIFFSDDIHWVRQQFKNISNQKIYVS limnaea] GNLNHNSWKDMYLMSLCDHNIIANSSFSWWGAWLNKNPEKIIIAPKRWFADTEQDKNS IDLIPSEWYRI Methylotenera YP_ 253996403 glycosyl 29.19 MLVSRIIGGLGNQMFEYAAARAASLRISVQLKLDLSGFETYDLHAYGLNNFNIVEDVA 30 mobilis; 003048467.1 transferase KKDDYFIGAPESLLKKIKKYLRGLIQLESFRESDLSFDSKVLELNDNTYLDGYWQCER Methylotenera family protein YFIDFDKQIRQDFSFKFAPDALNQRYLELIDSVNAVSVHIRRGDYVSNSTTNEIHGVC mobilis JLW8 [Methylotenera DLDYYQRAAEFMRARIGPENLHFFVFSDDTDWVKENISFGSDTTFISHNDAAKNYEDM mobilis JLW8] RLMSACKHHIIANSSFSWWAAWLNPSKQKVVIAPRQWFKSTLLNSDDIVPASWVRL Runella YP_ 338214504 glycosyl 29.14 MIIVKLSGGLGNQLFQYAFGRHLATVNQKELKLDTSALTKTSDWINRSYALDAFNIRA 31 slithyformis; 004658567.1 transferase QEATPEEIKALAGKPNRLLQRVGRKVGITPIQYFQEPHFHFYSSALSIKSSHYLEGYW Runella family protein QSEKYFEAITPILREEFAFTISPSTHAQTIKEKISNGTSVSIHLRRGDYVKISKANRY slithyformis DSM [Runella LRPLTMDYYQKAIDYINQRVKNPNFFLFSDDIKWAKSQVTFPPITHFSTGTSAHEDLW 19594 slithyformis LMTHCRHHIIANSTFSWWGAWLNQQPDKIVIAPQKWFSTERFDTKDLLPEPWIQL DSM 19594] Pseudoalteromonas WP_ 489048235 alpha-1,2- 29.1 MIKVKAIGGLGNQLFQYATARAIAEKRGDGVVVDMSDFSSYKTHPFCLNKFRCKATYE 32 haloplanktis; 002958454.1 fucosyl- SKPKLINKLLSNEKIRNLLQKLGFIKKYYFETQLPFNEDVLLNNSINYLTGYFQSEKY Pseudoalteromonas transferase FLSIRECLLDELTLIEDLNIAETAVSKAIKNAKNSISIHIRRGDYVSNEGANKTHGVC haloplanktis [Pseudo- DSDYFKKALNYFSERKLLDEHTELFIFSDDIEWCRNNLSFDYKMNFVDGSSERPEVDM ANT/505 alteromonas VLMSQCKHQVISNSTFSWWGAWLNKNDEKVVVAPKEWFKSTDLDSTDIVPNQWIKL haloplanktis] uncultured EKE06679.1 406985989 glycosyl 28.67 MLTLKLKGGLGNQMFQYAASHNLAKNKKTKIFDLSFFSDIEVRDIKRDYLLDKFNISA 33 bacterium transferase DISFDQKNSISGFRKFLVKVISKFFGEVFYYRLKFLSSKYLDGYFQSEKYFKNVEEDI family 11 RKDFTLKDEMGVEAKKIEQQIVNSKNSVSLHIRRGDYVDDLKTNIYHGVCNLDYYKRS [uncultured IKYLKENFGEINIFVFSDDIAWVKENLAFENLQFVSRPDIKDYEELMLMSKCEHNIIA bacterium] NSSFSWWGAWLNENKNKIIIAPKEWFQKFNINEKHIVPKSWIRL Clostridium sp. WP_ 545396696 glycosyl- 28.57 MVIVQLSGGLGNQMFEYALYLSLKAKGKVVKIDDITCYEGPGTRPKQLDVEGVSYERA 34 KLE 021636949.1 transferase, TKQELTEMTDSSLDPVSRIRRKLTGRKTKAYREKDINFDPQVMERDPALLEGCFQSEK 1755 family 11 YFQDCREQVREAYRFRGIESGAYPLPEAYRRLEKEIADCKSVSVHIRRGDYLEESHGG [Clostridium  LYTGICTEQYYQEAFARMEKEVPGAKFFLFSNDPDWTREHFKGENRILVEGSTEDTGY sp. KLE 1755] LDLYLMSKCKHNIIANSSFSWWGAWLNDNPEKKVTAPARWLNGRECRDIYTERMIRI Francisella WP_ 490414974 alpha-1,2- 28.57 MKIIKIQGGLGNQMFQYAFYKSLKNNCIDCYVDIKNYDTYKLHYGFELNRIFKNIDLS 35 philomiragia; 004287502.1 fucosyl- FARKYHKKEVLGKLFSIIPSKFIVKFNKNYILQKNFAFDKAYFEIDNCYLDGYWQSEK Francisella transferase YFKKITKDIYDAFTFEPLDSINFEFLKNIQDYNLVSIHVRRGDYVNHPLHGGICDLEY philomiragia [Francisella YNKAISFIRSKVANVHFLVFSNDILWCKDNLKLDRVTYIDHNRWMDSYKDMHLMSLCK subsp. philomiragia] HNIIANSSFSWWGAWLNQNDDKIVIAPSKWENDDKINQKDICPNSWVRI philomiragia ATCC 25015 Pseudomonas WP_ 515906733 protein 28.52 MVIAHLIGGLGNQMFQYAAARALSSAKKEPLLLDTSSFESYTLHQGFELSKLFAGEMC 36 fluorescens; 017337316.1 [Pseudomonas IARDKDINHVLSWQAFPRIRNFLHRPKLAFLRKASLIIEPSFHYWNGIQKAPADCYLM Pseudomonas fluorescens] GYWQSERYFQDAAEEIRKDFTFKLNMSPQNIATADQILNINAISLHVRRGDYVNNSVY fluorescens AACTVEYYQAAIQLLSKRVDAPTFFVFSDDIDWVKNNLNIGFPHCYVNHNKGSESYND NCIMB 11764 MRLMSMCQHNIIANSSFSWWGAWLNSNADKIVVAPKQWFINNTNVNDLFPPAWVTL Herbaspirillum WP_ 495392680 glycosyl 28.48 MIATRLIGGLGNQMFQYAAGRALALRVGSPLLLDVSGFANYELRRYELDGFRIDATAA 37 sp. 008117381.1 transferase SAQQLARLGVNATPGTSLLARVLRKVWPQPADRILREASFTYDARIEQASAPVYLDGY YR522 family 11 WQSERYFARIRQHLLDEFTLKGDWGSDNAAMAAQIATAGAGAVSLHVRRGDYVSNAHT [Herbaspirillum AQYHGVCSLDYYRDAVAHIGGRVEAPHFFVFSDDHEWVRENLQIGHPATFVQINSADH sp. YR522] GIYDMMLMKSCRHHIIANSSFSWWGAWLNPAEDKIVVAPQRWFKDATNDTRDLIPAAW VRL Prevotella WP_ 496097659 rotein 28.43 MKIVKILGGLGNQMFQYALYLSLKETFPQENVTVDLSCFHGYHLHNGFEIARIFSLHP 38 histicola; 008822166.1 [Prevotella DKATVMEILRIAYYYPNYFFWQIGKRVLPQRKTMCTESTKLLFDKSVLQREGDRYFDG Prevotella histicola] YWQDERYFIDCRRTILNIFKFPPFTDDNNLALLKKMDINSVSIHVRRGDYVGNKLYQG histicola F0411 ICDLNYYREAIMKISSYISPSMFCVFSNDIEWCRDNLESFIKAPIYYVDWNSGTESYR DMQLMSCCGHNIIANSSFSWWGAWLNQNSSKIVIAPKRWINLKNCGFMLPSRWVKI Flavobacterium WP_ 516064371 protein 28.42 MIVVQLIGGLGNQLFQYAAAKALALQTKQKFSLDVSQFESYKLHNYALNHENVISKNY 39 sp. 017494954.1 [Flavobacterium KKPNRYLRKIKSFYQKNVEYKEVDEGYNPDLIHLKGGIIFLEGYFQSEKYFIKYEKEI WG21 sp. WG21] REDFELRTPLKKETKAAIAKIESVNSVSIHIRRGDYINNPLHNTSKEEYYNKALEIVE NKINNPVYFVFSDDMEWVKANFSTKQETIFIDENDASTNFEDLKLMTSCKHNIIANSS FSWWGGWLNKNPDKIVIAPKRWENDDSINTNDIIPTNWVKI Polaribacter WP_ 517774309 protein 28.42 MIIVRIVGGLGNQMFQYAYAKALQQKGYQVKIDITKFKKYNLHGGYQLDQFKIDLETS 40 franzmannii 018944517.1 [Polaribacter SPIANVLCRIGLRRSVKEKSLLFDEKFLEIPQREYIKGYFQTEKYFSSITPILRKQFI franzmannii] VQKELCNTTLRYLKEITIQKNACSLHIRRGDYISDEKANSVHGTCDLPYYKKSIKRIQ DEYKDAHFFIFSDDISWAKKNLINKNTTFIEHIVMPHEDMHLMSLCKHNITANSSFSW WGAWLNQHENKTVIAPKNWFVNRENEVACANWIQL Polaribacter sp. YP_ 472321325 glycosyl 28.42 MVVVRILGGLGNQMFQYAYAKSLAEKGYEVQIDISKFKSYKLHGGYHLDKFRIDLETA 41 MED152 007670847.1 transferase NSSSAFLSKIGLKKTIKEPNLLFHKDLLKVNNNAFIKGYFQAEQYFSDIREILINQFK family 11 IKKELAKSTLAIKNQIELLKTICSLHVRRGDYISDKKANKVHGTCDLDYYSSAIEHIS [Polaribacter KQNSNVHFFVFSDDIAWVKDNLNITNATYIDHNVIPHEDMYLMTLCNHNITANSSFSW sp. MED152] WGAWLNQNPDKIVIAPKNWFVDKENEVACKSWITL Methanococcus YP_ 150402264 glycosyl 28.19 MKIIQLKGGLGNQMFQYALYKSLKKRGQEVLLDISWYLKNNAHNGYELEWVFGLSPEY 42 maripaludis; 001329558.1 transferase ASIRQCFKLGDIPINLIYNVKRKVFPKKTFIFFEKSNENYDNNVFEVTNGYFEGYWQN Methanococcus family protein ENYFKNFRSEILNDFSFKNIDKRNAEFSEYLKSINSVSVHVRRGDYVINQKALNVHGN maripaludis [Methanococcus ICNLEYYNKAINLANNNLKNPKNIFSDDITWCKSNLGIDDPVYVDWNTGPYSYQDMYL C7 maripaludis C7] MSNCKNNIIANSSFSWWGAWLNQNTEKKVFSPKKWVNDRNNVNIVPNGWIKIK Gallionella sp. WP_ 517104561 protein 28.15 MIIAHIIGGLGNQMFQYAAGRALSLARGVPFKLDISGFEGYDLHQGFELQRVFNCAAG 43 SCGC 018293379.1 [Gallionella IASEAEVRDSLGWQFSSPIRRIVARPSLAVLRRSTFVVEPHFHYWAGIKQVPDNCYLA AAA018-N21 sp. GYWQSEQYFQSHAAVIRTDFAFKPPLSGQNSKLAMQIAQGNAVSLHIRRGDYANNPKT SCGC AAA018- TATHGLCSLDYYRAAIQHIAERVQSPHFFIFSDDIAWVKSNLAINFPHQYVDHNQGTE N21] SYNDMRLMSLCQHNIIANSSFSWWGAWLNINAHKIVIAPKQWFANTTHVADLIPSSWE RL Azospira YP_ 372486759 Glycosyl 28.04 MQSPACIAGARAWWVGYGMAEAMQPVVVGLSGGLGNQMFQYAAGRALAHRLGHPLSLD 44 oryzae; 005026324.1 transferase LSWFQGRGDRHFALAPFHIAASLERAWPRLPPAMQAQLSRLSRRWAPRIMGAPVFREP Dechlorosoma family 11 HFHYVPAFAALAAPVFLEGYWQSERYFRELREPLLQDFSLRQPLPASCQPILAAIGNS suillum PS [Dechlorosoma DAICVHVRRGDYLSNPVAAKVHGVCPVDYYQQGVAELSASLARPHCFVFSDDPEWVRG suillum PS] SLAFPCPMTVVDVNGPAEAHFDLALMAACQHFVIANSSLSWWGAWLGQAAGKRVIAPS RWFLTSDKDARDLLPPSWERR Prevotella WP_ 517274199 protein 28 MKIVKIIGGLGNQMFQYALAMALNKNFTDEEVKLDIHCFNGYTKHQGFEIDRVEGNEF 45 paludivivens 018463017.1 [Prevotella ELASYRDVAKVAYPYFNFQLWRIGSRIFPDRRHMISEDTSFKIMPEVITSHNYKYYDG paludivivens] YWQHEEYEKNIHDEILDAFKFPKFQDERNKALAERLSDSNSISIHIRRGDYLNDELFK GTCGIEYYKKAIEEINERTVPTLFCVFSNDIHWCKENIEPLLNGKETIYVDWNTGSDN YRDMQLMTKCKHNIIANSSFSWWGAWLNNTKDKIVIAPRIWYNTKEKVSPVANSWIKL Gramella YP_ 120434923 alpha-1,2- 27.96 MSNKNPVIVEIMGGLGNQMFQFAVAKLLAEKNSSVLLVDTNEYKEISQNLKDFPRYFS 46 forsetii; 860609.1 fucosyl- LGIFDISYKMGTENGMVNEKNLSFKNRVSRKLGLNYPKIFKEKSYRFDADISNKKTPI Gramella transferase YLKGYFQSYKYFIGVESKIRQWEEFPYENLGVGNEEIKSKILEKTSVSVHIRRGDYVE forsetii KT0803 [Gramella NKKTKEFHGNCSLEYYKNAITYFLDIVKEFNIVFFSDDISWVRDEFKDLPNEKVFVTG forsetii NLHENSWKDMYLMSLCDHNIIANSSFSWWAAWLNNNSEKNVIAPKKWFADIDQEQKSL KT0803] DLLPPSWIRM Mariprofundus WP_ 497534831 alpha-1,2- 27.92 MIIVQFTGGLGNQMFQYALGRRLSLLHDVELKFDLSFYQHDILRDFMLDRFQVNGQVA 47 ferrooxydans; 009849029.1 fucosyl- TEKEIEAYTNTPIFALDRPLLDRLVRWGLYRGIVSVSDEPPGKQALMVYNSRVLQAPR Mariprofundus transferase NTYVQGYWQSEKYFMPIRQKLLDDFSLVDKADQANGAMLEKIRQCHSVSLHVRRGDYV ferrooxydans PV-1 [Mariprofundus SNPLINHSHGTCGLEYYEKAIALIGSKVDDPHFFVFSDDPEWTRDHLKCRFPMTYVTC ferrooxydans] NSADSCEWDMELMRHCRDHIIANSSFSWWGAWLNMNPDKVVVAPAAWENNFSADTSDL IPDSWVRI Bacillus WP_ 488102896 protein  27.91 MKIIQVSSGLGNQMFQYALYKKISLNDNDVFLDSSTSYMMYKNQHNGYELERIFHIKP 48 cereus; Bacillus 002174293.1 [Bacillus RHAGKEIIDNLSDLDSELISRIRRKLFGAKKSMYVELKEFEYDPIIFEKKETYFKGYW cereus VD107 cereus] QNYNYFKDIEQELRKDFVFTEKLDKRNEKLANEIRNKNSVSIHIRRGDYYLNKVYEEK FGNIANLEYYLKAINLVKKKIEDPKFYIFSDDIDWAQKNINLINDVVYISHNQGNESY KDMQLMSLCKHNIIANSTFSWWGAFLNNNDDKIVVAPKKWINIKGLEKVELFPENWIT Y Firmicutes WP_ 547951299 protein 27.81 MIIIRMIGGLGNQMFQYALYLKLRAMGKEVKMDDFTEYEGREARPLSLWAFGIEYDRA 49 bacterium 022352106.1 [Firmicutes SREELCRMTDGFLDPVSRIRRKLFGRKSLEYMEKDCNFDPEILNRDPAYLTGYFQSEK CAG:534 bacterium YFADIEEEVRQAFRFSERIWEGIPSQLLERIRSYEQQ1KTTMAVSVHIRRGDYLQNEE CAG:534] AYGGICTERYYKTAIEYVKKRQQDASFFVFTNDPDYAGEWILKNFGQEKERFVLIEGT QEENGYLDLYLMSLCRHHILANSSFSWWGAYLNPSREKMVIVPHKWEGNQECRDIYME NMIRIAKEQS Sideroxydans YP_ 291615344 glycosyl 27.81 MVISNIIGGLGNQMFQYAAARALSLKLEVPLKLDISGFTNYALHQGFELDRIFGCKIE 50 lithotrophicus; 003525501.1 transferase IASEADVHEILGWQSASGIRRVVSRPGMSIFRRKGFVVEPHFSYWNGIRKITGDCYLA Sideroxydans family 11 GYWQSEKYFLDAAVEIRKDFSFKLPLDSHNAELAEKIDQENAVSLHIRRGDYANNPLT lithotrophicus [Sideroxydans AATHGLCSLDYYRKSIKHIAGQVRNPYFFVFSDDIAWVKDNLEIEFPSQYVDYNHGSM ES-1 lithotrophicus SENDMRLMSLCKHHIIANSSFSWWGAWLNPNPEKVVIAPERWFANRTDVQDLLPPGWV ES-1] KL zeta  WP_ 517092760 protein [zeta 27.81 MIVSQIIGGLGNQMFQYATGRALSHRLHDIFFLDLDGFSGYQLHQGFELSNVFQCEVN 51 proteobacterium 018281578.1 proteo- VATRSQMQALLGWRSFSSVRRLLMKRSLKWARGHRVMIEPHFHYWSRFAEINEGCYLS SCGC AB-137-009 bacterium GYWQSERYFKPIENIIRQDFKFNHLLKGVNLDLAQQMTEVNSVSLHVRRGDYASDANT SCGC AB-137- NHTHGLCPLDYYRDAILYIAQNTVAPSFFIFSDDIEWCREHLKLSFPATYIDHNKGSN C09] SYCDMQLMSLCHHHIIANSSFSWWGAWLNTRLDKIVIAPKQWFANGNRTDDLIPAEWL VM Pedobacter YP_ 255530062 glycosyl 27.8 MKIIRFLGGLGNQMFQYAFYKSLQHREPHVKADLQGYQEYTLHNGFELEHIFNIKVNS 52 heparinus; 003090434.1 transferase VSSFTSDLFYNKKWLYRKLRRILNLRNTYIEEKKLFSFDPSLLNNPKSAYYWGYWQNF Pedobacter family protein QYFEHIADDLRKDFQFRAPLSAQNQEVLDQTKLSNSISLHIRRGDYIKDPLLGGLCGP heparinus DSM [Pedobacter EYYQTAINYITSKVNAARFFIFSDDIDWCIANLKLQDCSFISWNKGTSSYIDMQLMSS 2366 heparinus DSM CKHHIVANSSFSWWAAWLNPNPDKIVIAPEKWINDKDINVRMSFPQGWISL 2366] Methylophilus WP_ 517814852 protein 27.78 MFQYAMGLSLAENNQTPLKLDLSQFTDYKLHNGFELSKVFNCSAETASVTQIETLLGI 53 methylotrophus 018985060.1 [Methylophilus NCKYSFIRRILKNTYLKLRPAQYVVEPFEGYWDGVNFLGDNVYLEGYWQSQKYFIDYE methylotrophus] STIRTHFTFKNILSGENLKLSDRIKGSNSVSLHIRRGDYVINKNNAFIGTCSLIYYQN AIEYFSTKIADPIFFIFSDDITWAKSNLRLANEHYFVGHNQGEDSHFDMQLMSLCKHH IIANSSFSWWGAWLNPSKDKIIIAPKKWFASGLNDQDLVPKDWLRI Rhodobacterales WP_ 495309205 alpha-1,2- 27.7 MIYTRIRGGLGNQLFQYSAARSLADYLNVSLGLDTREFDENSPYKMSLNHFNIRADLN 54 bacterium 008033953.1 fucosyl- PPDLIKHKKDGKIAYIIDHIKGNQKKVYKEPFLSFDKNLFSNVDGTYLKGYWQSEKYF HTCC2255 transferase LRNRKNILSDINLIKKTDKENTINLKEIKKSTSISLHIRRGDYLSNESYNETHGICSL [Rhodo- SYYTDAVEYIKNRLGENIKVFAFSDDPDWVLENLKLSVDIKIINNNTSANSFEDLRLM bacterales LNCDHNIIANSSFSWWGAWLNQNPEKIVISPKKWYNKKQLQNADIVPSSWLKY bacterium HICC2255] Spirulina WP_ 515872075 protein 27.69 MAKIIARIRGGIGNQIFIYAAARRLELINNAELVLDSVSGFVHDLQYRQHYQLDHFHI 55 subsalsa 017302658.1 [Spirulina PCRKATPAERFEPFSRVRRYLKRQLNQRLPFEQRRYVIQESIDFDPRLIEFKPRGTVH subsalsa] LEGYWQSEDYFKDIEATIRQDLQIQPPTDPTNLAIVQHIHQHTSVAVHIRFFDQPNAD TMNNAPSDYYHRAVEAMETFVPGAHYYLFSDQPEAAKSRIPLPDERVTLVNHNRGNKL AYADLWLMTQCQHFIIANSTFSWWGAWLAENQKKQVIAPGFEKREGVSWWGFKGLLPK QWIKL Vibrio WP_ 498119755 glycosyl 27.67 MVIVKITGGLGNQLFQYATGSALANKLSCELVLDLSFYPTQTLRKYELAKENNARVAT 56 cyclitrophicus  010433911.1 transferase DREIFLAGGGNDFFSKALKKLGLTSIIFPEYIKEQESIKYVGKIDLCKSGAYLDGYWQ family 11  HNPLYFSQNKIELTREFLPRAQLSPSALAWKDISQASNSVSLHVRRGDYVENAHTNNI [Vibrio HGTCSLEYYQHAIEKIRSEVHNPVFFVFSDDIEWCKLNLSSLAEVEFVDNTTSAIDDL cyclitrophicus] MLMRQCKHSIIANSTFSWWGAWLKLDGLVIAPRNWFSSASRNLKGIYPKEWHIL Lachnospiraceae WP_ 551039510 protein 27.65 MRSVVDIKGGYGNQLFCYSFGYAVSKETGSELIIDTSMLDMNNVKDRNYQLGVLGITY 57 bacterium NK4A179 022783177.1 [Lachno- DSHISYKYGKDFLSRKTGLNRLRKKSAIGEGTVVFKEKEQYVYDPSVFEIKRDTYFDG spiraceae FWQSSRYFEKYSDDLRKMLKPKKISNAAEKLAEDARDCLSVSVHIRRGDYVSLGWILK bacterium DDYYIKALDIIKERYGSEPVFFVFSDNKKYADDFFSAAGLKYRLMDYETDDAVRDDMF NK4A179] LMSRCSHNIMANSSYSWWGAFLNDNKDKTVICPETGVWGGDFYPEGWMKVTASSGK uncultured EKE02186.1 406980610 glycosyl 27.57 MIIVNLYGGLGNQMFQYALGRHLAEKNNTELKLDISAFESYKLRKYELGNLNIIEKFA 58 bacterium transferase LPEEISRLSTLPTGKIERFIRKTLRKPVKKPESYIKENITGGENPKILDLQNNIYLEG family protein YWQSEKYFIEIEDIIRKEFSFKFPATGKNKEILENILNINSVSLHIRRGDYVINPEVN [uncultured QVHGVCSLDYYKSCVDFIEKKLESPYFYIFSDDIEWVKNNLQIQSQVYYVDHNTVDNA bacterium] IEDMRLMFSCKHNILANSSFSWWGAWLNSNPDKMVITPRKWENTTYDSNDLIPERWIK L Bacteroides WP_ 492366053 protein 27.46 MKIGIIYIVTGPYIKFWNEFYSSSQLYFCVEAEKNYEVFTDSSELASQRLPNVHMHLI 59 fragilis; 005822375.1 [Bacteroides EDKGWIVNVSSKSKFICEIRNQLTSYDYIFYLNGNFKFISPIYCDEILPQAEHNYLTA Bacteroides fragilis] LSFSHYLTIHPDHYPYDRNKNCNAFIPYGQGKYYFQGGFYGGRTQEVLSLSEWCRDAI fragilis HMW 616 EADFNKKVIARFHDESYINRYLLTQHPKVLNDKYAFQDIWPYEGEYKAIVLNKEEVPE DNNLQEMKQNYIDPSLSFLLNDELKFIPISIVQLYGGLGNQMFGYAFYLYIRHISTQE RKLLIDPAPCKRYGNHNGYELPSIFSKICQDIHISDETKNNIRKLRKGTSLSIEEVRA SMPQSFKEKKQPIIFYSGCWQCVTYVETVKDEIKKDFIFDESKLNEPSAQMLRIIRRS NSVSVHIRRNDYLIGNNEFLYGGICTKSYYEKAISQMYTLLKDEPIFIYFTDDPEWVR SNFALDKSYLVDWNKNKDNWQDMYLMSACRHHIIANSSFSWWAAWLGGFPEKKVIAPS TWLNGMQTPDILPTEWIKIPITPDKKILDRICNHLILHSSYMKQLGLNSGKMGVVIFF FHYARYTQNPLYENYAGDLFDELYEEIHKGISFSFLDGLCGIAWAVEYLVHEQFIEGN TDDSLAEIDFKVMQIDPRRFTDYSFETGLEGIACYVLSRLLSPRVCSSSLILDSVYLK DLTEACRKVPVDKANYTRLFLNYIESKEVGYSFKDVLMQVLNHSEKAFGSDGLTWQTG LTMIMR Butyrivibrio sp. WP_ 551034739 protein 27.46 MIIIQLKGGLGNQMFQYALYKELRSRGKEVKIDDVTGFVDDELRTPVLQRFGIEYDRA 60 AE3009 022778576.1 [Butyrivibrio TREEVVKLTDSKMDIFSRIRRKLTGRKTCRIDEESGTFNPDILELDEAYLVGYWQSDK sp. YFRNEDVIAQLRQEFQKRPQEIMTDSASWATLQQIECCQSVSLHIRRIDYIDEEHNHI AE3009] HNLCTEKYYKGAIDRIRSQYPSAVFFIFTDDKEWCRNHFRGPNFFVVELAEKENTDIA EMLLMSSCKHHICANSSFSWWSAWLNDSPEKMVIVPNKWINNRDMDDIYTDRMTKMAI Bacteroides WP_ 490447027 protein 27.43 MKQTIILSGGLGNQMFQYAFFLSMKAKGKSCSLDTTLFQINKMHNGFELKSVFDIPDS 61 ovatus; 004317929.1 [Bacteroides PNQASALHSLLIKMLRRYKPKSILTIDEPYTFCPDALESKKSFLMGDWLSPKYFESIK Bacteroides ovatus] DVVVNAYRFHNIGNKNVDTANEMHGNNSVSIHIRRGDYLKLPYYCVCNENYYRQAIEQ ovatus CL02T12C04 IKDRVDNPIFYVESNEPSWCDSFMKEFRVNFKIVNWNQGKDSYQDMYLMTQCKHNIIA NSTFSWWGAWLNNNTDKIIVAPSKWFKNSEHNINCKEWLLIDTSK Desulfospira WP_ 550911345 protein 27.42 MGKKYVETVVNGGLGNQIFQFSAGFALSKRLNLDLVLNISTFDSCQKRNFELYTFPKI 62 joergensenii 022664368.1 [Desulfospira SKNSFACIKDDDPGVFRLRIPFLNEKEKIKQFHESHEFFDPAFFDIREPVRIEGYFQS joergensenii] YKYFEKYSDQLKDILLDIPLTSRLKTVLKVISSKKESVSVHIRRGDYISDQGINEVHG TLNEAYYLNSIKLMEKMFPESEFFLFTDDPHYVEENFKFLEDTSCIISDNDCLPYEDM YLMANCHHNIIANSSFSWWGAWLNQNPEKIVIAPRKWFSRKILMEKPVMDLLPDDWIL L Lachnospiraceae EOS74299.1 507817890 protein 27.39 MNIIRMTGGLGNQMFQYALFLRLKAQGKEVKFDDRTEYKGEEARPILLWAFGIDYPAA 63 bacterium 10-1 C819_03052 GEEEVNELTDGVMKFSHRLRRKLFGRKSKEYREKSCNFDQQILEKEPAYFTGYFQSER [Lachno- YFEEVKEQVRKAFQFSGKIWGSVSKELEERIREYQTKIENKSQMPVSVHIRRGDYLEN spiraceae DEAYGGICTDAYYRKAIEMMEEKFPNTVFYIFSNDTGWAKQWIDHFYKEKSRFIVIEG bacterium 10- TTEDTGYLDLFLMSKCRAHIIANSSFSWWGAWLDPDQEKIVIAPSKWVNNQDMKDIYT 1] REMIKISPKGEVR Bacteroides WP_ 495107639 protein 27.33 MVVVYVGAGLANRMFQYAFALSLREKGLDVFIDEDSFIPREDFERTKLDSVFVNVNIQ 64 dorei; 007832461.1 [Bacteroides RCDKNSFPLVLREDRFYKLLKRISEYMSDNRYIERWNLDYLPYIHKKASTNCIFIGFW Bacteroides dorei] ISYKYFQSSEDAVRKAFTFKPLDSIRNVELATKLVTENSVAVHFRKNIDYLKNLPNTC dorei DSM 17855 PPSYYYEAINYIKKYVPNPKFYFFSDNWDWVRENIRGVEFTAVDWNPSSGIHSHCDMQ LMSLCKHNIIANSTYSWWSAYLNENNNKIVVCPKDWYGGMVKKLDTIIPESWIIING Firmicutes WP_ 547127421 protein 27.33 MVIVKMSGGLGNQMFQYALYRKIQQTGKDVKLDLFSFQDKNAFRRFSLDIFPIEYQTA 65 bacterium 021916201.1 [Firmicutes NLEECRKLGECSYRPVDKIRRKMFGLKESYYQEDLDKGYQPEILEMNPVYLDGYWQCE CAG:24 bacterium RYFQDIREKILEDYTFPKKISIESSRLQERIKNTESVSIHIRRGDYLDAANYKIYGNI CAG:24] CTIEYYQSAISRMRKLCEKPNFYLFSNDPEWAKEIFGDTEDITIVEEDKERPDYEDMF LMSRCKHNIIANSSFSWWAAWLNQNENKRVIAPVKWENNHSVTDVICDDWIRIDGDHK GA Clostridium WP_ 547299420 epsH 27.3 MIYVNIRGRLGNQLFIYAFARALQKSTNQQITLNYTSFRKHYNNTAMDLEQFNIPEDI 66 hathewayi CAG:224 022031822.1 [Clostridium MFENSKELPWFANTDGKVIRILRHYFPKLIRSILQKMNVLMWLGDEYVEVKVNKRRDI hathewayi YIDGFWQSSRYFKSVYKELKNELIPKMEMSKEIKTMGDLINQKESVCVSVRRGDYVTV CAG:224] KKNRDVYYICDEKYLNTSIMRMVELVPNVTWFIFSDDADWVKDNIVFPGEVFYQPPRV TPLETLYLMKACKHFIISNSSFSWWGQYLSNNDNKIVIGPAKWYVDGRKTDIIEEEWI KIEV Syntrophus YP_462663.1 85860461 alpha-1,2- 27.3 MVIVRLIGGIGNQMFQYAAARRVSLVNNAPLFLDLGWFQETGSWTPRKYELDAFRIAG 67 aciditrophicus fucosyl- ESASVGDIKDFKSRRQNAFFRRLPLFLKKRIFHTRQTHIIEKSYNFDPEILNLQGNVY SB; Syntrophus transferase LDGYWQSEKYFSDVDSEIRREFSFQTDPAERNRKILERIASCESVSIHIRRGDYVTLP aciditrophicus [Syntrophus DANAFHGLCIPAYYRLAVEQISRKVVEPVFFVFSDDIAWARGNLKLGFETCFMDQNGP aciditrophicus DRGDEDLRLMIACRHHIIANSSFSWWGAWLCSNPEKIVYAPRKWENNGLDTPDNIPAS SB] WIRI Bacteroides WP_ 491931393 protein 27.27 MKIVKIIGGLGNQMFQYALYLSLKKKYPKEKIKIDISMFETYGLHNGFELKRIFDIDA 68 caccae; 005678148.1 [Bacteroides EYASREEIRELSFYIKIYKLQRIFRKIFPVRKTECVEKYDFKFMSEVWSNCDRYYEGY Bacteroides caccae] WQNWEYFIEAQTEVRSTFTFKKELVGRNAKVIREIQYAKMPVSLHIRRGDYLHHKLEG caccae ATCC 43185 GLCDLNYYKKAIDYVLNNYDTPQFYLFSNDIEWCKTYILPLVQGYPFILVDWNSGVES YIDMQLMSCCRINIIANSSFSWWAAWLNDSSEKIVIAPKLWAHSPYGKEIQLKSWLLF Butyrivibrio WP_ 551011888 protein 27.24 MIIIEMSGGLGNQMFQYALYKSMLHKGLDVTIDKSIYRDVDHKEQVDLDRFPNVSYIE 69 fibrisolvens 022756304.1 [Butyrivibrio ADRKLSSTLRGYGYNDSIIDKIRNKLNKSKRNLYHEDLDKGYQPEIFEFDNVYLNGYW fibrisolvens] QCERYFKDIKNEIKKDFIFPCTQSGDDKIKALTIEMESCNSVSLHVRRGDYLKPGLIE IYGNICTEEYYKKSIEYIKERVDNPVFYIFSNDMAWVRDNEKSDDFRYVNEDGAFDGM TDMYLMTRCRHNIVANSSFSWWGAWLNKHDDNIVICPNRWVNTHTVTDIICEDWIRID V Parabacteroides WP_ 492476819 protein 27.24 MIVGGNDYCKVKVVNIIGGLGNQMFQYAFALSLKEHFPKEEIRIDISHENYLFVNKVG 70 distasonis; 005857874.1 [Para- AANLHNGYELDKIFFNIELKKANAWQLMKLTWFIPNYLISRIARKILPVRNSEYIQNS Parabacteroides bacteroides SDCFFYDPMVYNKQGSCYYEGYWQAIGYYESMRDKLCKIFQHPSPEGKNKQYIENMES distasonis distasonis] SNSVGIHIRRGDYLLSDNFRGICEVDYYKRAIDKILQDGEKHVFYLFSNDQKWCEEYI CL03T12C09 LPLLGNYEIIFVTGNIGRDSCWDMFLMTHCKDLIIANSSFSWWGAFLNKRGGRVVTPK RWMNRNIRYDLWMPEWIRI Geobacter YP_ 148263741 glycosyl 27.21 MIIARLQGGLGNQMFQYAVGLHLALTHNVELKIDITMFSDYKWHTYSLRPFNIRESIA 71 uraniireducens; 001230447.1 transferase TEEEIKALTDVKMDRPYKKIDNFLCRLLRKSQKISATHVKEKHFHYDPDILKLPDNVY Geobacter family protein LDGYWQSEKYFKEIENIIRQTFIIKNPQLGRDKELACKILSTESVCLHIRRGNYVTDK uraniireducens [Geobacter TINSVLGPCDLSYYSNCIKSLAGNNKDPHFFVFSNDHEWVSKNLKLDYPTIYVDHNNE Rf4 uraniireducens DKDYEDLRLMSQCKHHIIANSTFSWWSAWLCSNPDKVIYAPQKWERVDEYNTKDLLPS Rf4] NWLIL Lachnospiraceae WP_ 511026085 protein 27.21 MIIVKIYEGLGNQLFQYAFARSIQVNGKKVFLDTSGYTDQLFPLCRTSTRRRYQLNCF 72 bacterium A4 016280341.1 [Lachno- NIRIKEVEKKNIEKYSFLIQEDMFGKLISKLAKLHLWMYKVTIQQNAQEYKESYLNTR spiraceae GNVYYKGWFQNPKYFSSIRRLLLKEITPKYKIRIPAELRELLQEDNIVAVHCRRGDYQ bacterium A4] YIRNCLPVNYYKKAMAYMEKKLGVPRYLFFSDDLSWVKRQFGNKDNNYYIEDYGKFED YQELMIMSRCRNFIIANSTFSWWAAWLCSYENKVVIMPRVWTYVGGQGVEMSDFPADW IRI Colwellia YP_270849.1 71282201 alpha-1,2- 27.15 MKVVRVCGGEGNQLFQYAFYLAVKHKFNETTKLDIHDMASYELHNGYELERIFNLNEN 73 psychrerythraea; fucosyl- YCSAEEKLAVQSTKNIFTKLLKEIKKYTPFIPRTYIKEKKHLHFSYQEVDLGTKDTSI Colwellia transferase YYRGSWQNPQYFNSIASEIREKLTFPEFTEPKSLALHQEISEHETVAVHIRRGDYLKH psychrerythraea [Colwellia KALGGICDLPYYQNAIKEIEGLVEKPLEVIFSDDITWCRANINVEKVRFVDWNSGEQS 34H psychrerythraea FQDMHLMSLCIHNIIANSSFSWWGAWLNANPNKIVISPNKWIHYTDSMGIVPSEWIKV 34H] ETSI Roseobacter sp. WP_ 497495952 alpha-1,2- 26.96 MITSRLHGRLGNQMFQYAAARALAHRLGCGVALDGRGAELRGEGVLTRVFDLPLSAAP 74 MED193 009810150.1 fucosyl- KLPPLKQHAPLRYGLWRGLGLAPRFRRERGLGYNTAFETWEDGCYLHGYWQSERYFEE transferase ISDLIRADFTFPDFSNRQNAEMAARIMEDNAISLHVRRGDYVALSAHVLCDQAYYEAA [Roseobacter LTRLLEGLSQDAPTVYVFSDDPDWAKANLPLPCKKVVVDENGPETDFEDMRLMSLCKH sp. MED193] NIIGNSSFSWWAAWLNANPQKRVAGPANWFGDPKLSNPDILPSQWLKVAP Cesiribacter WP_ 496488826 Glycosyl 26.89 MMIVRLCGGLGNQLFQYAVGKQLSVKNNIPLKIDDSWLRLPDARKYRLQFFQIEEPLA 75 andamanensis; 009197396.1 transferase SPQEVERFVGPYESQSLYARLYRKVQNMLPRHRRRYFQESGFWAYEPELMRIRSQVFL Cesiribacter family 11 EGFWQHHAYFTRLHPQVLEALQLREEYRQEPYAVLDQIREDAASVSLHIRRGDYVSDP andamanensis [Cesiribacter YNLQFFGVMPLSYYQQAVAYMQEQLHAPTFYIFSDDLDWARAHLKLQAPMVFVDIEGG AMV16 andamanensis] RKEYLELEAMRLCRHNILANSSFSWWGAYLNINPHKRVIAPRQWVADPELKDKVQIQM PDWILL Rhodopirellula WP_ 495954476 glycosyl 26.89 MIATRLIGGLGNQMFQYAYGFSLARRRSERLVLDVSAFESYDLHALAIDQFDISAARM 76 sallentina; 008679055.1 transferase TQAEFARIPGRYRGKSRWAERVANFAGGLQSCDKRPLRLRREKPFGFAEKYLAEGSDL Rhodopirellula family 11 YLDGYWQSERYFPGLQAELKKEFQLKRGLSDESSRVLDEIQSSMSVAMHVRRGDYVTN sallentina SM41 [Rhodopirellula AETLRIYRRLDAEYYRKCLNDLRQRFSNLNVFVFSNDIQWCQDHLDVGLKQRPVTHND sallentina] ATTAIEDMFLMSQCDHSIIANSSFSWWAAFLGRSDAQRRVYYPDPWFNPGTLNGDSLG CANWVSESSISVSRPSRAA Butyrivibrio sp. WP_ 551018054 protein 26.85 MIIIRMMGGLGNQMFQYALYLCILKALGKEVKIDDVYGERDDPQRDPVLEKMYGITYT 77 AD3002 022762282.1 [Butyrivibrio KASDAEVVDITDSHLDIFSRIRRKLFGRKSHEYIEETGLFDPKVFEFETAYLNGYFQS sp. DKYFPDKEVLAQLRREFVIKPDDVFTSADSWELYRQIRETESVSIHVRRGDYLLPGTV AD3002] ETFGGICDNDYYKRAIDRMVSEHPDAIFFVFTSDKEWCEQNVSGKKFRIVDTKEENDD AADLLLMSLCKHHILANSSYSWWSAWMNDSPEKTVIVPSKWLNTKPMDDIYISRMTKI Segetibacter WP_ 517440157 protein 26.78 MVVVKLIGGMGNQMFQYAIGRHLAIKNKCPLYFDHIELENKNTANTPRNYELDIFNVQ 78 koreensis 018611017.1 [Segetibacter YQKNPFLQSNRFVAKVYFIKLFSVQRIKEPDFTFHPHILNVQGNIHLNGYWQNENYFK koreensis] EIEEIIRQDFTFKTPANEKIESILQQ1AAINSVSLHVRRGDYITLTEANQFHGVCSDT YYQKAIAKIKEAIPAPHLFVFSDDIHWVKQNMPFTEEHTFVDGNTGKNSFEDLRLMAA CRHNILANSSFSWWAGWLNKNPEKMVIAPEKWFRAVHTDIVPPSWIKM Amphritea WP_ 518450815 protein 26.76 MVIVRLIGGLGNQLFQYAYALSLLEQGYDVKLDASAFESYTLHGGFGLGEYAERLEVA 79 japonica 019621022.1 [Amphritea TTEEVDMVSRVGRISTLLRKLQGKKSRRVIKESNFSYDEKMLTPEDSHYLVGYFQSEL japonica] YFNKIRGELLSALDLKHKLSPYTEASYLAIADASVSVSMHIRRGDYVSDKAAHNTHGV CSLDYYYAAVTFFEERYPDVDFYIFSDDIEWVKENLNVQRAHYISSEEKRFAGEDIYL MSQCDHNIVANSSFSWWGAWLNANEDKIVVAPRQWYADSNMQRLSKTLVPDTWIRL Desulfovibrio YP_ 218887785 glycosyl 26.76 MRPVVVDIFGGLGNQMFQYAAAKSLAERLGVRLELDVSMFSGDPLRAFSLGEFAITDH 80 vulgaris; 002437106.1 transferase VRGKSRSSLLVRFARSLGFGSSSKCVEPFFHYWEGINEIEAPVHMHGYWQSEKYFKAY Desulfovibrio family protein EDLIRRTFSFSACEGVASSGKYAGVSSPMSVSVHLRRGDYKEQKNVVVHGILGREYYD vulgaris str. [Desulfovibrio AAYSIIKQGCPSACFFVFTDAINEAVDFFSHWNDVLFVDGNNQYQDMYLMSQCRHHII ′Miyazaki vulgaris str. ANSSYSWWGAWLGAFSDGMTVAPKMWFAYDVLKEKSIKDLFPEDWIVL F′ ′Miyazaki F′] Spirosoma WP_ 522095677 protein 26.76 MIISRITSGLGNQLFQYAVARHLSLKNKTSLYVDLSYYLYQYHDDTSRNFKLGNFSVP 81 spitsbergense 020606886.1 [Spirosoma YHTLQQSPVEYVSKATKLLPNRSLRPFFLFQKERQFHFDEQILQSRAGCVILEGFWQS spitsbergense] EAYFRDNADTIRRDLQLSGTPSPEFNQYRELIRETPMSVSIHVRRSDYVNHPEFSQTF GFVGIDYYKRAIELARKELANPRFFVFSDDKEWSKTNLPLGEDSVFVQNTGLNGDVAD LVLMSHCQHHIIANSSFSWWGAWLNPNAGKLVITPKNWYKNKPAWNTKDLLPPTWLSI Lachnospiraceae WP_ 511037988 protein 26.73 MNIIRMSGGIGNQMFQYALYLKLVSLGKEVKFDDVTEYELDNARPIMLSVFGIDYPKA 82 bacterium 28-4 016292012.1 [Lachno- SREELVELTDASMDFLSRVRRKIFGRKSGEYHEASADYDETVLEKEHAYLCGCFQSER spiraceae YFKDIEYEVREAYRFRNVVVPEEIRGGIETYERQIGESLSVSIHIRRGDYLDAADVYG bacterium 28- GICTDAYYNQAIRYMIKKYENPSFFVFINDTFWAEKWCEVREREIGKRFTVIKGTDEE 4] TGYIDLMLMSRCKAHIIANSSFSWWGAWLDASPDKCVVAPVKWINTRECRDIYTEDMV RIGSNGKISFSNCSSL Lachnospiraceae WP_ 511048325 protein 26.71 MVVVRIWEGLGNQLFQYAYARALSLRTKDRVYLDISEYEMSPKPVRKYELCHFKIKQP 83 bacterium COE1 016302211.1 [Lachno- VINCGRIFPFVNKDSFYTKNNQYLRYFPAGLIKEEDCYFKRDFCELKGLLYLKGWFQS spiraceae  EKYFKEFESHIREEIYPRNKIKITRGLRKILNSDNIVSVHIRRGDFGKDHNILPIEYY bacterium COE1] ENSKRVILERVDNPYFIIFSDDILWVKENMNFGLNCFYMDKEYSYKDYEELMIMSRCK HNIIANSTFSWWGAWLNPSKDKIVIAPKKWFLYNPKKDFDIVPNDWIRV Parabacteroides; WP_ 492502331 alpha-1,2- 26.69 FutZB MKIVNIIGGLGNQMFQYAFAVALKAKYPNEEVFIDTQHYKNAFIKVYHGNNFYHNGYE 84 Parabacteroides 005867692.1 fucosyl- IDKVFPNATLEPARPKDLMKVSFYIPNQVLARAVRRIFPKRKTEFVTDQQPYVFIPEA sp. 20_3; transferase LSVIDDCYFDGYWMTPLYFDKYRDRILKEFTFRPFDTKENLELEPLLKQDNSVIVHIR Parabacteroides [Para- RGDYVGSSSFGGICTLDYYRNAIREAYNLITSPEFFIFSNDQKWCMENMRNEFGDAKV distasonis bacteroides] HFIAHNRGADSYRDMQLLSIARCNILANSSFSWWGAYLNQRKNCFIICPHKWHNTLEY CL09T03C24 SDLYLPTWIKI Bacteroides sp. WP_ 488624717 protein 26.62 MFVIRLIGGVGNQLFQYTFGQFLRHKFGVEVCYDIVAFDTVDKGRNLELQLLDESLPL HPS0048 002561428.1 [Bacteroides FETSNFFFSKYKSWKKRLFLYGELLKKNNKYYTKYAPEEISLFTEKGLSYFDGWWQYP sp. ALLRDTINNMEDFFIPKQPIPVQIQKYYNEILLNNFAVALHVRRGDYFTSKYAKTYAV HPS0048] CNVEYYTSAVNLMCEKLRSCKFYVFSDDLDWVKSNLILPSNTVYVKNYDINSYWYIYL 85 MSLCRHIIISNSSFSWWGATLNRNFHKIVIAPKYWSTKKNNTLCDNSWIKI Bacteroides WP_ 511013468 protein 26.58 MKIINILGGLGNQMFEYAMYLALKNAHSEEEILCSTRSFCGYGLHNGYELGRIFGIQV 86 thetaiotaomicron; 016267863.1 [Bacteroides KEASLLQLTKLAYPFFNYKSWQVMRHWLPVRKTMTRGAINIPFDYSQVMREDSVYYDG Bacteroides theta- YWQNEKNFLHIREEILTAYTFPKFDDEKNQELADIIVKSNAVSCHIRRGDYLKEINMC thetaiotaomicron iotaomicron] VCTSSYYAHAISYMNEEINPNLYCVFSDDIEWCRNNICELMGEDKKIIFIDWNKGEKS dnLKV9 FRDMQLMSLCKHNIIANSSFSWWGAWLNRNDKKIVVAPTRWIASEVKNDPLCDSWKRI E Desulfovibrio YP_389367.1 78357918 glycosyl 26.56 MKFVGVWILGGLGNQMFQFAAAYALAKRMGGELRLDLSGFKKYPLRSYSLDLFTVDTP 87 alaskensis; transferase LWHGLPMSQRRFRIPMDAWTRGSRLPLVPSPPFVMAKEKNFAFSPIVYELQQSCYLYG Desulfovibrio [Desulfovibrio YWQSYRYFQDVEDDIRTLFSLSRFATLELAPVVAQLNEVESVAVHLRRGDYITDAASN alaskensis G20 alaskensis G20] AVHGVCGIDYYQRSMSLVRRSTTKPIFYIFSDEPEVAKKLFATEDDVVVMPSRRQEED LLLMSRCKHHIIANSSFSWWAAWLGKRASGLCIAPRYWFARPKLESTYLFDLIPDEWL LL Prevotella oralis ETD21592.1 564721540 protein 26.56 MDIVVIENGLGNQMSQYAFYLAKRKSGSRCHCIFHNVSTGEHNGSELDKVEGIKYEKG 88 CC98A HMPREF1199_ IFSKLLSKIYDIFDGIPKLRKKLNSLGIHIIREPRNYDYTASLLPRVSRWGLNYFVGG 00667 WHSEKYYTEILQEIKNIFSFKIDDEIKDIDFYEFYSLIHNDINSVSLHIRRGDYVGAN [Prevotella EYSYFQFGGVATLEYYHKAIDEIYQRIENPTFYVFSDDIGWCKTTFLKNNFIFVDCNC oralis CC98A GEKSWRDMFLISQCKHHIIANSTFSWWGAWLSIFHNSITICPKEFIKGVVIRDVYPDT WIKLSS Comamonadaceae YP_ 550990115 glycosyl- 26.54 MASKISKIIPRIFGGLGNQLFIYAAARRLALVNGAELALDDVSGFVRDHEYNRHYQLD 89 bacterium CR 008680725.1 transferase HFNIPCRKATAAERLEPFARVRRYLKRKWNQRLPFEQRKYLVQESVDFDERLLTFKPR [Comamonadaceae GTVYLEGYWQSEDYFKDIEPQIRADLRIHPPIDTVNQQMAERIRATNAVAVHVRFFDA bacterium PAQSALGVGGNNAPGDYYQRAIKVMQEQAPDAQYYIFSDQPQAARARIPLRDDHVTLV CR] NHNQCDAVAYADLWLISQCQHFIIANSTFSWWGAWLGKTPESIVIAPGFEKREGAMFW GFRGLLPDRWVKL Vibrio WP_ 550250577 WblA protein 26.51 MKDSRIVKLNGGLGNQMFQFALAFALKKKLNVAVKFDTELLDTNRTEFKLSLERFGLI 90 nigripulchritudo; 022596860.1 [Vibrio VDKLTITEKFKYKGLESCKYRKICNWISNFTTINIHKGYYKEKERGVYDRGIFDSNVK Vibrio nigri- YIDGYWQNQEYENDFRSELLNKFNLNGKVSNHAIQYLKEITSVQNSVSIHVRRGDYLL nigripulchritudo pulchritudo] LDVYRNLTLDYYSEAIKLVRITNPDSKFFIFSNDINWCKSNEKSVDNAIFVDSTVDEF AM115; Vibrio DDMFLMSKCKTNIIANSTFSWWAAWLNNNSGKIVYCPKKWRNDTTEVHKGLPEGWNII nigripulchritudo DK FTn2; Vibrio nigripulchritudo Pon4; Vibrio nigripulchritudo SO65 Sulfurospirillum YP_ 268680406 glycosyl 26.48 MIIIKIMGGLISQMHKYALGRVLSLKYNVPLKLDLTWFDNPKSDTPWEYQLDYFNINA 91 deleyianum; 003304837.1 transferase TIATVSEIKKLKGNNLFNRIARKIEKFFSIRIYKKSYINKSFISISDFHKLKSDIYLD Sulfurospirillum family protein GEWNGFKYFEDYQDTIKNELTLKRGSSINIQNTIKELKSSDNSVFLHIRRGDYLSNKN deleyianum [Sulfuro- AAAFHAKCSLDYYYKAIQIVKEKIDNPIFYIFSDDILWVKKNEVINESCRFMEKNQNF DSM 6946 spirillum EDLLLMSYCKHGITANSGFSLMAGWLNQNKDKMIIVPQTWVNDDRININILNSLEQDN deleyianum FTIIR DSM 6946] Escherichia coli; WP_ 486318742 glycosyl 26.47 MTFIVRLTGGLGNQMFQYALARSLAKKYNARLKLDISYYHNQPHKDTPRTFELNQLCI 92 Escherichia coli 001581194.1 transferase 11 VDNILNSSSFSEKFLYIYDKLRVKLSKKISLPYFRNIVTPVNENCIDFAEDKDYYFLG Jurua family protein HFQELSNIYSIDESLRSEFKPNQEIMNLAHQSKIYELIKQSRGSVALHIRRGDYVINK 18/11; [Escherichia NAAEHHGVIGLSYYVNALSYLENVSEFFDVFVFSDDPEWARKNIKNSRNLFFCDEGNC Escherichia coli coli] RYSKKYSTIDMYLMSQCDHFIIANSTYSWWAAWLGNYPSKHVVAPARWNANNSPYPIL 180600; QNWKAIHE Escherichia coli P0304777.1; Escherichia coli P0304777.2; Escherichia coli P0304777.3; Escherichia coli P0304777.4; Escherichia coli P0304777.7; Escherichia coli P0304777.9; Escherichia coli P0304777.10; Escherichia coli P0304777.11; Escherichia coli P0304777.12; Escherichia coli P0304777.13; Escherichia coli P0304777.14; Escherichia coli  P0304777.15 Firmicutes WP_ 547109632 protein 26.44 MVGVQLSGGLGNQMFEYALYLKLKSMGKDVRIDDVTCYGAQEKQRVNQLSVFGVSYEH 93 bacterium 021914998.1 [Firmicutes MTKQEYEQITDSSMSPLHRARRLLCGRKDBYREASCNYDPEILRREPALLLGYFQTER CAG:24 bacterium YFADIKDQVREAFTFRNLTLIKESAAMEQQMKECESVSVHIRRGDYLTPANQALFGGI CAG:24] CDLDYYHRAVAEIRKRKPDVKFFLFSNDMEWTKEHFCGSEFVPVEGNSEQAGEQDLYL MSCCKNHILANSSFSWWGAWLDNGKDKLVIAPEKWMNGRGCCDIVIDEMIRV Amphritea WP_ 518452719 protein 26.42 MVKIKIIGGLGNQMFQYAAAKSLAVLNNTRVSANVWFSNYKTHPLRLNKLNCDCEFDF 94 japonica 019622926.1 [Amphritea IRDFRLVLSGFPLLGSAFSKKSMLLNHYVEKDLLFDSSFFDLDDNVLLSGYFQSEKYF japonica] SNIRELLIQEFSLDDRLTEAELAINNKIESCNSIAIHIRRGDYITDLSANNIFIGICH EYFEKALNYLDSINVLSDPTTTLFIFSDDILWCKDNLAFKYRTVFVEGSVDRPEVDIH LMSKCKHQVISNSTFSWWGAWLNINLDKCVIAPLKWFNSLHDSTDIVPKQWMRL Bacteroides WP_ 492689153 protein 26.41 MKQIIIMSGGLGNQMFQYALYCSMREKGIRVKIDISLYEFNRMHNGYMLDYAFGLNIS 95 salyersiae; 005923045.1 [Bacteroides HNKINKYSVLWTRLIRSNRAPFLLFREDESRFCDDVETTYKPYIDGCWIDERYFFNIK Bacteroides salyersiae] KKIISQFSFHNIDQKNLMVANMMKVCNSVSLHIRRGDYLSQSMYNICNESYYKSAIEY salyersiae WAL IISRVEDSKFFIFSDDPEWCKYFMEKENVDYEIIQHNFGKDSYKDMYLMTQCKHNIIA 10018 = DSM 18765 NSTFSWWGAWLNNNAGKNVVCPSVWINGRDFNPCLEEWYHI = JCM 12988 Bacteroides WP_ 492241663 protein 26.38 MDIILLHNGLGNQMSQYAFYLSKKKNGIHTSYICLSNDHNGIELDKVEGVECQMGCKK 96 fragilis; 005786334.1 [Bacteroides IFLLFILRLLMSNRTGFLIRKVNLLFSKIKIKLITENLDYSFHPSFLSASPYCLAFWV Bacteroides fragilis] GGWHHPQYYSEISSQIKEAFTFKRSLLDERNICIEKRMREPNSVCLHIRRGDYLTGIN fragilis YELFGKVCNEQYYQKAIDYIEGKLSDICYYVESNDMEWAKKILLGKNAVFVDWNRGEE CL03T00C08; SWKDMYLMSKCSNLIIPNSTFSWWAAWLCEHPVNIVCPKISVYGDEQSDIYLDNWHKI Bacteroides E fragilis CL03T12C07 Bacteroides WP_ 494751435 protein 26.37 MMGIEKTNMVIVRLWGGIGNQLFQYSFGEFLREKYQVDVIYDIASFGKSDKLRKLELS 97 nordii; 007486843.1 [Bacteroides VVVPGIPVTTDISFSKYVGTKNRLLRFIYGLKNSFIEEKYFSDEQLFKYLSKRGDVYL Bacteroides nordii] QGYWQKTIYAETLRRKGSFELSQEEPIVLHTIKAKIQEAEGAIALHVRRGDYFSSKHI nordii CL02T12C05 NTFGVCDAHYYEKAVDIMRGRVSNAMIFVFSDDLDWVRRYVNLPTNVIYVPNYDIPQY WYIYLMSLCRHNIISNSSFSWWGAFLNMNINKIVVSPSKWILNSDKTIALDEWFKI Butyrivibrio YP_ glycosyl 26.37 MECSMIIIKFCGALGNQLFQYALYEKMRILGKDVKADISAFGDGNEKRFFYLDELGIE 98 proteoclasticus; 003829743.1 302669783 transferase 11 FNIASADEIAEYLNRKTIRFVPGFLQHRHYYFEKKPYVYNKKILSYDDCYLEGYWQNY Butyrivibrio [Butyrivibrio RYFDDIKDELLKHMKFPCLPLEQKKLAEKMENENSVAVHVRMGDYLNLQDLYGGICDA proteoclasticus proteoclasticus DYYDRAFSYIEGNISNPVYYGFSDDVDKASALLAKHKINWIDYNSEKGAIYDLILMSK B316 B316] CKNNIIANSSFSWWGAYLEYNNGKVVVSPNRWMNCFENSNIAYWGWISL Prevotella YP_ 294674032 family 11 26.33 MRIVKVLGGLGNQMFQFALYKALQKQYPEERVLLDLHCFNGYHKHRGFEIDSVFGVIY 99 ruminicola; 003574648.1 glycosyl EKATLKEVASLAYPYPNYQCWRIGSRILPVRKTMLKEEPNFTLEPSALSLPDSTYYDG Prevotella transferase YWQHEEYFMHIREEILSTYAFPAFDDERNKTTAQLAASTNSCSIHIRRGDYLTDPLRK ruminicola 23 [Prevotella GTINGNYVIAAIKEMQQEVKPEKWLVFSDDIAWCQQHLASTLDATNTIYIDWNTGANS ruminicola 23] IHDMHLMALCRHHIIANSSFSWWGAWLSQQDGITIAPSNWMNLKDVCSPVPDNWIKI Prevotella WP_ 494223898 protein 26.33 MKIIKIIGGLGNQMFQYALAIALQQQYKDEEIRLDLNCFRGYNKHQGYLLDEIFGRRF 100 salivae; 007135533.1 [Prevotella RAASLQEVARLAWPYPHYQLWRVGSRVLPRRQTMVCEPADGSFSPDVLTLEGNRYYDG Prevotella salivae] YWQDERYFKAYRKEIIEAFKFSPFVGDGNRHVENMLRNERFASLHVRRGDYLNDALYQ salivae DSM 15606 NTCGIDYYQRAISQMNAMANPSCYFIFSDDIAWCKTHIEPLCEGHRPYYIDWNKGKEA YRDMQLMALCKYHIIANSSFSWWGAWLNDAEDGITIAPQQWYSHGNKPSPASESWIKV Lachnospiraceae WP_ 511045640 protein 26.3 MNIVRISDGLGNQMFQYAYARKISILSRQRTYLDIRFINNEDLVKKGNHVQFRKKLGH 101 bacterium COE1 016299568.1 [Lachno- RKYGLSHENVSLQIADLKMLSHWEYLIQSNCMQQLIYSLSMQDKWIWRYRHEEVNYDG spiraceae  MLSKVELLFPTYYQGYFFALKYYDDIKHILQHDFSLKDKMKLLPELRDALYNRNTISL bacterium COE1] HVRRGDFLEINRDISGSEYYEKAVQMIGSKVESPIFLIFSDDIEWVKEHIRIPNDKIY VSGIGYEDYEELTIMKHCKHNIIANSTFSYWAAYLNSNKDKIVICPKHWRERIIPKDW ICI Bacteroides WP_ 495118115 alpha-1,2- 26.28 MIVVNVNAGLANQMFHYAFGRGLEAKGWNIYFDQINFKPRKEWSFENVQLQDAFPNLG 102 dorei; 007842931.1 fucosyl- LKMMPEGKFKWICVNNINKLSKGLHLAMINLHNLIGDEKYIFETTYGYDPDIEKEITK Bacteroides transferase NCILKGFWQSEKYFAHCKDDIRKQFSFLPFDEEKNIVIMNKMVKENSVAIHLRKGADY dorei 5_1_36/D4 [Bacteroides LKSELMGKGLCGVEYYIKAIEYIKKNIDNPVFYVFIDNPVWVKNNLPKFDYILVDWNE dorei] VAGKKNFRDMQLMSCAKHNIIANSTYSWWGAWLNPNPNKIVIGPAKFFNPINNFFSSS DIMCEDWVKI Roseobacter sp. WP_ 495485361 alpha-1,2- 26.28 MLSKDPGMITTRLHGRLGNQMFQYAAGRALAARLGVPLALDSRGAKLRGEGVLTRVFD 103 SK209-2-6 008210047.1 fucosyl- LPLAQPLSLPPLKQDAPLRYAAWRLTGRTPRFRREQGLGYNPAFETWGDDSYLHGYWQ transferase SEAYFDSIADQIRQDFTFPEFSNSQNREMAQRIAGSTAISLHVRRGDYVALAAHVLCD [Roseobacter QAYYEAALTRILEGVEGSPTVYVFSDDPNWAKENLPLPCEKVVVDENGPDTDFEDMRL sp. SK209-2-6] MSLCQHNIIGNSSFSWWAAWLNTHNEKRVAGPAHWEGNPKLQNPDILPESWLKISV alpha WP_ 518900826 protein [alpha 26.26 MIYSRIRGGLGNQLFQYCVARSLADNLGTSLGLDVRDFNENSPYLMGLKHFNIRADFN 104 proteobacterium 020056701.1 proteobacterium PPGMIEHKKNGYFRYLIDVVNGKQKFVYKEPHLNFDKNIFSLPNSSYLKGYWQTEKYF SCGC AAA076-C03 SCGC IKNKVNILNDLKIISHQSDKNKTISSKIANNTSVSLHIRRGDYISNSAYNSTHGTCSL AAA076-C03] AYYTNAVNFLVNKIGGNEKVFAFSDDPEWVSSNLKLPVDICFVKNNSSEYNYEDLRLM SECNHNIIANSSFSWWGAWLNINHNKTVITPCKWYADNSTKNADITPSNWIKI Helicobacter WP_ 490188900 protein 26.26 MGGGGQDLRLFELMLYNISLPLCFDYKTLVKYFYSNDKSLKYNFPLQYIRYATRSKYH 105 bilis; 004087499.1 [Helicobacter KLYWLALKHYKYFYDEDPQGDNIVKMYLNNSLEKHAYPEGYFQNLIYFDEIDSIIREE Helicobacter bilis] FCLKIPLKPHNQALKEKIEKTENSVFLHVRLGDYLKMEATDGGYVRLGKTYYQSALEI bilis LKTRLGQPHIFIFSNDIEWCEKNLCNLLDFTGCHIEFVKANGEGNAAEEMELMRACKH WiWa AVIANSTFSWWASYLIDNPDKQIIMPTQVFNDTRRIPKSNMLAKKGYILIDPFWGMHS IV Ralstonia sp. WP_ 498513378 glycosyl 26.26 MIVIRVIGGLGNQMFQYAAGRALARRLGVPLKIDSSGFADYPLHNYGLHHFALKAVQA 106 GA3-3 010813809.1 transferase GDREIPSGRAENRWAKALRRFGLGTELRVFRERGFAVDPEVMKLPDGTYLDGYWQSES family protein YFAEMTQELRRDFQIATPPTSENAEWLARIGGDEGAVSIHVRRGDYVTNASANAVHGI [Ralstonia sp. CSLDYYMRAARYVAENIGVKPIFYVFSDDPDWVAGNLHLGHETRYVRHNDSARNYEDL GA3-3] RLMSACRHHIIANSTFSWWGAWLNASEKKVVIAPAQWERDEKYDTRDLLPPTWTKL Bacteroides WP_ 490431888 protein 26.25 MVVVYIAAGLANKMFQYAFSRGLMSHGLDVFLDQTSFQPEWSFEDIALEEVFPNIEIK 107 ovatus; 004303999.1 [Bacteroides DNAPNNMFSLAYKKLLSRIYRRMSAFFPNNRYLMERPFIYDELIYKKATNNCIFCGLW Bacteroides ovatus] QTELYFNFCERDVRRNFVFTPFQDDQNIKLAEKMKNENSVAIHIRKGADYLKRNIWDG ovatus 3_8_47FAA ICSVEYYNQAINYLKEHVSNPVFYLFTDNPEWVEENLKNIDYKLVDWNPVSGKQSYRD MQLMSCAKHNIIANSTYSWWGAWLNNNPQKIVVAPKIWFNPKIEKAPYIIPDRWIRL Loktanella WP_ 518799952 protein 26.23 MIITKLIGGLGNQMFQYAAGRSLAMRHGVPLLLDITELRSYPKHQGYQFEDVFAGRFE 108 vestfoldensis 019955906.1 [Loktanella IAGLIPLIRVLGRKARKVPKTVAVVSPKWPPMGDHVWVRQRTHDYDAAFESIGADCYL vestfoldensis] SGFWQSEKYFATIAPQIRESFRFKEALTGANAAIASRMKEAPSAAIHIRRGDYVTDKG AHAFHGLCAWDYYDAAIDHISRHEPDARFFVFSDDVVAAQERFANRQRAEVVAVNSGR HSYRDMMLMAQCKHQIIANSTFSWWAAWLNQNPDKIVVAPGTWFSGNDGQIKDIYCKD WIVI Flavobacterium WP_ 515558304 protein 26.14 MDVVIIFNGLGNQMSQYAFYSQKKKINNSTYFVPFCKDHNGLELETVFSLNTKETLIQ 109 sp. 016991189.1 [Flavo- KSLYILFRILLTDRLKIVSDPLKWILNLFKCKIVKESFNYNYNPEYLKPSKGITFYYG ACAM 123 bacterium GWHAEKYFAKENQQIKSVFEFTGDLGKINKEHVKDIASTNAVSLHVRRGDFMNEANIG sp. ACAM 123] LFGGVSTKAYFEGAIKLIATKVDHPHFFVFSNDMDWVKENLSMDTVTYVTCNSGKDSW KDMCLMSLCQHNIIPNSTFSWWGAWLNKNPHKIVVCPSRFLNNDTYTDIYPDSWVKIS DY Bacteroides WP_ 492219620 glycosyl 26.1 MMKLVRMIGGLGNQMFIYAFYIQMKTIFPELRIDMSEMKKYKLHNGYELEDVFSIRPQ 110 fragilis; 005779407.1 transferase TISAHKWLKRVIVYAFFSIIREKSEEELSIHKYTQHKRWPLVYYKGFFQSELFFKESS Bacteroides family 11 DTIRDIFSENTENANFRTKEWAKIIKEQRSSVSIHIRRGDYTSAKNKIKYGNICTEEY fragilis 3_1_12 [Bacteroides YQKAISIILKKEPKAFFHIFSDDVEWTKAHLKIHHLPHQYISWNKGPDSWQDMMLMSL fragilis] CRHNIIANSSFSWWGAWLNAYKDKTVIAPSRWSNVKKTPHILPESWISIDI Spirosoma WP_ 522086793 protein 26.09 MIISRVTSGLGNQLFQYAAARSLSLRNKTAFYVDLSYYLVEYPDDISRSFKLGFFSVP 111 panaciterrae 020598002.1 [Spirosoma YRILQESPVEYLSKSTKLFPNRSLRPFFLFLKEKQFHFDPTILQAHAGCVIMEGFWQS panaciterrae] ECYFRDHAEIIRRELQLSKSPSSEFEGYHQQIQATPVPVSVHVRRGDYVNHPEFSKTF GFIGLDYYKTAIRHLTKTIKNPHFYVFSDDKEWARANLPLPTDSVFVTNTGPSGDVAD LVLMSTCHHHIIANSSFSWWGAWLNPNPDKLVITPKLWYKNQPTWNTKDLLPPTWVSL uncultured EKE06672.1 406985982 glycosyl 26.09 MIITKLTGGLGNQLFQYAIGRNLIYINGSDLKLDVSEYDVSNKGNFRHYALDKFNTIQ 112 bacterium transferase NFASKKETNNFKFGVFKKWLYKSGIVKNKNYFLEKKENFDKEILKIKDNAFLQGYWQS family 11 EKYFIGIRDILLQEFSLKENIELKFGEILKEINESNSVSIHVRRGDYVKNPKNLSFHG [uncultured VCSPKYYSESTSKIASLIEKPVFFVFSDDIEWVKENLNITFPVVYLSGIKNIKSYEEL bacterium] VLMSKCKHNIIANSSFSWWGAWLNINQKKIVIAPKRWENDVKLDTTDLIPENWIRI Thermo- NP_681784.1 22298537 alpha-1,2- 26.07 MIIVHLCGGLGNQMFQYAAGLAAAHRIGSEVKFDTHWFDATCLHQGLELRRVFGLELP 113 synechococcus fucosyl- EPSSKDLRKVLGACVHPAVRRLLAGHFLHGLRPKSLVIQPHFHYWTGFEHLPDNVYLE elongatus; transferase GYWQSERYFSNIADIIRQQFRFVEPLDPHNAALMDEMQSGVSVSLHIRRGDYFNNPQM Thermo- [Thermo- RRVHGVDLSEYYPAAVATMIEKTNAERFYVFSDDPQWVLEHLKLPVSYTVVDHNRGAA synechococcus synechococcus SYRDMQLMSACRHHIIANSTFSWWGAWLNPRPDKVVIAPRHWFNVDVFDTRDLYCPGW elongatus BP-1 ococcus IVL elongatus BP-1 Colwellia WP_ 517858213 protein 26.03 MKIVKIAGGEGNQLFQYAFYLALDKKYAEQVCLDSLDMAKYRLHNGYELEGIFKLDAR 114 piezophila 019028421.1 [Colwellia YCTEEQRIIVRKDNNIFTKLLSSLKKKLGNNKNYILEPKQEHFTFHEKSFGQANTPTY piezophila] YKGYWQDVKYLENIEEELKSSLVFPEFELGKNIELANFISSNSSVSLHVRRGDYVQHK AFGGICDLSYYQRAVEQINTLVKDPIFIVFSDDIQWCKDNLNLEKAKFVDWNIGENSF RDMQLMTLCKHNIIANSSFSWWGAWLNANDDKNVICPDKWVHYTSATGVLPSEWIKIK ASV Prevotella WP_ 518810840 protein 26 MKIVKIIGGLGNQMFQYALAIALQERWKDEEIKLDLHGFNGYHKHQGYQLDMLFGHRF 115 maculosa 019966794.1 [Prevotella EAATLTDVAQLAWPYPHYQLWRVGSRLLPKRRSMLCEPSKGLLPSDVLKQKGSLYYDG maculosa] YWQDERYFRAIRPQIMAAFKFPDFTDRRNLETEKRLKASEAVSIHVRRGDYLDDVLFQ GTCNIAYYQRAIARLCQLKTPVFCIFSNDMAWCKVHIEPLLHGKEILYVDWNRGKESY RDLQLMTLCRHHIIANSSFSWWGAWLSKAEDGITIAPRHWYAHDAKPSPAAERWIKV Salmonella YP_ 525860034 fucosyl- 25.99 MYSCLSGGLGNQMFQYAAAYILKQYFQSTTLVLDDSYYYSQPKRDTVRSLELNQFNIS 116 enterica; 008261369.1 transferase YDRFSFADEKEKIKLLRKFKRNPFPKQISEILSIALFGKYALSDRAFYTFETIKNIDK Salmonella [Salmonella ACLFSFYQDADLLNKHKQLILPLFELRDDLLDICKNLELYSLIQRSNNTTALHIRRGD enterica subsp. enterica subsp. YVTNQHAAKYHGVLDISYYNHAMEYVERERGKQNFIIFSDDVRWAQKAFLENDNCYVI enterica serovar enterica NNSDYDFSAIDMYLMSLCKNNIIANSTYSWWGAWLNKYEDKLVISPKQWFLGNNETSL Worthington str. serovar RNASWITL ATCC Cubana str. 9607; Salmonella CFSAN002050 enterica subsp. enterica serovar Cubana str. CFSAN001083; Salmonella enterica subsp. enterica serovar Cubana str. CFSAN002050; Salmonella enterica subsp. enterica serovar Cubana str. CVM42234 Bacteroides sp. WP_ 495935021 protein 25.94 MKKVIFSGGLGNQMFQYAFYLFLKKKGIKAVIDNSLYSEFKMHNGFELIKVFDIKESI 117 3_2_5 008659600.1 [Bacteroides YRTYFLKVHLIFIKLLMKIPPVRKLSCKDDVIPIGDHEFDPPYARFYLGYWQSKKIVN sp. YVIEELRAQFIFRNIPQMTIEKGDFLSSINSVSIHIRRGDYMGIPAYQGICNEIYYER 3_2_5] AISFMKEHFLNPRFYVESNDSIWAKLFLEKFDIDMEIIVTPPIYSYWDMYLMSRCRNH IIANSTFSWWAAVLNINKDKIVISPTIFKKDECIDIIFDDWVKISNI Clostridium sp. WP_ 547662453 protein 25.86 MIMLQMTGGMGNQMFTYALYRSLRQKGKEVCIEDFTHYDTPEKNCLQTVFHLDYRKAD 118 CAG:510 022124550.1 [Clostridium REVYQRLTDSEPDFLHKVKRKLTGRKEKIYQEKDAIIFEPEVFQTDDVYMIGYFQSGR sp. YFEKAVFDLRKDFTFAWNTFPEKAKKLREQMQAESSVSLHIRRGDYMNGKFASIYGNI CAG:510] CTDAYYEAARRYMKEHFGDCRFYLFTDDAEWGRQQESEDTVYVDASEGAGAYVDMALM SCCRHHIIANSSFSWWGAWLDENPDKTVIAPAKWLNISEGKDIYAGLCNCLIDANGSV QGE Rhodopirellula WP_ 495940880 glycosyl 25.86 MIVIRLIGGLGNQLFQYAFGHSLARSTYQTLLIDDSAFIDYRLHPLAIDHFTISASRL 119 europaea; 008665459.1 transferase SDADRSRVPGKFLRTPVGRALDKVSRFVPGYQGVLPVRREKPFGFRESLLARESDLYL Rhodopirellula family protein DGYWQSEKFFPGLRGSLREEFQLREQPSETTRRLSAQMKSENSVAIHVRRGDYVISAK europaea SH398 [Rhodo- AKQIYRILDADYYRRCLLDLAAHETDLKLYLFSNDVPWCESNLDVGIPFTPVQHTDGA pirellula TAHEDLHLIAQCRHVVIANSTFSWWGAYLGQLHPIRRVYYPEPWFHPGILDGSAMGCD europaea] DWISEASLEEQSSLKSSRRAA uncultured EKD23702.1 406873590 glycosyl 25.82 MIIVKLKGGMGNQMFQYAIGRNLATKLGTQLRLDLTFLLDRSPRKDFVFRDYDLDIFA 120 bacterium transferase LDVAFAGPTDLKPFTQFRISHLTKIYNIFPRLLGRPYVISEPHFHFSEAILKSSDNVY family protein LDGYWQSEKYFKEIENSIRDDFKFRQPLEGRAAEMAAQIKNEDRAVCLNVRRADEVIS [uncultured KKAQEFHGFIGLDYYQKAVDLLVSKVGPLHLFIFSDDVDWCAANLKENYPTTFVTKDY bacterium] SGKKYEAYLQLMTLCRHYIIPNSTFAWWGAWLNSDPNKIVIAPKQWFKEASIDTTDII PSTWIRL Bacillus WP_ 446510160 protein 25.74 MIIVKLKGGLGNQMFQYALGKSLALYYDKPLKIDADYIKNNEGYVPRDFSLSKFNIEL 121 cereus; Bacillus 000587678.1 [Bacillus DLYQEADKERVGFILKNNFLAKKLRNYFLKKGKYKGKYIIENPDNLGLFKKELFENHN cereus AH1271 cereus] ESMYIDGYWQSYLYENNIRECLIKEFNLKPEYTKEMTEIMQRINETNSVAVHIRRGDY VKLGWILDTTYYKKAIAEIVKNVDNPKFYVFSDDTDWVRSNLQELDNAVFIGECNLFD YQELWLMSTCKHNIISNSTFSWWGAWLNQNDHQVVVSPSAWINGMSVETTSLIPDSWK RV Firmicutes WP_ 548309386 protein 25.74 MDIIRMEGGLGNQLFQYALYRQLQFMGRTVKMDVTTEYGREHDRQQMLWAFDVHYEEA 122 bacterium 022499937.1 [Firmicutes TQEEINRLTDGEMDLPSRIRRKLTGRRTKKYAEADSNFDPQVLLKTPVYLTGYFQSEK CAG:95 bacterium YFKDVEGILHTELGFSDRIYDGISEVFADQIRNYQKQIRETESVSLHVRRGDYLEHPE CAG:95] IYGMSCTMEYYQAGVRYIRERHPDAEIFVFTNDPVFTEKWLQENFLGDFTLIQGTSEE TGYLDLMLMSQCKHQIMANSSFSWWGAWLNPNKDKIVVAPEPWFGDRNFHDIYTEEMI RISPRGEVKKHG Prevotella WP_ 490508875 alpha-1,2- 25.74 MIAATLFGGLGNQMFIYATVKALSLHYQVPMAFNLNHGFANDYKYHRKLELCKFNCQL 123 oris; Prevotella 004374901.1 fucosyl- PTAKWITFDYRGELNIKRISRRIGRNLLCPNYQFVIEEEPFHYEKRLFEFINKNIFLE oris transferase GYWQSPCYFENYSKEIRADFQLKVPLSKEMLEEIYALKATGKTLVMLGIRRYQEVEGR F0302 [Prevotella DICTYKLCDKEYYIKAITYIQERIPNALFVVFTQDKEWATTHLPKGAEFYFVKDKQDE oris] YATVADMFLMTQCTHAIISNSTFYWWGAWLQCTTKNHIVIAPDSFINSDCVCKEWIIL KRNSLC Escherichia coli AAo37719.1 37528734 fucosyl- 25.73 MYSCLSGGLGNQMFQYAAAYILQRKLKQRSLVLDDSYFLDCSNRDTRRRFELNQFNIC 124 transferase YDRLITSKEKKEISIIRHVNRYRLPLFVTNSIFGVLLKKNYLPEAKFYEFLNNCKLQV [Escherichia KNGYCLFSYFQDATLIDSHRDMILPLFQINEDLLHLCNDLHIYKKVICENANTTSLHI coli] RRGDYITNHASKFHGVLPMDYYEKAIRYIEDVQGEQVIIVFSDDVKWAENTFANQPNY YVVNNSECEYSAIDMFLMSKCKNNIIANSTYSWWGAWLNTFEDKIVVSPRKWFAGNNK SKLTMDSWINL Leeia oryzae WP_ 516890767 protein [Leeia 25.71 MIIVKIIGGLGNQMMQYAFAHACAKRLGVPFKLDITAFESYKLWPYGLHNFEITAPIA 125 018150480.1 oryzae] SLEEIEHAKSMGVITETSFRFDDSLVSAVKDGMYLDGYWADYRYSESVWGELKPVFIL MDPLTPEQQALAMNLSAPNAVALHVRRGDYVINPNCELLPQQYYRDAIKLVLDQQPDA VFYCFSDDPDWVEAHLDIPAPKVVVRGQGIDNGFVDMILMSKARHRIVANSTFSIWAS RLADQDGLTIVPSQFFRKDDPWLLQVYGEVLQPCYPPQWRVVDVTGDGKKEAENTSTA LLQIAGGDVRGRKLRIGVWGFYEEFYQNNYIFLNKNAPIGHELLKPFNQLYQYGQAHN LEFVTLDLVADLSTLDAVLFFDAPNMRSPLVSSVMQLDIKKYLCLLECELIKPDNWQQ SLHELFTRIFTWHDGLVDNHRYIKVNYVTDLMPWIESAQSLTAPFEETARKGYLQKKL ICNISGNKLVSHPFELYSKRIEVIRWFESHHPEHFDLYGMGWSASDYPSYKGKIDDKL EVLKGYRFSLCYENAKELPGYITEKIIDCFKAGVVPVYSGAPNIADWIPDNCFIDSGK FPDTDALYTYLISMTEEVHADYLENIRQFFLGGKAYPFSADAFINTITRTIVQDCLEP HERTDVSVVVPNYNHGNFVVSAITSALNQNVSVELLVLDNASTDDSWSQLQFFADYPQ VRLIRNRWNIGVQHNWNHATWLATGRYVVMLSADDLLLPGHLEQAVKRLDENPASSLY YTPCLWINEHDQPLGTLNHPGHLESDYVGGRDEISDLLKFDSYITPSAAVIRRETLNR IGSMNLHLKGAIDWDLWIRIAEISPAFIFRKQPGVCYRQHSGNNSVDFYASTAPLEDH IRIVESIIDRKVAVKYLLKAKEEIIAHLDNRASSYPENQIQHLLSRINNIKDYLRKGA GPVISVIIPTKNRPGLLANALESLTYQTFKDFEVVIHNDGGCDIGGIVDFFSDQLQIS YVRSSQSGGAAASRNRALKLAKGRIIAYLDDDDVYLDSHLEKLVDAYKGRSEKFIYIN CEYLIQERKEGRLIELGRERRYAGISYSRAQLLVSNFIPTPTWSHTKELIDTIGDFDE SLEILEDWDFLLRASKVIEFYQVNATTVEVRSDRSRDDHTLRANADKLLAYHQKIYAK HPVENESILANRQSLINSLSNRQDVTPKNENSYQGWVNARQPNELAVQILAERMMLQW SKQYQFMIVMVVKQSQQNLLANTIDSFCQQLYSGWKLIVISDFEAPDESFINNEVLGW LTLETVEDENLLTQAFNGVLAEVPSDWVTILPVGIRLTSTALLKVGDRLLLNGGACVI YTDHDYVSDDGMIKDPVLKPAFNLDMLRSQDYIGSSIFFRIDSLAAVGGFASFPGART YEACFRMLDNYGPQTIEHLPEPVMTFPENQPENSLRVAAMQLALEEHLHRNNISASIE EGYVTGTFLVQYHHSEQPFVSIIIPNKDKHEFLAPCIETLMKVTQYPAFEVIIVDNQS TDPDTLSYYEEIESRFANNVKVIQYDNPFNFSAQCNLGAESARGDFILFLNNDTEIVQ ANWLERMMQHAQRNDVGVVGARLVFPETVTIQHAGIVLGGKYPDEVFQFPYMNFPVDK DVSLNRTKVVQNYSAVTGACLLVRKSLYQQVGGMNEQNLAVLYGDVDLCLRIRQLHKS VVWTPFSTLVHHIGKILNSNSDHEKHLMMVIQTRQEREYMLSHWLDIIANDPYYHRLL DKSECNGTIDCTHTPLWDDIPSARPRLQGMALVGGSGEYRVNMPFRTLERSALAEIVL SNMTSKARLPSITELARNAPDVFVVQNALADEFIRMLEMYKKYLPSVFRIQMLDDLLT EIPDASSFKRHFQKNWRDAKARLRKSLKFCDRLIVSTEPLRTFAEDMIDDIIVVPNML ERSVWGDLVSKRRAGKKPRVGWVGAQQHAGDLALMTDVVKATGHEVDWVFQGMCPDDI RPYVAEVNTEWLTYDKYPQGIAALNLDLAIAPLEINAFNEAKSNLRLLEYGALGWPVI CTDIYPYQTNNAPVCRVPNDASAWIEAIRSHIADLDATAQKGDQLRQWVHDHYMIEDH AQEWLSALTRPAGK Desulfovibrio WP_ 492830219 Glycosyl 25.68 MFQYAAARALSLRHSASLAADLTWFSQQFDVQTTPREYALPAFRLNLPEADKRIVATF 126 africanus; 005984173.1 transferase RLNPTELRIVSFLRHRICFPSRFLPRHITELSFDYWDGFRDILPPAYLDGYWQSERYF Desulfovibrio family 11 SDYPDIIRADFSMLSISEQAAWMSAKIASVQDSISLHIRRGDYVNSLATRKAHGIDTE africanus PCS [Desulfovibrio RYYAKALEWIADRIGAATIFAFSDDPRWVRANFDFGKHKGIVVDGSWTAHEDMHLMSL africanus] CSHHIIANSSFSWWGAWLSTSQGITIAPKSWFSNPHIWTPDVCPATWERIPC Akkermansia WP_ 547786341 glycosyl 25.66 MAKGKIIVMRLFGGLGNQLFQYAFLFALSRQGGKARLETSSYEHDDKRVCELHHFRVS 127 muciniphila 022196965.1 transferase LPIEGGPPPWAFRKSRIPACLRSLFAAPKYPHFREEKRHGFDPGLAAPPRRHTYFKGY CAG:154 family 11 FQTEQYFLHCREQLCREFRLKTPLTPENARILEDIRSCCSISLHIRRIDYLSNPYLSP [Akkermansia PPLEYYLRSMAEMEGRLRAADAPQESLRYFIFSDDIEWARQNLRPALPHVHVDINDGG muciniphila TGYFDLELMRNCRHHIIANSTFSWWAAWLNEHAEKIVIAPRIWFNREEGDRYHTDDAL CAG:154] IPGSWLRI Dysgonomonas WP_ 493897667 protein 25.66 MKIVKLQGGLGNQMFQYAIARTLETNKKKDIFLDLSFLRMNNVSTDCFTARDFELSIF 128 mossii; 006843524.1 [Dysgonomonas PHLRAKKLNSLQEKFLLSDRVRYKFIRKIANINFHKINQLENEIVGIPFGIKNVYLDG Dysgonomonas mossii] FFQSESYFKHIRFDLIKDFEFPELDTRNEALKKTIVNNNSVSIHIRRGDYVHLKNANT mossii DSM 22836 YHGVLSLEYYLNCIKRIGEETKEQLSFFIFSDDPEYASKSLSFLPNMQIVDWNLGKNS WKDMALMLACKHHIIANSSFSWWGAWLSERNGITYAPVKWENNESQYNINNIIPSDWV II Prevotella WP_ 490506359 glycosyl 25.66 MDIVLIFNGLGNQMSQYAFYMSKKKFVPQSKCMYYKGASNNHNGSELDKLFDIKYSET 129 oris; Prevotella W004372410.1 transferase, FFCKLILLLFKLYENIPRLRKYFHILGINIVSEPQNYDYNESILKKKTRFGITLYKGG oris family 11 WHSEKYFLANKQDVLNTFSFKIAKEDKNFIDLAKSIEEDINSVSLHVRRGDYLNISPT F0302 [Prevotella DHYQFGGVATTNYYKNAVSYMLKRNKQAHFYIFSDDITWCKAEYKDLMPTFIECNKKN oris] KSWRDMLLMSLCINHINANSTFSWWGAWLSTKNGITICPTEFIHNVVIRDIYPETWVQ L Pseudo- WP_ 496239055 glycosyl 25.66 MIIVRLMGGMGNQLFQYATAFALSKRKSEPLVLDTRFFDHYTLHGGYKLDHFNISARI 130 gulbenkiania 008952440.1 transferase LSKEEESLYPNWQANLLLRYPIIDRAFKKWHVERQFTYQDRIYRMKRGQALLGYWQSE ferrooxidans family 11 LYFQEYRKEISAEFTLKEQSSVTAQQ1SVAMQGGNSVAVHIRRGDYLSNPSALRTHGI 2002; [Pseudo- CSLGYYNHAMSLLNERINDAQFYIFSDDIAWAKENIKIGKTSKNLIFIEGESVETDFW Pseudo- gulbenkiania LMTQSKHHIIANSTFSWWGAWLANNTDEQLVICPSPWFDDKNLSETDLIPKSWIRLNK gulbenkiania ferrooxidans] DLPV ferrooxidans Salmonella WP_ 446208786 protein 25.66 MYSCLSGGLGNQMFQYAAAYILKQYFQSTTLVLDDSYYYSQPKRDTVRSLELNQFNIS 131 enterica 000286641.1 [Salmonella YDRFSFIDEKEKIKLLRKFKRNPFPKKISEILSIALFGKYALSDSAFYAVETIKNIDK enterica] ACLFSFYQDADLLNKHKQLILPLFELRDDLLDICKNLDVYPLILRNNNTTALHIRRGD YLTNQHAAKYHGVLDTSYYNNAMEYVERERGKQNFIIFSDDVKWAQKAFLGNENCYIV NNGDYDYSAIDMYLMSLCKNNIIANSTYSWWGAWLNKSEDKLVISPKQWFLGNNETSL RNASWIIL Carnobacterium YP_ 554649642 glycosyl 25.59 MLIVKVYGGIGNQMFQYSFYKYLQKNNDDVFLDISDYKVHNHHNGFELIDVFNIEVKQ 132 sp. 008718688.1 transferase ADMSKFKGHVSSKNSIFYRLTSKLFKRNILGYSEFMDSNGISIVRNEKILTDHYFIGF WN1359 family 11 WQDVLYLQSVEEEIKEAFNEKNVAIGKQNLELISLSESVESVSVHIRKGDYANNSDLS [Carno- DICDLEYYEEAMKIIDSKVSEPLYFIFSDDIEWCKQKFGKRDNLIYVDWNIAKKSYID bacterium MLLMSKCKHNIIANSTFSWWGAWLNNNSKKIVICPKTWDRKKNENHLLLNDWIAI sp. WN1359] Prevotella sp. WP_ 547227670 protein 25.58 MMKIIVNMACGLANRMFQYSYYLFLMHKGYNVKVDFYNSAKLAHEKVAWNDIFPKARI 133 CAG:1185 021964668.1 [Prevotella sp. EQASFSDILKSGGGSDVISKIRRKYLPFLSSVVNMPTAFDANLPVENKKLQYIIGVFQ CAG:1185] NANMVEAVEEDVKRCFKFQPFTDERNLKLQNEMQSCESVAIHVRKGKDYAQRIWYQNT CPIEYYQNAIRLISEKVNNPKLYVFTDNPEWVKEHFKDFPYTLVEGNPASGWGSHFDM QLMSVCKHNIISNSTYSWWSAFLNVHNEKIVIGPKVWFNPDSCSEFTSERILCKDWIA V Selenomonas sp. WP_ 497331130 glycosyl- 25.58 MFQYAMASSVARRAGEILKLDLSWIRQMEKKLSADDIYGLGIFSFDEKFSTSNEVQKF 134 CM52 009645343.1 transferase, LPSGKFSAKIYRAVNRRMPFSWRRVLEEGGMGWHPQIMEIRRSVYFYMGYWQSEKYFS family 11 DFIQEIRKDFTFREEVRQSIEERRPIVEKIRKSDAVSLHIRRGDYAQNPALGEIFLSF [Selenomonas TMQYYIDAARYISERVKTPVFFIFSDDIPWAKENLPLPYEVCYIDDNIQTNEREIGHK sp. CM52] SKGYEDMYLMTQCQHNIIANSSFSWWGAWLNHNPNKIVVAPKKWCNGSFNYADIVPEQ WVKL Bacteroides WP_ 494751213 protein 25.57 MEIVFIENGLGNQMSQYALYLSKRNLGCKVRYAYNIRSLSDHNGFELDRVEGITYPNN 135 nordii; 007486621.1 [Bacteroides LENKCINIIYRLLFANKYLFLVQKMIYVLRQMNVYSIKEKDNYDYDYKILTRHKGIVL Bacteroides nordii] YYGGWHSEKYFLSNADIIKDKFRFNISKLNSESLVLYHRLSSLNAVALHVRRGDYMAP nordii EHYNVFGCVCGIEYYKAAIQYIQSQILNPVFIVESNDIEWVKENITGIQMIFVDFNKK CL02T12C05 ENSWMDMCLMSCCEHNIISNSTFSWWGAWLNNNKNKIVVCPKYFMSNIDTKDIYPESW IKI Parabacteroides WP_ 491855386 protein 25.54 MKKKDIILRVWGGVGNQLFIYAFAKVLSLITDCKVILDIRTGFANDGYKRVYRLGDFS 136 merdae; 005635503.1 [Para- ISLLPALRFYILLSFAQRKMPYIRHLLAYKFDFFEEDQKYPLETLDSFFKIYSDKNLY Parabacteroides bacteroides LQGYWQYFDFSSYRDVLLKDLRFEVEINNTYLYYSDLIEKSNAVAIHFRRIQYEPVIS merdae ATCC merdae] IDYYKKAIKYISENVENPIFFIFSDDINWCRENLSINGICFFVENFKDELYELKLMSQ 43184; CNHFIIANSTFSWWGAWLSVNADKKVIMPDGYTDVSMNGSIVHI Parabacteroides  merdae CL09T00C40 Butyrivibrio sp. WP_ 551024004 protein 25.51 MIIIQLKGGLGNQMFQYALYKELKHRGRDVKIDDESGFIGDKLRVPVLDREGVEYDRA 137 NC2007 022768139.1 [Butyrivibrio TKDEVIALTDSKMDIFSRIRRKLTGRKTFRIDEMEGIFDPKILETENAYLVGYWQSEK sp. YFTSPEVIEQIQEAFGKRPQEIMHDSVSWSTLQQIECCESVSIHVRRIDYMDAEHIKI NC2007] HNLCSEKYYKNAISKIREEHPNAVFFIFTDDKEWCKEHFKGPKFITVELQEGEFTDVA DMLLMSRCKHHIIANSSFSWWSAWLNDSPEKIVIAPSKWINNKKMDDIYTERMTKVAI Bacteroides WP_ 490430100 protein 25.5 MIVVYSNAGLANRMFHYALYKALEVKGIDVYFDEKSYVPEWSFETTILMDVFPNIQYR 138 ovatus; 004302233.1 [Bacteroides ESLQFKRASKKTFLDKIVIHCSNLFGGRYYVNYRFKYDDKLFTKLETNQDLCLIGLWQ Bacteroides ovatus] SEKYFMDVRQEIQKCFQYRSFVDDKNVKTAQQMLSENSVAIHVRKGADYQQNRIWKNI ovatus ATCC CTIDYYRLAIDYIRMHVQNPVFYVFTDNKDWVIENFTDLDYTLCDWNPTSGKQNYLDM 8483;Bacteroides QLMSCAKHNVIANSTYSWWGAWLNENSDKIVIAPKRWENKIVTPDILPEQWIKI ovatus CL02T12C04 Mesotoga prima YP_ 389844033 glycosyl 25.5 MRVVWFGGGLGNQMFQYGLYCFLKKNNQEVKADCTQYSTIPMNNGFELERLFNLDIAH 139 MesG1.Ag.4.2; 006346113.1 transferase ANLDVISKLIGGNRLSPRKVIWKLFRKPKVYFEEKIPFSFDPDVLKGNNRYLKGYWQN Mesotoga prima family protein MNYLEPCAKELRDVFTFPAFSSDNNKRLADEIAKVEAVGVHFRRGDFLKSSNLGLEGG [Mesotoga ICSDQYYLRAIQTMENTVVEPVFYVFCDDPQWAKNSFSDARFTVIDWNIGSNSYRDMQ prima LMSLCKHNIIANSTFSWWAAWLNRNPNRIVIAPERMVNRDLDFSGIFPNDWIRLQG MesG1.Ag.4.2] Clostridium WP_ 545399562 glycosyl- 25.49 MIVLKLQGGLGNQMFEYAFARTIQEQKKDKKLILDTSDFQYDKQREYSLGHFILNENI 140 sp. KLE 021639228.1 transferase, EIDSSGKENLWYDQRKNPLLKVGFKFWPKFQFQTLKLEGIYVWDYAKYIPVDVSKKHK 1755 family 11 NILLHGLWQSDKYFSQISEIIRKEFAVKDEPSQGNKAWLERISSANAVCVHIRRGDFL [Clostridium AKGSVLLTCSNSYYLKAMEIISKKVNEPEFFIFSDDIEDVKKIFEFPGYQITLVNQSN sp. KLE 1755] PDYEELRLMSKCKHFIIANSTFSWWSSLLSENEDKVIVAPRLWYSDGRDTSALMRDEW IIIDNE Bacteroides WP_ 547321746 glycosyl- 25.42 MDLVTLSGGLGNQMFQFAFYWALKKRGKKVFLYKNKLAAKEHNGYELQTLFGVEEKCV 141 plebeius 022052991.1 transferase DGLWMTRLLGCPLLGKILKHILFPHKIRERVLYNYSIYLPLFERNGLHWVGYWQSEKY CAG:211 family 11 FQDVADDIRRIFCFDHLSLNPATSAALKCMSEQVAVSVHIRRGDYYLPCNVATYGGLC [Bacteroides TVEYYENAIRYVKERYPQAVFYVFSDDLDWVRENIPSAGKMVFVDWNRGKDSWQDMFL plebeius MSKCHHNILANSSFSWWGAWLNTHPEKLVIAPERWANCPAPDALPDGWVRIEGVSRR CAG:211] Treponema WP_ 545448980 glycosyl- 25.4 MAIKIVKISGGLGNQMFCYAFACALQKCGHKVYVDTSLYRKATVHSGIDFCHNGLETE 142 lecithinolyticum; 021686002.1 transferase, RLFGIKFDEADTADVRRLSTSAEGLLNRIRRKYFIKKTHYIDTVFKYTPELLSDKNDC Treponema family 11 YLEGYWQTEKYFLPIEKDIRRLFTFRPTLSEKSAAVQSALQAQQAAVLSASIHVRRGD lecithinolyticum  [Treponema FLNIKTLNVCTETYYNNAIKYAVKKHAVSRFYIFSDDIPWCREHLCFCNAHAVFIDWN ATCC 700332 lecithino- IGNDSWQDMALMSMCRCNIIANSSFSWWAAWLNNASDKTVLAPAIWNRRQLEYVDRYY lyticum] GYDYSDIVPESWIRIPID Bacteroides WP_ 490419682 glycosyl 25.34 MRLIKMTGGLGNQMFIYAFYLRMKKRHTNTRIDLSDMMHYNVHHGYEMHRVFNLPKTE 143 eggerthii; 004291980.1 transferase FCINQPLKKVIEFLFFKKIYERKQDPSSLLPFDKKYLWPLLYFKGFYQSERFFADMEN Bacteroides [Bacteroides DIRIAFTENSDLFNEKTQAMLIQIKHNEHAVSLHIRRGDYLEPKHWKTIGSVCQLPYY eggerthii DSM eggerthii] LNAITEMNKRIEQPSYYVFSDDIAWVKENLPLPQAVFIDWNKGAESWQDMMLMSHCRH 20697 HIICNSTFSWWGAWLNPRENKTVIMPERWFQHCDTPNIYPDGWIKVPVN Bacteroides WP_ 491891563 glycosyl 25.34 MRFIKMTGGLGNQMFIYAFYMRMKKHYSNTRIDLSDMVHYKAHNGYEMHRVFNLPPIE 144 stercoris; 005656005.1 transferase FRINQPLKKVIEFLFFKKIYERKQVPSSLVPYDKKYFWPLLYFKGFYQSERFFADMAD Bacteroides [Bacteroides DIRKAFTENPRLSNRKTKEMSEQ1DHDENAVSIHVRRGDYLEPKYWIMGCVCQLPYYL stercoris ATCC stercoris] NAIAEMNKRISQPSYYVFSDDIAWVKENLPLPKAFFIDWNKGAESWQDMMLMSRCRHH 43183 IICNSTFSWWGAWLNPRENKTVIMPERWFRHCETPDICPDKWIKVPINQPDSIQ Butyrivibrio YP_ 302671882 glycosyl 25.34 MIIIQLKGGMGNQMFQYALYRQLKKLGREVKIDDETGFVDDELRIPVLQRFGISYDKA 145 proteoclasticus; 003831842.1 transferase 11 TREEIVKLTDSKMDIFSRIRRKLTGRKTFRIDEESGIFDPRILEVEDAYLVGYWQSDK Butyrivibrio [Butyrivibrio YFANEEVEKEIREAFEKRPQEVMQDSVSWTILQQIECCESVSLHIRRIDYIDEEHIHI proteoclasticus proteoclasticus HNICTEKYYKSAIDEVRNQYPSAVFFIFTDDKDWCRQHFRGPNFFVVDLDEDINTDIA B316 B316] EMTLMSRCKHHILANSSFSWWAAWLNDNPGKIVIAPSKWINNRKMDDIYTARMKKIAI Roseobacter sp. WP_ 495504071 alpha-1,2- 25.34 MSPIVHFPSDRLLRYEHLNSLWKTAMIYIRLLARLGNQMFQYAAGRGLAARLGVDFTV 146 GAI101 008228724.1 fucosyl- DSRRAVHKGDGVLTRVFDLDWAAPENMPPAQHERPLAYYAWRGLRRDPKIYRENGLGY transferase NAAFETLPDNTYLHGYWQCERYFAHIADDIRAAFVPRHPMSAQNADMARRIASGPSVS [Roseobacter LHVRRGDYLTVGAHGICDQTYYDAALAAVMQGLPSPTVYVFSDDPQWAKDNLPLIFEK sp. GAI101] VVVDFNGPDSDYEDMRLMSLCQHNVIANSSFSWWGAWLNANPQKRVAGPANWFSNPKL SNPDILPSRWIRI Thalassobacter WP_ 544666256 alpha-1,2- 25.34 MGQDMIYSRIFGGLGNQLFQYATARAVSLRQGVELVLDTRLAPPGSHWAFGLDHFNIS 147 arenae; 021099615.1 fucosyl- ARIAEPSELPPSKDNFFKYVMWRAFGHDPAFMRERGLGYQSRIAQAPDGTYLHGYFQS Thalassobacter transferase, ERYFADVLDHLENELRIVTPPDTRNAEYADRIASAGHTVSLHVRRGDYVETSKSNSTH arenae DSM 19593 [Thalassobacter ATCDEAYYLRALARLSEGKSDLKVFVFSDDPEWVRDNLKLPYDTTPVGHNGPDKPHED arenae] LRLMSCCSDHVIANSTFSWWGGWLDRRPEARVVGPAKWFNNPKLVNPDILPERWIAI Prevotella WP_ 490511493 protein 25.33 MKIIKIIGGLGNQMFQYALAVALQKKWKDEEIKLDLHGENGYHKHQGYQLDEIFGHRF 148 oris; Prevotella 004377401.1 [Prevotella KAASLKEVAQLAWPYPHYQLWRVGSRLLPKRKTMVCESADCRFQSDLLNLEGSLYYDG oris oris] YWQDERYFKAFRTEIIEAFKFTPLVGDSNRKVENMLKEGRFASLHVRRGDYLKEPLFQ C735 STCDIAYYQRAISRLNQMADPYCYLIFSNDIAWCKTHIEPLCDGRRTHYVDWNHGKES YRDMQLMTFCKHHIIANSSFSWWGAWLSTANDGITIAPHQWYANDRKPSPAAEAWLKL Prevotella WP_ 490514606 protein 25.33 MKIVRIIGGLGNQMFQYALALALKQQQENEEVKLDLSAFRGYKKHGGFQLVQCFGTTL 149 oulorum; 004380180.1 [Prevotella PAATWQEVAQLAWYYPHYQLWRLGHRVLPVCKTMLKEPDNGAFLPEVLQRKGDAYYEG Prevotella oulorum] CWQDERYFSHYRPAILQAFTFPTFTNPRNLAMQQQINTTESVAIHVRRGDYLHDALFR oulorum F0390 NICGLAYFQRAITCILQHVAHPVFYVFSDDMAWCRQHIQPLLQINEAVFVDWNHGKAS ICDLHLMTLCRHHIIANSSFSWWGAWLSPHQAGWIIAPKQWYAHEEKMSPAAERWLKL Spirosoma WP_ 522084965 protein 25.33 MNRRVAVQLKGGLGNQLFQYALGRRLSLQLEAELLFDCSVLENRIPVINFTFRSFDLD 150 panaciterrae 020596174.1 [Spirosoma MFRIAGRVATPSDLPLFPKSASIRSPWPHLVQLARLWKQGYSYVYERGFAYNPKMLRQ panaciterrae] LSDRVYLNGYWQSYRYFEDIAATLRADCSFPDPLPDSAVGLAGQINATNSICLHIRRT DFLQVPLHQVSNADYVGRAIAYMAERVNDPHFFVFSDDIAWCQTNLRLSYPVVFVPNE LAGPKNSLHFRLMRYCKHFITANSTFSWWAAWLSEPSDGKVIVTPQTWFSDSRSIDDL IPANWIRL Butyrivibrio YP_ 302669866 glycosyl 25.26 MNYVEVKGGLGNQLFQYTFYKYLEKKSGHKVLLHTDFFKNIDSFEEATKRKLGLDRFD 151 proteoclasticus; 003829826.1 transferase 11 CDFVAVSGFISCEKLVKESDYKDSMLSQDEVEYSGYWQNKRFFLEVMDDIRKDLLLKD Butyrivibrio [Butyrivibrio ENIQDEVKELAKELRAVDSVAIHFRRGDYLSEQNKKIFTSLSVDYYQKAIAQLAERNG proteoclasticus proteoclasticus ADLKGYIFTDEPEYVSGIIDQLGSIDIKLMPVREDYEDLYLMSCARHHIIANSSFSWW B316 B316] GAALGDTESGITIAPAKWYVDGRTPDLYLRNWISI Butyrivibrio sp. WP_ 551021623 protein 25.26 MIIIQLKGGLGNQMFQYALYKELKHRGREVKIDDVSGFVNDKLRVPVLDREGVEYERA 152 XPD2006 022765786.1 [Butyrivibrio TREEVVELTDSRMDIFSRIRRKLTGRKTYRIDEMEGIFDPAILETENAYLVGYWQSEK sp. YFTSPEVIEQIQEAFGKRPQEIMHDSVSWSTLQQIECCESVSIHVRRIDYVDAEHIKI XPD2006] HNLCSEKYYKNAIGKIREKHPNAVFFIFTDDKEWCKDHFKGPNFITVELQEGEFTDVA DMLLMSRCKHHIIANSSFSWWSAWLNDSPEKMVIAPSKWINNKKMDDIYTERMTRVAI Bacteroides sp. WP_ 496041586 protein 25.24 MKIVNITGGLGNQMFQYAFAMALKYRNPQEEVFVDIQHYNTIFFKKFKGINLHNGYEI 153 1_1_6 008766093.1 [Bacteroides DKVFPKAKLPVAGVRQLMKFSYWIPNYILSRLGRKFLPIRKKEYIPPYSMNYSYDEKA sp. LNWKGDGYFEGYWQSYNHFGDIKEELQKVYAHPKPNQYNAALISNLESCNSVGIHVRR 1_1_6] GDYLAEPEFRGICGLDYYEKGIKEILSDEKKYVFFIFSNDMQWCQENIAPLVGDNRIV FISGNKGKDSCWDMFLMTHCKDLIIANSSFSWWGAFLNKKVDRVICPKPWLNRDCNID IYNPSWILVPCYSEDW Bacteroides YP_ 53713865 alpha-1,2- 25.17 MKIVTFQGGLGNQLFQYVFYLWLDMRCDKDNIYGYYPKKGLRAHNGLEIEKVFEVKLP 154 fragilis; 099857.1 fucosyl- NSSLSTDLIVKSIKLINKIFKNRQYISTDGRLDVNGVLFEGFWQDKYFWEDVDIVLNF Bacteroides transferase RWPLKLDVINSFIMTKIQANNSISIHIRRGDYLLPKYRNIYGDICNEEYYQKAIEYIL fragilis YCH46 [Bacteroides KCVDDPFFFVFSDDIDWAKSIINVSNVTFVNNNKGKDSYIDMFLMSLCHHNIIANSTF fragilis YCH46] SWWAAQLNKHSDKIMIAPIRWFKSLFKDPNIFTESWIRI Bacteroides sp. WP_ 495947264 alpha-1,2- 25.17 MIKIVSFSGGLGNQLFQYLLVVYLRECGHQVYGYYNRKWLIGHNGLEVNNVFDIYLPK 155 9_1_42FAA 008671843.1 fucosyl- TNFIVNALVKVIRVLRCLGFKKYVATDTYNNPIAIFYDGYWQDQKYFNIIDSKLSFKK transferase  FDLSAENKSILSKIKSNISVALHIRCGDYLSSSNVEIYGGVCTKEYYEKALELVCKIK [Bacteroides NVMFFVFSDDIEYAKLLLNLPNAIYVNANVGNSSFIDMYLMANCKVNVIANSTFSYWA sp. 9_1_42FAA] ARLNQDNILTIYPKKWYNSKYAVPDIFPSEWVGV Coraliomargarita WP_ 548260617 glycosyl 25.17 MIIVKVQGGLGNQMFQYAFGRALSEKHSQDLYLDCSEYLRPSCKREYGLDHFNIRAKK 156 sp. 022477844.1 transferase ASCGDVKSMVTPHFALRKKLKKIFAVPYSLSPTHILERNENFQPSILEFNCGYFDGFW CAG:312 family 11 QTQKYFSGISDIVRKDLTFKDAVKYSGGETFAKITSLNSVSLHIRRGDYVKVKRTRKR [Coralio- FSVIRAGYFKRAVEYMRSKLDTPHFFIFTDDPKWVSENFPAGEDYTLVSSSGMYEDLF margarita LMAQCRHNIIFNSSFSWWGAWLNGNPGKIVVAPDMWFTPHYKLDYSDVVPEEWIKLNT sp. CAG:312] GYFESKEF Pseudorhodobacter WP_ 550957292 alpha-1,2- 25.17 MIVMQIKGGLGNQMFQYAAGRALSLQTGMPLHLDLRYYRREREHGYGLGAFNIEASPL 157 ferrugineus 022705649.1 fucosyl- DESLLPPLPRESPLAWLIWRLGRRGPNLVRENGMGENPTLSNVTKPAWITGYFQSERY transferase FAAHAATIRAELTPVAAPDLVNARWLAEIAAEPRAVSLHVRRGDYVRDAKAAAKHGSC [Pseudo- IPAYYERALAHITARMGTAPVVYAFSDDPAWVRENLRLPAEIRVPGHNDTAGNVEDLR rhodobacter LMSACRHHIVANSSFSWWGAWLNPRADKIVASPARWFADPAFTNPDIWPEAWARIEG ferrugineus] Escherichia YP_ 215487252 fucosyl- 25.16 MMYCCLSGGLGNQMFQYAAAYILKQHFPDTILVLDDSYYFNQPQKDTIRHLELDQFKI 158 coli; Escherichia  002329683.1 transferase IFDRFSSKDEKVKINRLRKHKKIPLLNSFLQFTAIKLCNKYSLNDASYYNPESIKNID coli [Escherichia VACLFSFYQDSKLLNEHRDLILPLFEIRDDLRVLCHNLQIYSLITDSKNITSIHVRRG O127:H6 str. coli O127:H6 DYVNNKHAAKFHGTLSMDYYISAMEYIESECGSQTFIIFTDDVIWAKEKFSKYSNCLV E2348/69 str. ADADENKFSVIDMYLMSLCNNNIIANSTYSWWGAWLNRSEDKLVIAPKQWYISGNECS E2348/69] LKNENWIAM Lachnospiraceae WP_ 511537894 protein 25.16 MIIIKVMGGLGNQMQQYALYEKEKSIGKNVKLDISWEEDSSVCIEKVFARRSLELRQF 159 bacterium 016359991.1 [Lachno- KDLQFDTCSAEEKEALLGKSGILGKLERKLIPARNKHEYESDIYHSEVFNMSDAYLEG 3_1_57FAA_CT1 spiraceae HWACEKYYHDIMPLLQEKIQFPESANSQNITVKKRMKAENSVSIHIRRGDYLDPENEA bacterium MFGGICTNSYYKAAEEYIKSRVPDTHFYLFSDDTAYLRENYHGDEYTIVDWNKGEDSF 3_1_57FAA_CT1] YDMELMSCCRHNICANSTFSFWGARLNRTPDKIVIRPAKHKNSQEIEPQLLHELWDNW VIIDGDGRIV Butyrivibrio WP_ 551010878 glycosyl 25.09 MKPLVSLIVPVLNVEKYLECICLTSISSQTYDNFEVILVVGKCIDNSENICKKWCEKD 160 fibrisolvens 022755397.1 transferase HRFRIEPQLKSCLGYARNVGIDAAKGEYIAFCDSDDCITSDFLSCFVDTALKNSSDIV [Butyrivibrio ETQFTLCDQNLSPIYDYDRNILGHILGHGFLEYTSAPSVWKYFVKRDIFTSNNLHYPE fibrisolvens] IRFGEDISMYSLLFSYCNKIDYVEKPTYLYRQVPSSLMNNPQGKRKRYESLFDIIDFV TNEFKIRLLFQKSWLKLLFQLEMHSASIISDSATSDDEAISMRQEISGYLKKVFPVKN TIFEVTALGWGGEIVSSIASKENTLHGVSSSNMENRYFFELLEDSTRKKLEEMIINFS PDIFLIDLISEADYLSSYKGNLGTFVKNWKIGFSIFMKMICITHSNNSSIFLLENYMQ QAPDHVDNTNEILKMLYDDIKINHPDIICISPAPDILNRSSEPELPCIYQLKLVSDKL HTMYSPVINCVETKGGLGNQIFQYVFSKYIEKMTGYRPLLHIGFFDYVKAIPGGTKRI FSLDKLFPDIETTSGKIPCSHVVEEKSFISNPGSDIFYRGYWQDIRYFSDVKDEVLES ENVDTSSMSKDVIDFADTIRNANSIAMHIRRQDYLNENNVSLFEQLSIDYYKSAVDMI RKEYADDLVLFIFSDDPEYANSIADSFDIEGFVMPLHKDYEDLYLITLAHHHIIANST FSLWGALLSARKDGIRIAPRNWFKGTPATNLYPDKWLIL Anaeromusa WP_ 517532751 protein 25.08 MFCVRIYGGLGNQMFQYALGRAMAKHYSETAAFDLSWYEQKIKPGFEASVCQYNIELS 161 acidaminophila 018702959.1 [Anaeromusa RKDRPKAWYEPILKRISRHTDKLEMWEGLFFEKKYHYDSTVFERGLCKKNITLDGYWC acidaminophila] ISYKYFSAIEDDLRRELTIPKEREELIAISRSLPENSVSIHVRRGDYVSNPKANAMHG TCSWEYYQAAIEKMTGLVKEPQYVVFSDDITWTKENLPLPNAMYIGRELGLFDYEELI LMSRCKHNIMANSTFSWWGAWLNSNPNKVVIAPRKWFRHKKIKVNDLFPSSWVVL Bacteroides sp. WP_ 496044479 glycosyl 25.08 MDIVVIFNGLGNQMSQYAFYLAKKKDNLNCHVIFDPKSTNVHNGAELKRVFGIELNRN 162 2_1_16 008768986.1 transferase YLDKIISYFYGYIFNKRIVNKLFSLVGIRMIYEPKNYDYREELLKPSSNFISFYWGGW family 11 HSEKYFKDIELEVKKVFKFPEVINSPYFTEWFNKIFLDNNSVSIHIRRGDYLDKPSDP [Bacteroides YYQFNGVCTIDYYEKAILYLKERILEPNFYIFSNDINWCMKTFGTENMYYVDCNKGKD sp. 2_1_16] SWRDMYLMSECRHHINANSTFSWWAAWLSPYSNGIVLHPKYFIKDIETKDYYPQKWIM IE Chlorobium YP_ 189500849 glycosyl 25.08 MDKVVVHLTGGLGNQMFQYALGRSISINRNCPLLLNTSFYDTYDKFSCGLSRYNVKAE 163 phaeobacteroides; 001960319.1 transferase FIKKNSYYNNKYYRYVIRLLSRYGVACYFGSYYEKKIFSYDEKVYKRSCVSYYGTWQS Chlorobium family protein YGYFDSIRDILLRDYEMVGCLEEEVEKYVSDIKRVDSVSLHIRRGDYFDNKRLQSIFI phaeobacteroides [Chlorobium GILTMEYYYKAMSLFPDSSVFYVFSDDIEWVRENLITNTNIVYVVLESDNPENEIYLM BS1 phaeo- SLCKNNIISNSTFSWWGAWLNKNKYKKVIAPRMWYKDNQSSSDLMPSDWCLI bacteroides BS1] Treponema WP_ 551312724 protein 25.08 MIVISMGGGLGNQMFEYAFYTQLKHLYPKSEIKVDTKYAFPYSHNGIEVFKIFGLNPP 164 bryantii 022932606.1 [Treponema EANWKEVHSLVKTYPIEGNKAHFIKFFLYRILRKANLVEREPTSFCKQKDFTEFYNSF bryantii] FELPQNKSFYLYGPFVNYNYFAAIHNEIMDLYTFPEITDVINIEYKRKIESSHSISIH IRRGDYITEGVPLVPDAYYREALVYINKKIEDPHFFVFTDDKDYCKSLFSDNQNFTIV EGNTGANSFRDMQLMSLCKHNIIANSTFSFWGAFLNKNSEKIVIAPNIAFKDCSCPYI CPDWIIL Bacteroides YP_ 375358171 LPS 25 MVIAKLFGGLGNQMFIYAAAKGIAQISNQKLIFDIYTGFEDDSRFRRVYELKQFNLSV 165 fragilis; 005110943.1 biosynthesis QESRRWMSFRYPLGRILRKISRKIGFCIPLVNFKFIVEKKPYHFQNEIMRIASFSSIY Bacteroides alpha-1,2- LEGYFQSYKYFSKIEAQIREDFKFTKEVIGSVEKEASFITNSRYTPVAIGVRRYSEMK fragilis 638R fucosyl- GEFGELAVVEHDYYDAAIKYIANKVPNLIFIVFSEDIDWVKKNLKLDYPVYFVTSKKG transferase ELAAIQDMYLMSLCNHHIISNSSFYWWGAYLASTNNHIVIAPSVFLNKDCTPIDWVII [Bacteroides fragilis 638R] Firmicutes WP_ 547951298 protein 25 MSGGLGNQMFQYALYMKLTAMGREVKFDDINEYRGEKAWPIMLAVEGIEYPRATWDEI 166 bacterium 022352105.1 [Firmicutes VAFTDGSMDFSKRLKRLFRGRHPIEYVEQGFYDPKVLSFENMYLKGSFQSQRYFEDIL CAG:534 bacterium EEVQETFRFPELKDMNLPAPLYETTEKYLLRIEGCNAVGLHMYRGDSRSNEELYDGIC CAG:534] TEKYYEGAVRFIQDKCPDAKFFIFSNEPKWVKGWVISLMKSQIREDMSREEIRALEDH FVLIENNTEYTGYLDMFLMSRCRHNIISNSSFSWWAAFINENPDKLVTAPSRWVNGVP SEDVYVKGMTLIDEKGRVERTIKE Firmicutes WP_ 547971670 glycosyl 25 MVIVKIGDGLGNQMFNYVCGYSVAKHDNDILLLDTSDVDNSTLRTYDLDKFNIDFTDR 167 bacterium 022368748.1 transferase ESFTNKGFFHKVYKRLRRSLKYNVIYESRTENCPCVLDVYRRKFIRDKYLHGYFQNLC CAG:882 family 11 YFKTCKEDIMRQFTPKEPFSAKADELIHRFATENTCSVHVRGGDIKPLSIKYYKDALD [Firmicutes KIGEAKKDMRFIVFSNVRNLAEEYIKELGVDAEFIWDLGEFTDIEELFLMKACRRHIL bacterium SDSTFSRWAALLDEKSEEVFVPFSPDADKIYMPEWIMEEYDGNEEKR CAG:882] Vibrio WP_ 491639353 glycosyl 25 MVIVKVSGGLGNQLFQYAIGCAISNRLSCELLLDTSFYPKQSLRKYELDKFNIKAKVA 168 parahaemolyticus; 005496882.1 transferase TQKEVESCGGGDDLLSRFLRKLNLSSLFFPNYIKEKESLVYLAEISHCKSGSFLDGYW Vibrio family 11 QNPQYFSDIKDELVKQIVPIMPLSSPALEWQNIIINTKNCVSLHVRRGDYVNNAHTNS parahaemolyticus [Vibrio VHGVCDLSYYREAITNIHETVEKPKFFVFSDDISWCKDNLGSLGHFTYVDNTLSAIDD 10329; Vibrio para- LMLMSFCEHHIIANSTFSWWGAWLNDHGITIAPKRWFSSVERNNKDLFPEKWLIL parahaemolyticus haemolyticus] 10296; Vibrio parahaemolyticus 12310; Vibrio parahaemolyticus 10290 Herbaspirillum WP_ 493509348 glycosyl 24.92 MIVSRLIGGLGNQMFQYAAGRALALRRGVPFAIDSRAFADYKTHAFGMQCFCADQTEA 169 frisingense; 006463714.1 transferase PSRLLPNPPAEGRLQRLLRRFLPNPLRVYTEKTFTFDEAVLSLPDGIYLDGYWQSEKY Herbaspirillum family protein FADFADDIRKDFAVKAAPSAPNQAWLELIGRTHSVSLHIRRGDYVSNAAAAAVHGTCD frisingense [Herbaspirillum LGYYERAVAHLHQVTGQAPELFVFSDDLDWVATNLQLPYTMHLVRDNDAATNFEDLRL GSF30 frisingense MTACRHHIVANSSFSWWGAWLDGRSESITIAPARWEVADTPDARDLVPQRWVRL Rhizobium sp. WP_ 495034125 Glycosyl 24.92 MIITRILGGLGNQMFQYAAGRALAIANEAELKLDLIEMGAYKLRPFALDQFNIKAAIA 170 CF080 007759661.1 transferase QPDEVPAKPKRGLLRKFTSAFKPDRSSCERIVENGLIFDSRVPALRGSLHLSGYWQSE family 11 QYFASSADAIRSDFSLKSPLGPARQDVLARIGAATTPVSIHVRRGDYVINPSANAVHG [Rhizobium sp. TCEPPWYHEAMRRMLDRAGDASFFVFSDEPQWARDNLQSSRPMVFIEPQNNGRDGEDM CF080] HLMAACHAHIIANSSFSWWGAWLNPRPNKHVIAPRQWFRAPDKDDRDIVPATWERL Verrucomicrobium WP_ 497645196 glycosyl 24.85 MVISHISEGLGNQMFQYAAGRRLSYHLGTTLKLDDYHYRLHPFRSFQLDRFLITSPIA 171 spinosum 009959380.1 transferase, TDAEISHLCPLEGLARAIRARLPGKLRGATLRLLGNLGLGSPYQPRLHSFKEETPKQP family 11 LLIGKVVSERHFHFDPDVLECPDNVCLVGYWQDERYFGEIRDILLRELTLKSPPAGAT [Verru- KAVLERIQRSSSVSLHVRRGDKIKSSSYHCTSLEYCLAAMSEMRARLQAPTFFVFSDD comicrobium WDWVREQIPCSSSVIHVDHNRAEDVSEDFRLMKSCDHHIIASSSLSWWAAWLGTNENS spinosum] FVFSPPADRWLNFSNHFTADVLPPHWIQLDGSSLLPAQ Fibrella YP_ 436833833 glycosyl 24.83 MTANRVLVNSPMVIAKITSGLGNQLFQYALGRHLALQGNTSLWFDLRYFHQEYATDTP 172 aestuarina; 007319049.1 transferase RKFKLDRFNVRYNLLDSSPWLYASKATRLLPGRSLRPLIDTRFEADFHFDPTVIRPAA Fibrella family 11 PLTILWGFWQSEKYFAQSTPQIRQELTFNRPLSDIFVGYQQQIEQAEVPISVHVRRGD aestuarina BUZ 2 [Fibrella YVTHPEFSQSFGFVGLAYYQKALAHLQDLFPNATLFFFSDDPDWVRANIVTEQPHVFV aestuarina BUZ QNSGPDADVDDLQLMSLCHHHVIANSSFSWWGAWLNPRPDKVVIGPQRWFANKPWDTK 2] DLLPSGWLRL Rhodobacter sp. WP_ 563380195 alpha-1,2- 24.83 MIHMRLVGGLGNQLFQYACGRAVALRHGTELVLDTRELSRGAAHAVEGLDHFAIRARM 173 CACIA14H1 023665745.1 fucosyl- RGASADLPPPRSVLAYGLWRAGFMAPRFLRERGLGVNPAVLAAGDGTYLHGYFQSEAY transferase WFRDVVPQIRPELEIVIPPSDDNLRASRIAGDDRAVSLHVRRGDYVASAKGQQVHGTC [Rhodobacter DADYYARAVAAIRARAGIDPRLYVFSDDPHWARDNLALDAETVVLDHNPPGAAVEDMR sp. CACIA14H1] LMGVCRHHIIANSSFSWWGAWRNPSAGKVVVAPVRWFADPKLHNPDICPPEWLRV Rhodopirellula NP_868779.1 32475785 fucosyl 24.83 MATSAHLHLSDEKQTLDSKASDRDCATTEASASDKICTISISGGLGNQMLQYAAGRAL 174 baltica transferase SIHHDCSLQLDLKFYSSKRHRSYELDAFPIQAHRSIKPSFFSQILSKIQSESKHVPTY SH 1; [Rhodopirellula QEQSKRFDPAFFNTEPPVKIRGYFFSEKYFSPYADQIRTELTPPIPPDQPARDMAIRL Rhodopirellula baltica SH 1] KECVSTSLHVRRGDYVTNANARQRFWCCTSEYFEAAIERLPTDSTVFVFSDDIEWAKQ baltica NIRSSRTTVYVNDELKKAGSPETGLRDLWLMTHAKSHIIANSSFSWWGAWLANSEANL TIAPKKWENDPEIDDSDIVPSSWHRI Spirosoma WP_ 522092845 protein 24.83 MVVVELMGGLGNQMFQYAFGMQLAHQRQDTLTVSTFLLSNKLLANLRNYTYRPFELCI 175 spitsbergense 020604054.1 [Spirosoma FGIDKPKASPFNLLRALLPFDLNTSLLRETDDPEAVIPAASARIVCVGYWQSEHYFEE spitsbergense] VIVHVREKFIFRQPFNSFTSRLANNLNGIPNSVFVHIRRGDYVINKGANAHHGLCDRT YYERAVTFMREHLENPLFFIFSDDLEWVSQELGPILEPATYVGGNQKNDSWQDMYLMS LCRHAIVANSSFSWWGAWLSPHASKIVVAPKEWFGKPLLPVKINDLIPNSWIRI uncultured EKD71402.1 406938106 protein 24.76 MNAIIPRLIGGIGNQLFIYAAARRMAIANSMNLVIDDTSGFKYDVLYKRFYQLEKFNI 176 bacterium ACD_46C00193 TSRMATPTERLEPFSKIRRYLKRKINKTYPFAQRAYITQEKSGFDPRLLVERPKGNVY G0003 LDGYWQSENYFKDIEGIIRQDLIIKSPSDSLNIATAERIKNTLAIAVHVRFFDMVDIS [uncultured DSSNCQSNYYHTAIAKMEEKIPNAHYFIFSDKPVLARLAMPLPDDRITIIDHNIGDMN bacterium] AYADLWLMSLCKHEVIANSTFSWWGAWLSDNKEKIVIAPDIKITSGVTQWGEDGLIPD EWIKL Prevotella WP_ 494008437 protein 24.75 MDVIVIFNGLGNQMSQYAFYLEKRLRNRQTTYFVLNPRSTYELERLFGIPYRSNLMCR 177 micans; 006950883.1 [Prevotella MIYKLLDKAYFSNHIRLKKILRTALNAVGIRLIVEPITRNYSLSNFTHHPGLIFYRGG Prevotella micans] WHSELNFTSVVTELRRKFIFPPSDDEEFKRISALIIRTQSISLHIRRGDYLDYSEYQG micans F0438 VCTEEYYERAIEYIRSHVENPVFFVFSDDKEYAINKFSGDDSFRIVDENTGENSWRDM QLMSLCRHHILANSTFSWWGAWLDSAPEKIVLHPIYHMRDVPTRDFYPHNWIGISGE Thermo- AHB87954.1 564737556 alpha-1,2- 24.75 MIIVRLYGGLGNQMFQYAAGLALSLRHAVPLRFDLDWFDGVRLHQGLELHRVFDLDLP 178 synechococcus fucosyl- RAAPSEMRQVLGSFSHPLVRRLLVRRRLRWLLPQGYALEPHFHYWPGFEALGPKAYLD sp. NK55 transferase GYWQSERYFSEYQDAVRAAFRFAQPLDERNRQIVEEMAACESVSLHVRRGDFVQDPVV [Thermo RRVHGVDLSAYYPRAVALLMERMREPRFYVFSDDPDWVRANLKLPAPMIVIDHNRGEH synechococcus SFRDMQLMSACRHHILANSSFSWWGAWLNSQPHKLVIAPKRWFNVDDFDTRDLYCSGW ococcus sp. TVL NK55] Coleofasciculus WP_ 493031416 Glycosyl 24.73 MLSLNKNFLFVHIPKSCILKEVYIYMISFPNLGKGVRLGNQMFQYAFLRSTARRLGVK 179 chthonoplastes; 006100814.1 transferase FYCPAWSGDSLFTLNDQEERVSQPEGITKQYRQGLNPGFSENALSIQDGTEISGYFQS Coleofasciculus family 11 DKYYDNPDLVRQWFSLKEEKIASIRDRFSRLNFANSVGMHLRFGDVVGQLKRPPMRRS chthonoplastes [Coleo- YYKKALSYIPNQELILVFSDEPERTKKMLDGLSGNFLFLSGHKNYEDLYLMTKCQHFI PCC 7420 fasciculus CSYSTFSWWGAWLGGERERTVIYPKEGQYRPGYGRKAEGVSCESWIEVQSLRGFLDDY chthonoplastes] RLVSRLEKRLPKSLMNFFY Bacteroides WP_ 517496220 glycosyl 24.66 MRLIKMTGGLGNQMFIYAFYLRMKKRHTNTRIDLSDMMHYNVHHGYEMHHVFNLPKTE 180 gallinarum 018666797.1 transferase FCINQPLKKVIEFLFFKKIYERKQDSSNLLPFDKKYFWPLLYFKGFYQSERFFADMEN [Bacteroides DIRKAFTENSGLFNEKTQTMLKQIEHNEHAVSLHVRRGDYLEPKHWKTIGSVCQLPYY gallinarum] INAIAEMNRRIEQPFYYVFSDDIAWVKENLPLPQAVFIDWNKGVESWQDMMLMSHCRH HIICNSTFSWWGAWLNPKENKTVIMPERWFQHCETPNIYPAGWIKVPIN Firmicutes WP_ 547967507 glycosyl 24.66 MNNVEIMGGLGKQLFQYAFSRYLQKLGVKNVVLRKDFFTIQFPENNGITKREFVLDKY 181 bacterium 022367483.1 transferase NTRYVAAAGEKTYRDYCDENDYRDDYAIGSDEVLYEGYWQNIDFYNVVRKEMQEELKL CAG:882 GT11 family KPEFIDNSMAAVEKDMSSCNSVALHIRRSDYLTQVNAQIFEQLTQDYYASAVSIIEQY [Firmicutes THEKPVLYIFSDDPEYAAENMKDFMGCRTVIMPPCEPYQDMYLMTRAKHNIIANSTFS bacterium WWGATLNANPDNITVAPSRWMKGRIVNLYHKDWITL CAG:882] Bacteroides WP_ 495296741 protein 24.6 MIAVNVNAGLANQMFHYAFGRGLMAKGLDVCFDQSNFKPRSQWAFELVRLQDAFPSID 182 xylanisolvens; 008021494.1 [Bacteroides IKVMPEGHFKWVFPSLPRNGLERRFQEFMKKWHNFIGDEVYIDEPMYGYVPDMEKCAT Bacteroides xylanisolvens] RNCIYKGFWQSEKYFRHCEDDIRKQFTFLPFDELKNIEVAAKMSQENSVAIHLRKGDD xylanisolvens YMQSELMGKGLCTVDYYMKAIDYMRKHINNPHFYVFIDNPCWVKDNLPEFEYILVDWN CL03T12C04 EVSGKRNFRDMQLMSCAKHNIIGNSTYSWWAAWLNANQDKIVVGPKRFFNPINSFFST CDIMCEDWISL Geobacter sp. M18 YP_ glycosyl 24.58 MIGMVIFRAYNGLGNQMFQYALGRHLALLNEAELKIDTTAFADDPLREYELHRLKVQG 183 004197726.1 322418503 transferase MSIATPDEIAFFREENTHPQAYLRLTQKSRLFDPAILSARGNIYLHGFWQTEKYFADI family protein REILLDEFEPIVPAGEDSIKVLSHMKATNAVALHVRRSDYVSNPMTLRHHGVLPLDYY [Geobacter sp. REAVRRIAGMVPDPVFFIFSDDPQWAKDNIRLEYPAFCVDAHDASNGHEDLRLMRNCK M18] HFIIANSSFSWWGAWLSQNTGKKVVAPLKWFAKPEIDTRDIVPLQWIRI Ruegeria pomeroyi YP_168587.1 56698215 alpha-1,2- 24.57 MITTRLHGRLGNQMFQYAAARGLAARLGTQVALDTRLAESRGEGVLTRVFDLDLAQPD 184 DSS-3 fucosyl- QLPPLKGDGLLRHGAWRLLGLAPRFRREHGLGYNAAIETWDDGTYLHGYWQSERYFAH transferase, IAARIRADFAFPAFSNSQNAEMAARIGDTDAISLHVRRGDYVALAAHTLCDQRYYAAA [Ruegeria LTRLLEGVAGDPVVYLFSDDPAWARDNLALPVQKVVVDFNGPETDFEDMRLMSLCRHN pomeroyi DSS-3] IIGNSSFSWWAAWLNAHPGKRIAAPASWFGDAKLHNPDLLPPDWLKIEV Lachnospiraceae WP_ 511037973 protein 24.52 MIIIQLAGGLGNQMQQYAMYQKLLSLGKKVKLDISWFEEKNRQKNVYARRELELNYFK 185 bacterium 28-4 016291997.1 [Lachno- KAEYEACTEEERKALVGEGGFAGKIKGKLFPGTRKIFRETEMYHPEIFDFEDRYLYGY spiraceae FACEKYYADIMEILQEQFVFPPSGNPENQKMAERIADGESVSLHIRRGDYLDAENMAM bacterium 28- FGNICTEEYYAGAIREMKKIYPSAHFFVFSDDIPYAKETYSGEEFTVVDINRGKDSFF 4] DIWLMSGCRHNICANSTFSFWGARLNRNKGKVVMRPFIHKNSQKFEPELMHELWKGWV FIDNRGNIC Prevotella sp. WP_ 547254188 glycosyl 24.49 MRILVFTGGLGNQMFEYAFYKHLKSCFPKESFYGHYGVKLKEHYGLEINKWFDVTLPP 186 CAG:1092 021989703.1 transferase AKWWTLPVVGLFYLYKKLVPNSKWLDLFQREWKHKDAKVFFPFKFTKQYFPKENGWLK family 11 WKVDEASLCEKNKKLLQVIHDEETCFVHVRRGDYLASNFKSIFEGCCTLDYYKRALEY [Prevotella sp. MNKNNPKVRFICFSDDLEWMRKNLPMDDSAIYVDWNTGTDSPLDMYMMSQCDNGIIAN CAG:1092] SSFSYWGAYLGGKKTTVIYPQKWWNMEGGNPNIFMDEWLGM Spirosoma luteum WP_ 517447743 protein 24.41 MVISVLSGGLGNQLFQYAFGLKLAAQLQTELRLERHLLESKAIARLRQYTPRTYELDT 187 018618567.1 [Spirosoma FGVEAPAASLMDTVSCLSRVALSDKTALLLRESTLTPNAINNLNNRVRDVVCLGYWQS luteum] EEYFRPATEQLRKHLVERKNPAQSRSMADTILSCQNAAFVHIRRGDYVTNTHANQHHG LCDVSYYRRACEYVKECIPDVQFFVFSDDPDWAKRELGIHLQPARFIDHNRGADSWQD MYLMSLCRHAIVANSSFSWWGAWLNPVAERLVVAPGQWFVNQPVLSQQIIPPHWHCL Marinomonas YP_ 333906886 glycosyl 24.34 MIIVDLSGGLGNQMFQYACARSLSIELNLPLKVVYGSLASQTVHNGYELNRVFGLDLE 188 posidonica 004480472.1 transferase FATENDMQKNLGFFLSKPILRKIFSKKPLNNLKFQNFFPENSFNYNSSLFSYIKDSGF IVIA-Po- family protein LQGYWQTEKYFLNHKSQILKDFCFVNMDDETNISIANDIQSGHSISIHVRRGDYLTNL 181; Marinomonas [Marinomonas KAKAIFIGHCSLDYYLKAIEFLQEKIGESRLFIFSDDPEWVSENIATRFSDVSVIQHN posidonica posidonica RGVKSFNDMRLMSMCDHHIIANSSFSWWGAWLNPSQNKKIIAPKNWFVTDKMNTIDLI IVIA-P0-181] PSSWILK Bacteroides; WP_ 492425792 glycosyl 24.32 MKIVVFKGGLGNQLFQYAFYKYLSRKDETFYFYNDAWYNVSHNGFELDKYFKTDDLKK 189 Bacteroides sp. 005839979.1 transferase CSRFWIILFKTILSKLYHWKIYVVGSVEYQYPNHLFQAGYFLDKKYYDENTIDFKHLL 4_3_47FAA; family 11 LSEKNQSLLKDIQNSNSVGVHIRRGDYMTKQNLVIFGNICTQKYYHDAIRIITEKVND Bacteroides sp. [Bacteroides] AVFYVFSDDISWVQTHLDIPNAVYVNWNTGESSIYDMYLMSSCKYNIIANSTFSYWAA 3_1_40A; RLNKKTNMVIYPSKWYNTFTPDIFPESWCGI Bacteroides dorei 5_1_36/D4; Bacteroides vulgatus PC510; Bacteroides dorei CL03T12C01; Bacteroides vulgatus dnLKV7 Candidatus WP_ 519013556 protein 24.32 MTIRIKLIGGLGNQMFQFATGFAIAKKKNVRLSLDLKYINKRKIINGFELQKIFNIYS 190 Pelagibacter 020169431.1 [Candidatus KVSFLNKTLSEKSINFTEILNRIDTTFYNFKEPHFHYTSNILNLPKHSFLDGYWQSEL ubique Pelagibacter YFNEFATEIKRIFNFSGKLDKSNLLVADDINRNNSISIHIRRGDFLLKQNNNHHTDLK ubique] EYYLKAINETSKIFKNPKYFIFSDDTSWTVDNEVIDHPYIIVDINFGARSFLDMYLMS LCKSNIIANSSFSWWSAWLNNNKDKIIYAPKNWENDKSICTDDLIPESWNIIL Bacteroides sp. WP_ 547952428 uncharacterized 24.29 MSVIINMACGLANRMFQYAFYLYLQKEGYDAYVDYFTRADLVHENVDWLRIFPEATFR 191 CAG:875 022353174.1 protein RATARDIRKMGGGHDCFSRLRRKLLPMTTKVLETSGAFEIILPPKNRDSYLLGAFQSA [Bacteroides KMVESVDAEVRRIFTFPEFESGKNQYFQTRLAQENSVGLHIRKGKDYQERIWYKNICG sp. CAG:875] VEYYRKAVDLMKEKVDSPSFYVFMNPAWVKENLSWLEYKLVDGNPGSGWGSHCDMQLM SLCKHNIISNSSYSWWGAYLNNTLNKIVVCPRIWFNPESTKDFSSNPLLAEGWISL Butyrivibrio WP_ 551011911 protein 24.29 MIIIKLQGGLGNQLFLYGLYKNLKHLKRDVKMDIESGFEGDELRKPCLDCMNLEYAIA 192 fibrisolvens 022756327.1 [Butyrivibrio TRDEVTDIRDSYMDIFSRIRRKITGRKTFDYYEPEDGNYDPKVLEMTKAYLNGYFQSE fibrisolvens] KYFGDEESVKALKDELTKGKEDILTSTDLITKIYHDIKNSESVSLHIRRGDYLTPGII ETYGGICTDEYYDKAIAMIRETFPEARFFIFSNDIEWCKEKFAGDKNILFVNTIGINL DSEDNIKIGKSDKDISEYRDLAELYLMSACKHHILANSSFSWWGAWLSDHEGMTIAPS KWLNNKNMTDIYTKDMLLI Roseburia YP_ 347532692 glycosyl 24.22 MVIVKIGDGMGNQMYNYACGYAAAKRSGEKLRLDISECDNSTLRDYELDHFRVVYDEK 193 hominis; 004839455.1 transferase ESFPNRTFWQKLYKRLRRDIRYHVIRERDMYAVDARVFVPARRGRYLHGYWQCLGYFE Roseburia family protein EYLDDLREMFTPAYEQTDAVRELMQQFTQTPTCALHVRGGDLGGPNRAYFQQAIARMQ hominis A2-183 [Roseburia KEKPDVTFIVFTNDLPKAKECLDDGEARMRYIAEFGEALSDIDEFFLMSACQNQIISN hominis A2-183] STYSTWAAYLNTLPGRIVIVPKFHGVEQMALPDWIVLDGGACQKGEIDAV Rhodopirellula WP_ 495934621 alpha-1,2- 24.16 MATSVHPHLSDGKQALDSKAAQQVCSTQAASASDRACTISISGGLGNQMLQYAAGRAL 194 europaea; 008659200.1 fucosyl- SIHHDCPLQLDLKFYSSKRHRSYELDAFPIQAQRWIKPSFFSQVLDKIQGESKSAPTY Rhodopirellula transferase EEQSKRFDRAFFDIELPARIRGYFFSEKYFLPYADQIRTELTPPVPLDQPARDMAQRL [Rhodo- SEGMSTSLHVRRGDYVSNANARQRFWSCTSEYFEAAIEQMPADSTVFVFSDDIEWAKQ europaea 6C pirellula NIRSSRPTVYVNDELKLAGSPETGLRDLWLMTHAKSHIIANSSFSWWGAWLSGSEANL europaea] TIAPKKWENDPEIDDSDIVPTSWRRI Rudanella lutea WP_ 518832653 protein 24.16 MVIAKITSGLGNQLFQYALGRHLAIQNQTRLWFDLRYYHRTYETDTPRQFKLDRFSID 195 019988573.1 [Rudanella YDLLDYSPWLYVSKATRLLPGRSLRPLFDTRKEPHFHLDPAVPNAKGAFITLDGFWQS lutea] EGYFASNAATIRRELTFTRQPGPMYARYRQQIEQTQTPVSVHIRRGDYVSHPEFSQSF GALDDTYYQTALAQINGQFPDATLLVFSDDPEWVRQHMRFERPHVLVENTGPDADVDD LQLMSLCHHHIIANSSFSWWGAWLNPRPDKRVIAPKQWERNKPWNTADLIPAGWVRL Bacteroidetes; WP_ 495893515 glycosyl 24.15 MRLIKMTGGLGNQMFIYAMYLKMKTIFPDVRIDLSDMVHYQVHYGYEMNKVFHLPRTE 196 Capnocytophaga 008618094.1 transferase FCINRSLKKIIEFLISKTILERKQGGSLVPYTRKYHWPWIYFKGFYQSEKYFAGIEKE sp. oral [Bacteroidetes] VREAFVFDIRRASRRSLRAMQEIKADPHAVSIHVRRGDYLLEKHWKALGCICQSSYYL taxon 329 str. NALAELEKRVKHPHYYVFSEDLNWVRQNLPLIKAEFIDWNKGEDSWQDMMLMSHCRHH F0087; IICNSTFSWWGAWLNPLPDKIVIAPERWTQTTDSADVVPESWLKVSIG Paraprevotella clara YIT 11840 Smaragdicoccus WP_ 516906936 protein 24.08 MADVVVTLAGGLGNQLFQTAYAKNLEARGHRVTLDGTVVRWTRGLHIDPQICGLKILN 197 niigatensis 018159152.1 [Smaragdicoccus ATPPAPVPGRLAATVLRRALATRLRFGPDGRIVRTQRTLEFDEQYLNLNSPGRYRVEG niigatensis] YWQCERYFSDVGQTVRKVFLDMLGRHVSYNGLSRLPAMADPSSISLHVRRGDYVTANF IDPLALEYYERALEELAVPSPRIFVFSDDLDWATRELGRICDVIPVEPDWTSHPGGEI FLMSQCSHHIIANSSFSWWGAWLDGRTSSRVVAPRQWFSLETYSARDIVPDRWTKV Bacteroides WP_ 547279005 family 11 24.05 MIHLILGGGLGNQMFQYAFARSLALQYNENISENTILYKELKNEERSFSLGHLNINTM 198 fragilis 022012576.1 glycosyl- CIVETPDENKRIWELFNKQIFHQKIARKILPASIRWWWMSNRNIYANVCGPYKYYHPR CAG:558 transferase HRSQNTTIIHGGFQSWKYFKEHQSMIKAELKVITPISEPNKKILKEIQNSNSICVHIR [Bacteroides RGDFLSAQFSPHLEVCNKDYYEKAIKMISSQIENPTFFIFSNTHEDLVWIRKNYNIPQ fragilis NSVYVDLNNPDYEELRLMYNCKHFILSNSSFSWWAQYLSESKNKIIIAPKIWDKRKGI CAG:558] DFSDIYMPEWIIIK Desulfovibrio WP_ 550904402 protein 24.05 MSFSIDVAAIQRMALVKVDGGLGSQMWQYALSLAVGKSSSFTVKHDLSWERHYAKDIR 199 desulfuricans 022657592.1 [Desulfovibrio GIENRFFILNSVFTNINLRLASENERLFFHIALNRYPDSICNFDPDILALKQPTYLGG desulfuricans] YYVNAQYVISAEKEIREAYVFAPAVEESNQAMLQTIHAAPMPVAVHVRRGDYIGSMHE VLTPRYFERAFKILAAALQPKPIFFVFSNGMEWTKKAFAGLPYDNYVDANDNDNVAGD LFLMTQCKHFTISNSSLSWWGAWLSQRAENKTVIMPSKWRGGKSPIPGECMRVEGWHM CPVE Hoeflea WP_ 494373839 alpha-1,2- 24.05 MHGGLGNQLFQYAVGRAVALRIGSELLLDTREFTSSNPFQYDLGHFSIQAKVANSSEL 200 phototrophica; 007199917.1 fucosyl- PPGKNRPLAYAWWRKFGRSPREVREQDLGYNARIETIEADCYLHGYFQSQKYFEDIAS Hoeflea transferase, ILWKDLSFRQAISGENASMAERIQSAPSVSMHIRRGDYLTSAKARSTHGAPDLGYYGR phototrophica [Hoeflea ALGEIRARSGSDPVVYLFSDDPDWVRNNMRMDANLVTVAINDGKTAFEDLRLMSLCDH DEL-43 phototrophica] NIIVNSTFSWWGAWLNPSLDKIVVAPKRWFADPKLSNPDITPPGWLRLGD Vibrio WP_ 487957217 glycosyl 24.04 MKIISFSGGLGNQLFQYAFYLYLKDNSDFGNIFLDFSFYESQNKRDAVIRNFYGVDSL 201 cholerae; Vibrio 002030616.1 transferase, DIIKQSSYVRGKFLILKLINKFRFFNNLLEFVDKENGLDETLLSTNKVFFDGYWQSYR cholerae O1 str. family 11 YVKDYKSNIKELFSFYDFKGNILEVRKKICQSNSVCMHVRRGDYVAEKNTKLVHGVCS 87395 [Vibrio LQYYRDALNNIKNVDNSIDHIFIFSDDIDWVKNNISFDIPVTVVDFVGQSVPDYAEML cholerae] LFSCGKHKVIANSTFSWWGAFLSDRNGVIVSPKKWFAKEEKNYDEIFIEGSLRL Lachnospiraceae WP_ 551041074 protein 24.03 MIIVRFRGGMGNQMFQYAFLRYLEMKGATLKADLSEFKCMKTHAGYELDKAFDLHPAE 202 bacterium NK4A179 022784718.1 [Lachno- ASYKEIRAVADYIPVMHRFPFSRKVFEILYKKETKRVEAEGPKKSHISEEKYFDMSED spiraceae ERLHLASSSEDLYMDGFWIKPDMYDDEVLKCFTFSKTLDEKYKGTIEDEHSCSVHVRC bacterium GDYTGTGLDILGKEYYEKAAEKILSEDADVKFYVFSDDREKAEKLLSPFMKKMVFCDT NK4A179] PASHAYDDMYLMSRCRHHIIANSTFSFWGARLSADKSGITICPKYEDKNNTANRLVHE GWQML Cecembia WP_ 496476931 Glycosyl 24.01 MIIMKFMGGLGNQIYQYALGRKLSELHNSFLASDIHIYKNDPDREFVLDKFNIKVKHL 203 lonarensis; 009185692.1 transferase PWKVIKLLNSDYALKFDKVFHTEFYHELVLEKALESKDIPRKNNLYLRGSWGNRKYYE Cecembia family 11 DYIDKISDEITLKEKEKTKDENTVNKKVKNSDSVGIHIRRGDYEKVAHFKNFYGLLPP lonarensis LW9 [Cecembia SYYSAAVDFIGNRIEKSNFFIFSDDIDWVKENLPFLKDSFFVSDIIGSVDYLEFELLK lonarensis] NCKHQIIANSTFSWWAARLNSNPAKIVIKPKRWFADDRQQAVYEIEDSYYIKEAIKL Bacteroides WP_ 490423336 protein 24 MKIVNILGGLGNQMFVYAMYLALKEAHPEEEILLCRRSYKGYPLHNGYELERIFGVEA 204 ovatus; 004295547.1 [Bacteroides PEAALSQLARVAYPFFNYKSWQLMRHFLPLRKSMASGTTQIPFDYSEVIRNDNVYYDG Bacteroides ovatus] YWQNEKNFLSIRDKVIKAFTFPEFRDEKNKALSDKLKSVKTASCHIRRGDYLKDPIYG ovatus ATCC 8483 VCNSDYYTRAITELNQSVNPDMYCIFSDDIGWCKENFKFLIGDKEVVFVDWNKGQESF YDMQLMSLCHYNIIANSSFSWWGAWLNNNDDKVVVAPERWMNKTLENDPICDNWKRIK VE Bacteroides WP_ 547668508 glycosyl- 23.99 MRLIKMTGGLGNQMFIYAFYLKMKKLFPHTKIDLSDMMHYHVHHGYEMNRVFALPHTE 205 coprocola CAG:162 022125287.1 transferase FCINRILKKLMEFLLCKVVYERKQKNGSMEAFEKKYAWPLIYFKGFYQSERFFADIED family 11 DVRKTFCFNMELINSRSREMMKIIDADEHAVSIHIRRGDYLLPKFWANAGCVCQLPYY [Bacteroides KNAITELEKHESTPSFYVFSDDIEWVKQNLSLPNAHYIDWNQGNDSWQDMMLMSHCRN coprocola HIICNSTFSWWGAWLNPRKNKTVIVPSRWFMKEETPYIYPVSWIKVPIN CAG:162] Bacteroides WP_ 495110765 glycosyl 23.99 MRLIKVIGGLGNQMFIYAFYLRMKKYYPKVRIDLSDMMHYKVHYGYEMHRVFKLPHTE 206 dorei; Bacteroides 007835585.1 transferase FCINQPLKKIIEFLFFKKIYERKQAPNSLRAFEKKYFWPLLYFKGFYQSERFFADIKD dorei DSM [Bacteroides EVREAFTFDRSKANSRSLDMLDILDKDENAVSLHIRRGDYLQPKHWATTGSVCQLPYY 17855; dorei] QNAIAEMSKRVISPSYYIFSDDIVWVRENLPLQNAVYIDWNTGEDSWQDMMLMSHCKH Bacteroides HIICNSTFSWWGAWLNPSIDKTVIVPSRWFQYSETPDIYPTGWIKVPVD dorei CL03T12C01 Bacteroides; WP_ 494936920 protein 23.97 MIIVRLWGGLGNQLFQYSFGQYLEIETDKKVEYDVASFGTSDQLRKLELCSFIPDIPL 207 Bacteroides 007662951.1 [Bacteroides] YNAYFTRYTGVKNRLFKALFQWSNTYLSESMFDICLLEKARGKIFLQGYWQEEKYATY intestinalis DSM FPMQKVLSEWKNPNVLSEIEENIRSAKISVSLHVRRGDYFSPKNINVYGVCTEKYYEQ 17393; Bacteroides AIDRANSEIEEDKQFFVFSDDILWVKNHVSLPESTVFVPNHEISQFAYIYLMSLCKVN intestinalis IISNSTFSWWGAYLNQHKNQLVIAPSRWTFTSNKTLALDSWTKI CAG:564 Lachnospiraceae WP_ 511028838 protein 23.95 MIVIHVMGGLGNQLYQYALYEKLRALGREVKLDVYAYRQAEGAEREWRALELEWLEGI 208 bacterium A4 016283022.1 [Lachno- RYEVCTAAERQQLLDNSMRLADRVRRRLTGRRDKTVRECAAYMPEIFEMDDVYLYGFW spiraceae GCEKYYEDIIPLLQEKIVFPESSNPKNADVLRAMAGENAVSVHIRRKDYLTVADGKRY bacterium A4] MGICTDAYYKGAFRYITERVERPVFYIFSDDPAFAKTQFCEENMHVVDWNTGRESLQD MALMSRCRHNICANSTFSIWGARLNRHPDKIMIRPLHHDNYEALDARTVHEYWKGWVL IDADGKV Phaeobacter YP_ 399994425 protein 23.91 MIITRLHGRLGNQMFQYAAGRALADRLGVSVALDSRGAELRGEGVLTRVFDLDLATPD 209 gallaeciensis; 006574665.1 PGA1_c33070 ILPPLRQRAPLGYALWRGLGQHLGTGPKLRREVGLGYNPDFVDWSDNSYLHGYWQSER Phaeobacter [Phaeobacter YFAQSAERIRRDFTFPEYSNQQNAEMAARIGETNAISLHVRRGDYLTLAAHVLCDQAY gallaeciensis gallaeciensis YEAALAQVLDGLEGQPTVYVFSDDPQWAKENLPLPCDKVVVDFNGADTDYEDMRLMSL DSM 17395 = CIP DSM 17395 = CKHNIIGNSSFSWWAAWLNQTPDRRVAGPTKWFGDPKLNNPDILPPDWLRISV 105210 CIP 105210] Firmicutes WP_ 546362318 protein 23.88 MSGGLGNQMFQYALYLKLRSLGREVCFDDKSQYDEETFRNSSQKRRPKHLDIFGITYP 210 bacterium 021849028.1 [Firmicutes SAGKEELEKLIDGAMDLPSRIRRKILGRKSLEKNDRDFMFDPSFLEETEGYFCGGFQS CAG:791 bacterium PRYFAGAEEEVRKAFTFPEELLCPKEGCSRQEQKMLEQSASYAERIRKANCEAADRGV CAG:791] PGGGSASIHLRFGDYVDKGDIYGGICTDAYYDTAIRCLKERDPGMIFFVFSNDEEKAG EWIRYQAERSENLGRGHFVLVKGCDEDHGYLDLYLMTLCRNHVIANSSFSWWASFMCD APDKMVFAPSIWNNQKDGSELARTDIYADFMQRISPRGTRLSDRPLISVIVTAYNVAP YIGRALDSVCGQTWKNLEIIAVDDGSSDETGAILDRYAAGDSRIQVVHTENRGVSAAR NEGIAHARGEYIGFVDGDDRAHPAMYEAMIRGILSSGADMAVVRYREVSAEETLTDAE EQVASFDPVLRASVLLQQRDAVQCFIRAGMAEEEGKIVLRSAVWNKLFFIRRLLRDNR FPEGTSAEDIPFTTRALCLSKKVLCVPEILYDYVVNRQESIMNTGRAERTLIQEIPAW RTHLELLKESGLSDLAEESEYWFYRRMLSYEEEYRRCSETAKEAKELQERILKHRDRI LELAEEHSFGRRGDRERLKLYVNSPRQYFLLSDLYEKTVVNWKNRPDKT Butyrivibrio YP_ 302669773 glycosyl 23.84 MRKRIIALNGGLGNQMFQYAFARMLEDRKHCLIEFDTGFYSTVNDRKLAIQNYNIHKY 211 proteoclasticus; 003829733.1 transferase 11 DFCNHEYYNKIRLLFQKIPFVAWLAGTYKEYSEYQLDPRVFLENYRFYYGYWQNKQYF Butyrivibrio [Butyrivibrio EENISNDIRNELSYIGNVSEKENALLNMLAHNAIAIHVRRGDYTQEGYNKIYISLSKE proteoclasticus proteoclasticus YYKRAVSIACKELGDNNIPLYVFSDDIDWCKANLADIGNVTFVDNTISSSADIDMLMM B316 B316] KKSRCLITANSTFSWWSAWLSDRDDKIVLVPDKWLQDEEKNTKLMKAFICDKWKIVPV Bacteroides sp. WP_ 496043738 protein 23.81 >gi|496043738|ref|WP_008768245.1| protein [Bacteroides sp.] 212 2_1_16 008768245.1 [Bacteroides 2_1_16]MQVVARIIGGLGNQMFIYATARALALRIDADLILDTQSGYKNDLFKRNFLL sp. DSFCISYRKANCFQKYDYYLGEKVKSLGKKTHFSVIPFMKYISENTSCDFVDGLLKKH 2_1_16] ILSVYLDGYWQNEAYFKDYASIIKKDFQFCQVNDLRILSEAEIIKKSITPVAIGVRRY QELNSHQNTKVIDLDFYQKAINYIESKVDNPTFFIFSEDQEWVKNNLEQKSNFIMISP KEGNYSALNDMYLISLCKHHIVSNSSFYWWGAWLANNKNKIVVASDCFLNPQSIPDSW IKF Desulfomicrobium YP_ 256830317 glycosyl 23.76 >gi|256830317|ref|YP_003159045.1| glycosyl transferase  213 baculatum; 003159045.1 transferase family protein [Desulfomicrobium baculatum DSM Desulfomicrobium family protein 4028]MAKIVTRIMGGIGNQLFCYAAARRLALVNHAELVIDDVTGFSRDRVYRRRYML baculatum [Desulfo- DHFNISARKATNYERMEPFERYRRGLAKYISKKLPFFEREYIEQERIEFDPRFLEYRT DSM 4028 microbium YNNIYIDGLWQSENYFKDVEDIIRDDLKIIPPTDLENINIAKKIKNIQNTIAMHVRWF baculatum DLPGINLGNNVSTYYYHRAIAMMEQRINAPHYFLFSDNLEAVHSKLDLPEGRVTFVSN DSM 4028] NDGDDNAYADLWLMSQCKHFITANSTFSWWGAWLGESRDSVVLVPRFSPDGGVISWCF TGLIPERWEQVSSIR Prevotella WP_ 545304945 galactoside 2- 23.76 MDIVLIFNGLGNQMSQYAFYLAKRQRNNHTVYCVFGPRTQYSLDKLFDIPYRHNAVLV 214 pleuritidis; 021584236.1 alpha-L- LLYRALDKAHFSNHRWLRRLLRPTLQLLGVKMIVEPLSRDFDMRHFTHQKGIVFYRGG Prevotella fucosyl- WHSELNFTAVADAVKRRFRFPEIQDAAVLAVIDRIKSCQSVSLHLRRGDYLGLSEFQG pleuritidis F0068 transferase  VCTEAYYEHAIAYFESQIESPEYFVFSDDPTYAREQFGADPNFHIIDLNHGEDAWCDL [Prevotella LMMTQCRYNIIANSTFSWWGAWLNDNPSKIVVHPRYHLNGVETRDFYPRNWICIE pleuritidis] Bacteroides sp. WP_ 496038684 glycosyl 23.75 MKVIWENGNLGNQVFYCKYKEFLHNKYPNETIKYYSNSRSPKICVEQYFRLSLPDRID 215 1_1_14 008763191.1 transferase, SFKVRFVFEFLGKFFRRIPLKFVPKWYCTRKSLNYEASYFEHYLQDKSFFEKEDSSWL family 11 KAKKPDNFSEKYLIFENLICNINSVAVHIRRGDYIKPGSDYEDLSATDYYEQAIKKAT [Bacteroides EVYLDSQFFFFSDDLEFVKNNFKGDNIYYVDCNRGADSYLDILLMSQAKINIIANSTF sp. 1_1_14] SYWGAYMNHEKKKVMYSDLWFRNESGRQMPNIMLDSWICIETKRK Agromyces WP_ 551273588 protein 23.65 MVGRVGIARRQAADVSCIDGEGLVAWRIRTGEIVLGLQGGIGNQLFEWAFAMALRSIG 216 subbeticus 022893737.1 [Agromyces RRVLFDAVRCRGDRPLMIGPLLPASDWLAAPVGLALAGATKAGLLSDRSWPRLVRQRR subbeticus] SGYDPSVLERLGGTSYLLGTFQSARYFDGVEHEVRAAVRALLEGMLIPSGRRFADELR ADPHRVAVHVRRGDYVSDPNAAVRHGVLGAGYYDQALEHAAALGHVRRVWFSDDLDWV REHLARDDDLLCPADATRHDGGEIALIASCATRIIANSSFSWWGGWLGAPSSPAHPVI APSTWFADGHSDAAELVPRDWVRL Prevotella WP_ 494220705 alpha-1,2- 23.59 MIATTLFGGLGNQMFIYATAKALSLHYRIPMAFNLRQGFEQDYKYQRHLELNHFKCQL 217 salivae; 007133870.1 fucosyl- PTAKWITFNYKGELNIKRISRRIGRNLLCPHYQFIKEKEPFHYEKRLFEFTNKNIFLE Prevotella transferase GYWQSPRYFENYSDEIRRDFQLKSILPHTITDELQMLKGTGKPLVMLGIRRYQEVKDK salivae DSM 15606 [Prevotella KDSPYPLCNKDYYAKAISHVQEQLPAPLFVVFTQEQAWAMNNLPTNANLYFVKEKDNA salivae] WATIADMYLMTQCQHAIISNSTFYWWGAWLQHPIENHIVVAPNNFINRDCVCDNWIIL D Carnobacterium YP_ 554649641 glycosyl 23.57 MIFVDLSEGLGNQMFQYAYSRYLQELYGGTLYLNTSSFKRKNSTRSYSLNNFYLYENV 218 sp. 008718687.1 transferase KLPSKFRRVIYNFYSKTIRMFIKKVIRMNPYSDKYYFSMIPYGFYVSSQVFKYLTVPI WN1359 [Carno- TKRHNIFVMGTWQINKYFQSINDKIKDELKVKTEPNELNKKLITEINSNQSVCVHIRL bacterium GDYTNPEFDYLHVCTSDYYLKGMDYIVSKVKEPNFYIFSNSSSDIEWIKNNYNFKYKV sp. WN1359] KYIDLNNPDFEDFRLMYNCKHFIISNSTFSWWAQFLSNNDKKIIVAPSKWQKSNENEA KDIYLDHWKLIEIE Butyrivibrio sp. WP_ 551018062 glycosyl 23.55 MLIIQIAGGLGNQMQQYAMYRKLLKAGADRNIKLDTKWFDEDKQSGVLAKRKLELEYF 219 AD3002 022762290.1 transferase TGLPLPVCSESERARFTDRSVARKVVEKLVPGMGSRFTESCMYHPEIFELKDKYIEGY [Butyrivibrio FACQKYYDDIMGELQELFVFPTHPDEEINIKNMNLMNEMEMVPSVSVHIRRGDYLDPE sp. NAALFGNIATDAYYDSAMEYFKAIDPDTHFYIFINDPEYAREKYADPGRYTIVDHNIG AD3002] KYSLLDIQLMSHCRGNICANSTFSFWGARLNRRKDKIPVRTLVMRNNQPVTPELMHEY WPGWVLVDKDGKVR Clostridium sp. WP_ 545396682 glycosyl- 23.55 MIVIRVMGGLGNQMQQYALYEKFKALGKETRLDTSWFDNASMQENVLARRSLELRFFD 220 KLE 021636935.1 transferase, NLTYEACTPQEREALLGKEGFFNKLERKLEPSKNKHEYESEMFHPEIFKLDNVYLEGH 1755 family 11 WACEKYYHDIMPLLQSKIIFPKTDNIQNNMLKNKMNSENSVSIHIRRGDYLDPENAAM [Clostridium FGGICTDSYYKSAEGYIRNRVINPHFYLFSDDPAYLREHYKGEEYTVVDWNHGADSFY sp. KLE 1755] DMELMSCCKHNVCANSTFSFWGARLNRTEKKIVIRPAKHKNSQQAEPERMHELWENWV IIDEEGRIV Bacteroides; YP_ 150005950 glycosyl 23.47 MKFFVFGGGLGNQLFQYSYYRYLKKKYPSERILGIYPDSLKAHNGIEIDKWFDIELPP 221 Bacteroides 001300694.1 transferase TSYLYNKLGILLYRVNRFLYNHGYRLLFCNRVYPQSMKHFFQWGDWQDYSIIKQINIF vulgatus ATCC family protein EFRSELPIGKENMEFLKKMETCNSISVHIRRGDYLKTDLIHIYGGICTSKYYREAIKF 8482; Bacteroides [Bacteroides MEQEVEEPFFFFFSDDCLYVETEFADIRNKIIISHNRDDRSFEDMYLMAHAKNMILAN dorei DSM vulgatus ATCC STFSCWAAYLNRTAKIIITPDRWVNTDFSKLEALPNEWIKIRV 17855; Bacteroides 8482] massiliensis dnLKV3 Paraprevotella WP_ 495902050 glycosyl 23.47 MRLIKMTGGLGNQMFIYAMYLKMRAVFPDTRIDLSDMVHYRVHYGYEMNKVFNLPRTE 222 xylaniphila; 008626629.1 transferase FRINRSLKKIIEFLISKTILERKQGGSLVPYIRKYHWPWIYFKGFYQSEEYFAGVEKE Paraprevotella [Paraprevotella VREAFVFDVRRVNRKSLCAMQEIMADPDAVSIHVRRGDYLQGKHWKSLGCICQRSYYL xylaniphila  xylaniphila] NALSELEKRIVHPHYYVFSEDLDWVRQYLPLENAVFIDWNKGEDSWQDMMLMSHCRHH YIT 11841 IICNSTFSWWGAWLNPSPDKIVIAPERWTQTTNSADVVPESWLKVSIG Thauera sp. 28 WP_ 489020296 glycosyl 23.47 MTDRALIAIVKGGLGNQLFIYAAARAMALRTGRQLYLDAVRGYLADDYGRSFRLNRFP 223 002930798.1 transferase IEAELMPEQWRVASTLRHPRAKLVRALNKYLPEAWRFYVAERGDTRPGALWNHGRNVK family protein RVTLMGYWQDEAYFLDYAELLRRELGPPMPDAPEVRARGERFAGTESVFLHVRRCRYS [Thauera PLLDAGYYQKAVDLACAELNKPVFMIFGDDIEWVVNNIDFRGAGYERQDYDESDELAD sp. 28 LWLMTRCRHAIIANSSFSWWAAWLGGAAGSGRHVWAPGQSGLALKCAKSWEAVDAQPE Subdoligranulum WP_ 494107522 alpha-1,2- 23.44 MIYAELAGGLGNQMFIYAFARALGLRCGEAVTLLDRQDWRDGAPAHTACALEGLNLVP 224 variabile; 007048308.1 fucosyl- EVKILAEPGFAKRHLPRQNTAKALMIKYEQRQGLMARDWHDWERRCAPVLNLLGLHFA Subdoligranulum transferase TDGYTPVRRGPARDFLAWGYFQSEAYFADFAPTIRAELRAKQAPAGVWAEKIRAAACP variabile DSM [Subdo- VALHLRRGDYCRPENEILQVCSPAYYARAAAAAAAAYPEATLFVFSDDIDWAKEHLDT 15176 ligranulum AGLPAVWMPRGDAVGDLNLMALCRGFILSNSTYSWWAQYLAGEGRTVWAPDRWFAHTK variabile] QTALYQPGWHLIETR Firmicutes WP_ 547127527 protein 23.4 MIIVEVMGGLGNQMQQYALYRKLESLGKDARLDVSWELDKERCQTKVLASRKLELSWE 225 bacterium 021916223.1 [Firmicutes ENLPAKYCTQEEKQAILGKNNLIGKLKKKLLGGSNRHFTESDMYHPEIFDLEDAYLSG CAG:24 bacterium FWACEAVYADILPMLRSQIHFPDPEKGEGWDLEAAAKNKETMERMKQETSVSIHIRRG CAG:24] DYLDAKNAEMFGGICTDAYYEAAISYIKEQTPDAHFYVFSDDSAYVKNAYPGKEFTVV DWNTGKNSLFDMQLMSCCNHNICANSTFSFWGARLNPSPDKVMIRPSKHKNSQNIVPE EMKRLWDGWVLIDGKGRII Prevotella sp. WP_ 547906803 glycosyl 23.39 MIITKLNGGLGNQLFEYACARNLQLKYNDVLYLDIEGFKRSPRHYSLEKFKLSSDVRM 226 CAG:474 022310139.1 transferase LPEKDSKSLILLQAISKLNRNLAFKLGPLFGTYIWKSSNYRPLKIKNTRGKKLYLYGY family 11 WQSYEYFKENEAIIKQELNVKTEIPIECSELLKEINKPHSICVHVRRGDYVSCGFLHC [Prevotella sp. DEAYYNRGINHIFDKHPDSNVVVFSDDIKWVKANMNFDHPVAYVEVDVPDYETLRLMY CAG:474] MCKHFVMSNSSFSWWASYLSDNKEKIVVAPSYWLPANKDNKSMYLDNWTIL Roseburia WP_ 493910390 glycosyl 23.38 intestinalis]MRGNRGMIAVKIGDGMGNQLFNYACGYAQARRDGDSLVLDISECD 227 intestinalis; 006855899.1 transferase NSTLRDFELDKFHLKYDKKESFPNRNLGQKIYKNLRRALKYHVIKEREVYHNRDHRYD Roseburia family 11 VNDIDPRVYKKKGLRNKYLYGYWQHLAYFEDYLDEITAMMTPAYEQSETVKKLQEEFK intestinalis [Roseburia KTPTCAVHVRGGDIMGPAGAYFKHAMERMEQEKPGVRYIVFTNDMERAEEALAPVLES L1-82 intestinalis] QKKDAVGQAENRLEFVSEMGEFSDVDEFFLMAACQNQILSNSTFSTWAAYLNQNPDKT VIMPDDLLSERMRQKNWIILK Bacteroides WP_ 490424433 protein 23.29 MKIVLFTPGLGNQMFQYLFYLYLRDNYPNQNIYGYYNRNILNKHNGLEVDKVFDIQLP 228 ovatus; 004296622.1 [Bacteroides PHTVISDASAFFIRALGGLGLKYFIGKDQLSPWKVYFDGYWQNKEYFQNNVDKMRFRE Bacteroides ovatus] GFLNKKNDDILSLIRNTNSVSVHVRRGDYCDSCRKDLFLQSCIPQYYESAISVMKEKF ovatus ATCC 8483 QKPVFFVFSDDIPWVKVNLNIPNAYYIDWNKKENSYLDMYLMSLCTASIIANSTFSFW GAMLGNKKELVIKPKKWIGDEIPEIFPPSWLSL Butyrivibrio sp. WP_ 551035785 glycosyl 23.25 MLIIQIAGGLGNQMQQYALYRKLLKYHPDGVRLDLSWFDSEVQKNMLAKREFELALFK 229 AE3009 022779599.1 transferase GLPYIECKPEERAAFLDRNAAQKLSGKVLKKLGLRDNANPNVFEESRMFHPEIFELDN [Butyrivibrio KYIIGYFACQKYYDDIMGDLCNLFEFPEHLDPELEKKNLELISKMEKENSVSVHIRRG sp. DYLDPENFKILGNIATDEYYESAMKYFEDRYEKVHFYIFTSDHEYAREHFADESKYTI AE3009] VDWNTGKDSLQDVRLMNHCLGNICANSTFSFWGARLNQRQDKVMIRTYKMRNNQPVDP DTMHDYWKGWILIDETGREV Butyrivibrio YP_ 302669752 glycosyl 23.23 MTKNEKKLIVKFQGGLGNQLYEYAFCEWLRQQYSDYEVLADLSYYKIRSAHGELGIWN 230 proteoclasticus; 003829712.1 transferase 11 IFPNINIEVASNWDIIKYSDQIPIMYGGKGADRLNSVRTNVNDRFFSKRKHSYYTEIS Butyrivibrio [Butyrivibrio NTDVSEVINALNNGIRYFDGYWQNIDYFKGNIEDLRNKLKFSEKCDKYITDEMLRDNA proteoclasticus proteoclasticus VSLHVRRGDYVGSEYEKEVGLSYYKKAVEYVLDRVDQAKFFIFSDDKYYAETAFEWID B316 B316] NKTVVAGYDNELAHVDMLLMSRMKNNIIANSTFSLWAAYLNDSMNPLIVYPDVESLDK KTFSDWNGIK Prevotella WP_ 517173838 protein 23.23 MDSQFLKHIKLSGGEGNQLFQYFFGEYLKEKYNCSISFFSEPALDINQLQIHRFFPAL 231 nanceiensis 018362656.1 [Prevotella RISHNTELRPYHYSFTQQLAYRCMRKLLLLFPFLNRKVKIENGSNYQNQSFNDTYCED nanceiensis] GYWQSYRYLSAFTPSLQFEDQLINDISADYINAIEQSEAVFLHIRRGDYLNKENQKVF AECPLNYFENAANRIKEDIKNVHFFVFSNDIQWVKSHLKLNDNEVTFIQNEGNSCDLK DFYLMTRCKHAIISNSTFSWWAAYLINNSDKKVIAPKHWYNDISMNNATKDLIPPTWI RL Ruegeria sp. R11 WP_ 495838392 alpha-1,2- 23.23 MIITRLHGRLGNQMFQYAAGRALADRAGVPLALDSRGAILRGEGVLTRVEDLELADPV 232 008562971.1 fucosyl- HLPPLKQTNPLRYAIWRGIGQKVGAKPYFRRERGLGYNPAFEDWGDNSYLHGYWQSQK transferase YFQNSAERIRSDFTFPAFSNQQNAEMAARIAESTAISLHVRRGDYLTFAAHVLCDQAY [Ruegeria sp. YDAALAKVLDGLQGDPIVYVFSDDPQWAKDNLSLPCEKVVVDENGPETDFEDMRLMSL R11] CQHNIIGNSSFSWWAAWLNQTPGRRVAGPAKWFGDPKLSNPDIFPHDWLRISV Winogradskyella WP_ 527072096 alpha-1,2- 23.21 MGNQLYEYATAKAMAVALNKKLVIDPRPILKEAPQRHYDLGLFNIQDEDFGSPFVQWL 233 psychrotolerans  020895733.1 fucosyl- VRWVASVRLGKFFKTIMPFAWSYQMIRDKEEGFDESLLQQKSRNIVIEGYWQSFKYFE RS-3; transferase SIRPTLLKELSFKDKPNAINQKYLDEIESVNAVAVHIRRGDYVANPVANAVHGLCDMD Winogradskyella [Wino- YYKKAIAIIKDKVENPYFFIFTDDPDWAEDNFKISEHQKIIKHNIGKQDHEDFRLLIN psychrotolerans gradskyella CKYFIIANSSFSWWGAWLSDYKNKIVISPNKWENVDAVPITERIPESWIRV psychro- tolerans] Lachnospiraceae WP_ 551041720 protein 23.2 MITVRIDGGEGNQMFQYAFFLHLKKTITDNKISVDLNCYNPHGSGDIFTRFKLAPEQA 234 bacterium NK4A179 022785342.1 [Lachno- APSEIKRFHRNSIYHLLRPLDSAGITTNPYYREEDIDDLNSVLNKKRVYLRGYWQDKR spiraceae YPFSVKDQLIDCFDLGKMDMTGASAENNVILEQIASEESRSVGVHLRGGDYIGDPVYS bacterium GICTPEYYEAAFKHVSEKIKDPVFHIFINDISMIEKCGLSGKYDLKITDINDEAHGWA NK4A179] DLKLMSACRHHIISNSSFSWWAAFLGEATTEASADVINVIPEYMRQGVSAETLRCPCW TTVTSDGRVYPS Prevotella sp. WP_ 496522549 alpha-1,2- 23.13 MKIVCIKGGLGNQLFEYCRYRSLHRHDNRGVYLHYDRRRTKQHGGVWLDKAFHITLPN 235 oral 009230832.1 fucosyl- EPLRVKLLVMVLKTLRRLHLFKRLYREEDPRAVLIDDYSQHKQYITNAAEILNFRPFE taxon 317 str. transferase QLDYAEEIQTTPFAVSVHVRRGDYLLLANKSNEGVCSVHYYLSAAVAVRERHPESRFF F0108; [Prevotella sp.  VFSDDMEWAKENLNLPNCVFVEHAQAQPDHADLYLMSLCKGHIIANSTFSFWGAYLSK Prevotella sp. oral taxon 317] GSSAIAIYPKQWFAEPTWNVPDIFPAHWMAL oral taxon 317 Butyrivibrio sp. WP_ 551021633 glycosyl 23.1 MLIIQIAGGLGNQMQQYAVYTKLRGMGKDVRLDLSWFDPSVQKNMLAPREFELSMFEG 236 XPD2006 022765796.1 transferase VDYTECTAEERDSFLKQGMIANVIGKMLKKLGLRDEANPKVFSEKEMYHPEIFELEDR [Butyrivibrio YIKGYFACQKYYDDIMGELWEKYTFPAHSDPDLHTRNMALVERMEKETSVSVHIRRGD sp. YLDPSNVEILGNIATEEYYQGAMDYFSVKDPDTHFYIFTSDHEYAREKFSDESKYTIV XPD2006] DWNSGRNSVQDLMLMSHCKGNICANSTFSFWGARLNRRPDKTVIRTYKMRNNQPVNPD IMHDYWKGWILMDEKGSII Butyrivibrio WP_ 551008140 protein 23.08 MIIIKLQGGLGNQLFLYGLYKNLKHLKRDVKMDIESGFEEDKLRVPCLKSMGLDYEVA 237 fibrisolvens 022752717.1 [Butyrivibrio TRDEIVAIRDSYMDIFSRIRRKITGRKTFDYYEPEDGNFDPRVLEQTHAYLDGYFQSE fibrisolvens] KYFGDSDDRKKLKDELLKEKIRVLDSSDILKDLYNMMSSGSSVSLHIRRGDYLTPGIM ETYGGICTDEYYDIAMNRIKNEYPDSKFFIFSNDIDWCKEKYGSRDDVIFVDSCDEHE GLINVSGDQDDIQVQGDIKEHGNNSLRDAAELYLMSACKHHILANSSFSWWGAWLSDH EGMTIAPSKWLNNKNMTDIYTKDMLLI Cylindro- WP_ 493321658 Glycosyl 23.05 MKKTVVLLKGGLGNQMFQYAFARSISLKNSSKLVIDNWSGFTFDYKYHRQYELGTFSI 238 spermopsis 006278973.1 transferase VGRPANLTEKFPFWFVELKSKFFPRLPKVFQQQFYGLLINEVGGEYIPEIEETKISQN raciborskii; family 11 CWLNGYWQSPLYFQKHSDSITRELMPPEPMEKHFLELGKLLRETESVALGIRLYEESK Cylindro- [Cylindro- NPGSHSSSGELKSHFEINQAILKLRELCNGAKFFVFCTHRSPLLQELALPENTIFVTH spermopsis spermopsis DDGYVGSMERMWLLTQCKHHIFTNSTFYWWGAWLSQKFYIQGSQIVFAADNFINSDAI raciborskii raciborskii] PKHWKPF CS-505 Prevotella WP_ 494609908 alpha-1,2- 23.05 MKIVNFQGGLGNQMFIYAFSRYLSRLYPQEKIYGSYWSRSLYVHSAFQLDRIFSLQLP 239 multiformis; 007368154.1 fucosyl- PHNLFTDCISKLARFFERLRLVPVEETPGSMFYNGYWLDKKYWEGIDLSEMFCFRNPD Prevotella transferase LSAEAGAVLSMIERSNAVSVHIRRGDYQSEEHIEKFGRFCPPDYYRIATERIRQREDD multiformis DSM [Prevotella PLFFVFSDDMMWVKSNMDVPNAVYVDCHHGDDSWKDMFLMAKCRHNIIANSTFSFWAA 16608 multiformis] MLNANPDKVVVYPQRWFCWPSPDIFPEMWLPVTEKEIKSSF Bacteroides sp. WP_ 548151455 protein 23 MIIVNMACGLANRMFQYAFYLSLKERGYNVKVDFYKSATLPHENVPWNDIFPYAEIDQ 240 CAG:462 022384635.1 [Bacteroides VSNFRVLILGGGANLLSKLRRKYLPSLINVITMSTAFDTDLQIDDDRKDKYIIGVFQS sp. AAMVEGVCKKVKQCFSFLPFTDLRHLQLEKEMQECESVAIHVRKGNDYQQRIWYQNTC CAG:462] TMDYYRKAIAEIKGKVKDPRFYVFTDNADWVRRNFTDFDYKMVEGNPVYGWGSHFDMQ LMSRCKYNIISNSTYSWWGAYLNANRNKIVICPNIWFNPESCNEYTSCKLLCKGWIAL Desulfovibrio WP_ 492830222 Glycosyl 23 MRIGILYICTGKYTVFWNHFFTSCEQHFLREHEKHYYIFTDGEIAHLNCNRVHRIEQQ 241 africanus; 005984176.1 transferase HLGWPDSTLKRFHMFERIADTLRQNSDFIVFFNANMVFLRDVGKEFLPTREQALVEHR Desulfovibrio family 11/ HPGLFRRPAWLLPYERRPESTAYIPYGSGSIYVCGGVNGGYTQPYLDEVAMLRRNIDI africanus PCS Glycosyl- DVERGIIARWHDESHINREVIGRHYKIGHPGYVYPDRRNLPFPRIIRVIDKASVGGHT transferase FLRGQTPEPAPEEQSKTVAKKLRSQLKRPCMPRAAQDEPIILARMMGGLGNQMFIYAA family 6 ARVLAERQGAQLHLDTGKLSGDSIRQYDLPAFSIDAPLWHIPCGCDRIVQAWFALRHV [Desulfovibrio AAGCGMPKPTMQVLRSGFHLDQRFFSIRHSAYLIGYWQSPHYWRGHEDRVRSSFDLTR africanus] FERPHLREALAAVSQPNTISVHLRRGDFRAPKNSDKHLLIDGSYYERARKLLLEMTPQ SHFYIFSDEPEEAQRLFAHWENTSFQPRRSQEEDLLLMSRCSASIIANSSFSWWGAWL GRPKQHVIAPRMWFTRDVLMHTYTLDLFPEKWILL Roseburia sp. WP_ 548374190 protein 22.98 MILIHVMGGLGNQLYQYALYEKMKSLGKKVKLDTYAYNDAAGEDKEWRSLELDRFPAI 242 CAG:100 022518697.1 [Roseburia sp. EYDKATSEDRTKLLDNSGLLTAKIRRKLLGRKDKTIRESKEYMPEIFHMDDVYLYGEW CAG:100] NCERYYEDIIPLLQDKLQFPISNNPRNQQCEQMQKENAVSIHIRRIDYLTVADGARYM GICTEDYYKGAMAYIEERVSNPVYYIFSDDVEYAKQHYHQDNMHVVDWNSKADSIYDM QLMSKCKHNICANSTFSMWAARLNQNKEKIMIRPLHHDNYETTTATQVKQNWKNWILL DQNGQVCE Lachnospiraceae WP_ 550997676 protein 22.96 MTMNIIRMSGGLGSQMFQYALYLKLKSMGKEVKFDDINEYRGEKARPIMLAVEGIEYP 243 bacterium 10-1 022742385.1 [Lachno- RATWDEITSFIDGSMDLLKRLRRKIFGRKAIEYEEQGFYDPNVLNFDSMYLRGNFQSE spiraceae KYFQDIKEEVRKLYRFSTLEDMRLPERLYKATKACLDGIESSESVGLHMYRSDSRVDG bacterium 10- ELYDGICIGNYYKGAVRFIQDKVPDAKFYIFSNEPKWVRGWVVDLIQSQIQEGMSPSQ 1] VKEMEKRFVMVEANTEYTGYLDMMLMSKCKHNIISNSSFSWWSAWMNDHPEKVVVAPD RWSSDKEGNEIYTTGMTLVNEKGRVNYTIHENSTVK Prevotella WP_ 490496500 protein 22.96 MILSYITGRLGNQLFEYAYARSLLLKRGKNEELILNFSLVRAAGKEIEGFDDNLRYFN 244 nigrescens; 004362670.1 [Prevotella VYSYTELDKDIVLSKGDLLQLFIYILFKLDQKLFRIIKKEKWFSFERREGIIFQDYLD Prevotella nigrescens] NISNLIIPRTKNVECYGKYENPKYFDDIRSILLKEFTPRIPPLKNNDQLYSVIESTNS nigrescens F0103 VCISIRRGDFLCDKFKDRFLVCDKEYFLEAMEEAKKRISNSTFIFFSDDIEWVRENIH SDVPCYYESGKDPVWEKLRLMYSCKHFIISNSTFSWWAQYLSRNEEKVVIAPDRWSNV PGEKSFLLSNSFIKIPIGILP Bacteroides sp. WP_ 547952493 fucosyl 22.95 MIYVEINGRLGNNMFEIAAAKSLTDEVTLWCKGDWQLNCIKMYSDTLFKNYPIVKSLP 245 CAG:875 022353235.1 transferase NNIRIYEEPEFTFHPIPYKENQDLLIKGYFQSYKYLDREKVLKLYPCPMPVKLDIEKR [Bacteroides FGDILSQYTVVSINVRRGDYLNLPHRHPFVGKKFLERAMLWFGDKVHYIISSDDIEWC sp. CAG:875] KAHFKQEDNVHYLINSYPLLDLYIQTACHHNIISNSSFSWWGAYLNNHPQKIVIAPHR WEGMSTNINTQDLLPPEWMIEQCVYEPKVFLKALPLHAKYLLKRVLK Prevotella sp. YP_ 532354444 protein 22.9 MDSQLLKHIKLSGGEGNQLFQYFFGEYLKEKYNCSISFFSEPALDINQLQIHRFFPTL 246 oral 008444280.1 HMPREF0669_ RISHNTELRREHYAFTQQLAYRCMRKLLLLFPFLNRKVKIENGSNYQNQSFNDTYCED taxon 299 str. 00176 GYWQSYRYLSAFTPSLQFEDQLINDISADYINAIEQSEAVFLHIRRGDYLNKENQKVF F0039; [Prevotella AECPLNYFENAVNKIKEGNKTYHFFVFSNDIEWVKCHLKLNNNEVTFIQNEGSSCDLK Prevotella sp. sp. oral taxon DFYLMTRCKHAIISNSTFSWWAAYLINNNDKKVIAPKRWYNDLSMNNATKDLIPPTWI oral taxon 299 299 str. F0039] RL Paraprevotella WP_ 495904204 alpha-1,2- 22.87 MKIVCLKGGLGNQMFEYCRFRDLMDSGNGKVYLFYDRRRLKQHDGLRLSDCFELELPS 247 xylaniphila; 008628783.1 fucosyl- CPWGIRLVVWGLKICRAIGVLKRLYDDEKPDAVLIDDYSQHRRFIPNARRYFSFRQFL Paraprevotella transferase AELQSGFVQMIRAVDYPVSVHVRRGDYLHPSNSSFVLCGVDYFRQAIAYVRKKRPDAR xylaniphila  [Paraprevotella FFFFSDDMEWVRENLWMEDAVYVEHTELMPDYMDLYLMTLCRGHIISNSTFSFWGAYL YIT 11841 xylaniphila] AVDGNGMKIYPRRWERDPTWITPPIFSEEWVGL Dethiosulfovibrio WP_ 491897177 glycosyl 22.84 MFQYAFGRALALDLGLDLKLDISNEGSDSRPFSLGIYSLTKNIPFGCYLSTSTRLKVK 248 peptidovorans; 005658864.1 transferase MTKKLRRWGVWGMDKNMPGVLVEPFPPVLVSLDEVLSEKLSHLFVDGYWQSEKYFSRY Dethiosulfovibrio family 11 SDVIRSDFRVIEESSAFLAWKKRMLSEPGGSISVHVRRGDYVTDSSANRVHGVLPIEY peptidovorans DSM [Dethio- YLRAKEILNTISDGLVFYVFTDDPVWARNNLCLGDKTIYVSGEDLKDYEELALMSCCD 11002 sulfovibrio HHVVANSSFSWWGAWLGQDTSTVTIAPGRWERKMDSSFVIPDNWIKIWT peptidovorans] Lachnospiraceae WP_ 510896192 protein 22.83 MIIIQVMGGLGNQLQQYALYRKFVRMGKEARLDISWELDKEKRGEVLAERELELDYFD 249 bacterium 10-1 016229292.1 [Lachno- RLIYETCTPEEKEQLIGSEGVAGKLKRKFLPGRIRWFHESKIYHPELLQMENMYLSGY spiraceae FACEKYYADILYDLREKIQFPVNDHPKNIKMAQEMQERESVSVHLRRGDYLDEKNTAM bacterium 10- FGNICTDAYYCKAIEYMKTLCSKPHFYIFSDDIPYVRQRFTGEEYTVVDINHGRDSFE 1] DMWLMSRCRHNICANSTFSFWGARLNSNDNKIMIRPTIHKNSQVFVKEEMEQLWPGWK FISPDGGIK Treponema WP_ 513872223 protein 22.82 MFCAAFVEALKHAGQKVFVDTSLYNKGTVRSGIDFCHNGLETEHLFGIKFDEADKADV 250 maltophilum; 016525279.1 [Treponema HRLSTSAEGLLNRIRRKYFIKKTHYIDTVERYTPEVLSDKSDRYLEGFWQTEKYFLPI Treponema maltophilum] ESDIRTLFRFRQPLSEKSAAVQSALQAQEPASLSASIHVRRGDFLHTKILNVCTETYY maltophilum NNAIEYAAKKYAVSAFYVFSDDIQWCREHLNFFGARSVFIDWNIGADSWQDMVLMSMC ATCC 51939 RCNIIANSSFSWWAAWLNAASDKIVLAPAIWNRRQLEYADRYYGYDYSDVIPETWIRI PI Bacteroides WP_ 511022363 protein 22.79 MKLVSFTAGLGNQLFQYCFYRYLLNKFPNEKIYGYYNKKWLKKHGGIIIEHFFDVKLP 251 massiliensis; 016276676.1 [Bacteroides RSTRWINLYGQYLRIIYKCFSCGVSKDDDFEMNRTMFVGYWQDQCFFSGINISYKKNL Bacteroides massiliensis] VISEKNTWLLGEILKCNSVAIHFRRGDYMLPQFKKIFGEVCIVKYYLKSIRKVEEKIS massiliensis EPVFFVFSDDIDWVKQNFTENKVYFVDWNKGQNSFWDMYLMSQCSANIIANSTFSFWG dnLKV3 AYLNKNNPFVIYPQKWVRTNLKQPNIFPKTWMAL Enterococcus YP_ 389869137 family 11 22.71 MIVLTLGGGLGNQMFQYGYARYIQKIHREKFIYINDSEVIKEADRENSLGNLNIVNIK 252 faecium; 006376560.1 glycosyl- VLPRIISKPLNETERLVRKIMVRLFGVAGFNESAIFQSLNKFGIYYHPSVYKEYESLK Enterococcus transferase TGFPIKIIEGGFQSWKYLETCPEIKQELRVKYEPMGENLRLLNLISQSESVCVHIRRG faecium [Enterococcus DYLSPKYKHLNVCDYQYYFESMNYIISKLNNPIFFIFSNTSDDLDWIKENYSLPGKIV DO; Enterococcus faecium DO] YVKNDNPDYEELRLMYSCKHFIISNSTFSWWAQYLSNNSGIVIAPEIWNRLNHDGIAD faecium EnGen0035 LYMPNWITMKVNR Bacteroides; WP_ 490442319 glycosyl 22.67 MDVVVIENGLGNQMSQYAYYLAKKKVNPNTKVIFDIMSKHNHYGYDLERAFGIEVNKT 253 Bacteroides sp. 004313284.1 transferase LLIKVLQIIYVLSRKFRLFKSVGVRTIYEPLNYDYTPLLMQKGPWGINYYVGGWHSEK 2_1_22;  family 11 NFMNVPDEVKKAFMFREQPNEDRFNEWLQVIRGDNSSVSVHIRRGDYMNIEPTGYYQL Bacteroides sp. [Bacteroides] NGVATLDYYHEAIDYIRQYVDTPHFYVESNDLDWCKEQFGVENFFYIECNQGVNSWRD 2_2_4; Bacteroides MYLMSECHYHINANSTFSWWGAWLCKFEDSITVCPERFIRNVVTKDFYPERWHKIKSC sp. D1; Bacteroides xylanisolvens SD CC 2a; Bacteroides xylanisolvens SD CC 1b; Bacteroides ovatus CAG:22 Synechococcus YP_ 326781960 glycosyl- 22.6 MIGFNALGRMGRLANQMFQYASLKGIARNTGVDFCVPYHEEAVNDGIGNMLRTEIFDS 254 phage 004322362.1 transferase FDLQVNVGLLNKGHAPVVQERFFHFDEELFRMCPDHVDIRGYFQTEKYFKHIEDEIRE S-SM2 family 11 DFTFKDEILNPCKEMIAGVDNPLALHVRRIDYVINSANHPPCTLEYYEAALKHFDDDR [Synechococcus NVIVFSDDPAWCKEQELFSDDRFMISENEDNRIDLCLMSLCDDFIIANSTYSWWGAWL phage S-SM2] SANKDKKVIAPVQWFGTGYTKDHDTSDLIPDGWTRIATA Geobacter YP_ 404496189 glycosyl- 22.58 MDIHVLSYGLGNQLSQYAFFINRRQLMQRAYAFYAFKQHNGYELDRIFGLKEGLPWYL 255 metallireducens; 006720295.1 transferase QFVRVVERLGISRRFYSKRTADFVLSLFRIKVIDEAYNYEFDPSLLKPWFGIRILYGG Geobacter [Geobacter WHDSRYFHPSEAAVRTAFSFPPLDDVNDAILQQIDAVYGVSIHVRRGDYLKGINSNLF metallireducens  metallireducens GGIATLEYYRNAIGWAITYCKHRSLEIKFYVFSDDIDWCKQNLGLRDAVYVSGNSKTD GS-15; Geobacter GS-15] SWKDILLMSHCRANIIANSTFSWWAAWLNQQPNKVVICPTKFINTDSPNQTIYPAAWH metallireducens QIEG RCH3 Lachnospiraceae WP_ 551037245 protein 22.58 MIIVRFHGGLGNQMFEYAFYRYMINKYGADNVIGDMTWFDRNYSEHQGYELKKVFDID 256 bacterium NK4A136 022780989.1 [Lachno- IPAIDYKTLAKIHEYYPRYHRFAGLRYLSRMYAKYKNKHLKPTGEYIMDFGPSQYIHN spiraceae DAFDKLDINKDYYIEGVFCSDAYIKYYENQIKKDLTFKPNYSQHTKDMLPKIEETNSV bacterium AIHVRRGDYVGNVFDIVTPDYYRQAVNYIRERVENPVFFVFSDDMDYIKANFDFLGDF NK4A136] VPVHNCGKDSFQDMYLISRCRHMIIANSSFSYFGALLGEKDSTIVIAPKKYKADEDLA LARENWVLL Bacteroides WP_ 495419937 protein 22.56 MGFIVNMACGLANRMFQYSYYLFLKKQGYKVIVDFYRSAKLAHEKVAWNSIFPYAEIK 257 coprophilus; 008144634.1 [Bacteroides QASRLKVFLWGGGSDLCSKVRRRYFPSSINVRITTGAFDASLPANTARNEYIIGVFLN Bacteroides coprophilus] ASIVEAVDDEIKKCFTFLPFTDEMNLRLKKEIEECESVAIHVRKGKDYQSRIWYQNTC coprophilus DSM SMEYYRKAILQMKEKLQHSKFYVFIDNVDWVKENFQEIDYTLVEGNPADGYGSHFDMQ 18228 = JCM 13818 LMSLCKHNIISNSTYSWWSAFLNRNPEKVVIAPEIWFNPDSCDEFRSDRALCKGWIVL Bacteroidetes; WP_ 495895157 alpha-1,2- 22.53 MKIVCLKGGLGNQMFEYCRFRDLMESGHDEVYLFYDHRRLKQHNGLRLSDCFELELPS 258 Capnocytophaga 008619736.1 fucosyl- CPWGIKLVVWGLKICRAVGVLKRLYDDEKPEAVLIDDYSQHRRFIPNARRYFFFRQFL sp. oral transferase AELQSGFVQMIRAVDYPVSVHVRRGDYLHPSNSSFGLCGVDYFQQAIAYVRKKRPDAR taxon 329 str. [Bacteroidetes] FFFFSDDMEWVRENLWMEDAVYVEHTELLPDYVDLYLMTLCRGHIISNSTFSFWGAYL F0087; AVDGNGMKIYPRRWERDPIWTSPPIFSEEWVGL Paraprevotella clara YIT 11840 Butyrivibrio sp. WP_ 551026242 glycosyl 22.47 MLIIQIAGGLGNQMQQYAVYTKLREMGKDVKLDLSWFDPQVQKNMLAPREFELPIFGG 259 NC2007 022770361.1 transferase IDYEECSAYERDALLKQGAFAAIAGKVLKKLGLRDEANPKVFSEKEMYHPEVFELEDK [Butyrivibrio YIKGYFACQKYYGDIMDKLQEKFIFPEHSDPDLHARNMALVERMEREPSVSVHIRRGD sp. YLDPSNVEILGNIATEQYYQGAMDYFTVKEPDTHFYIFTSDHEYAREKFSDESKYTIV NC2007] DWNNGKNSVQDLMLMSHCKGNICANSTFSFWGARLNKRPDKTVIRTYKMRNNQPVNPQ IMHDYWKGWILMDEKGSII Paraprevotella WP_ 495903957 glycosyl 22.45 MKILVFIGGLGNQMFAYAFYLYLKRLFPQERFYGLYGKKLSEHYGLEIDKWFKVSLPR 260 xylaniphila; 008628536.1 transferase QPWWVLPVTGLEYLYKQCVPNSKWLDLNQEICKNPRAIVFFPFKFTKKYIPDDNIWLE Paraprevotella [Paraprevotella WKVDESGLSEKNRLLLSEIRSSDCCFVHVRRGDYLSPTEKSLFEGCCTLSYYQRALKS xylaniphila YIT xylaniphila] MKEISPFVKFVCFSDDIQWVKQNLELGNRAVFVDWNSGTDSPLDMYLMSQCRYGIMAN 11841 STFSYWGARLGRKKKRIYYPQKWWNHGTGLPDIFPNTWVKI Blautia WP_ 492742598 protein 22.44 MEIHVYLTGRLGNQLFQYAFARHLQKEYGGKIICNIYELEHRSEKAAWVPGKENYEMS 261 hydrogenotrophica 005944761.1 [Blautia] NYKLNDSILIEDIKLPWFADFSNPIIRIVKKVIPRIYFNLMASKGYLLWQKNSYINIP DSM AIRNNEIIVNGWWQDVRFFHDVEAELSNEIVPITKPISENEYLYNIAERENSVCVSIR 10507; Blautia; GGNYLVPKVKKKLFVCDKEYFYNAIELIKSKVRNAIFIVFSDDLEWVKSYIKLEEKFP Blautia ECKFYYESGKDTVEEKLRMMTKCKHFIISNSSFSWWAQYLAKNENKIVIAPDAWFTNG hydrogenotrophica DKNGLYIDDWILIPTQTKDM CAG:147 Geobacter YP_ 189425804 glycoside 22.44 MITVLLNGGLGNQLFQYAAGRALAEKHDVELLLDLSRLQHPKPGDTPRCFELAPFNIK 262 lovleyi; 001952981.1 hydrolase ASLLAEEGRQPLGSYQACMHRLLLKASIPLWGSIILKEQGCGFDPLIFRAPSSCILDG Geobacter family protein FWQSECYFKQITSLLQQELSLKAPSPALRKASSVLSDATVAVHVRRGDYVINPAAASF lovleyi SZ [Geobacter HGICSQDYYQAAVANILTSYPDSQFLVFSDDPAWCQEHLDLGQPFRLAADFGLNGSAE lovleyi SZ] ELVLISRCAHQIIANSSFSWWGAWLNPSPHKLVVAPCRWFTDPAITTNDLLPETWVRL P Lachnospiraceae WP_ 551037435 protein 22.41 MVISHLSGGEGNQLYSYAFAYAVAKARKEELWIDTAIQDAPWFFRNPDILNLNIKYDK 263 bacterium NK4A136 022781176.1 [Lachno- RVSYKIGEKKIDKIFNRINFRNAIGWNTKIINESDMPNIDDWFDTCVNQKGNIYIKGN spiraceae WSYEKLFISVKQEIIDMFTEKNELSKEANDIAQDINSQETSVGIHYRLGDYVKIGIVI bacterium NPDYFISAMTSMVEKYGNPVEYSFSEDNDWVKKQFEGLPYNIKYVEYSSDDKGLEDER NK4A136] LYSMCKHQIASNSSYSWWGAYLNNNPNKYIIAPTDYNGGWKSEIYPKHWDVRPFEFLK Bacteroides WP_ 492426440 glycosyl 22.37 MEHYKELLEGGGLGNQIFEYYFYLWLRKKYPNIVELGCYRKASFKAHNGLEISDVEDV 264 vulgatus; 005840359.1 transferase DLPNDGGLSGRFISYVLSVLSRIIPSLSMKANTEYSSKYLLINAYQPNLLFYLNEEKI Bacteroides family 11 KERPFKLDEVNRRLLNSIKMESSVSIHVRRGDYLFGQYRDIYSNICTLAYYQKAVDKC vulgatus PC510 [Bacteroides KGILESPREFVFSDDIEWARDVEVGREYEEVSNNIGKNSFIDMELMSNCKIQIIANST vulgatus] ESYWAAYLSNSLVKIYPAKWINGIERPNIFPDNWIGL Planctomyces YP_ 325110698 glycosyl 22.37 MIIARIENGLGNQLFKYAAGRALSLKHRTSLYTIPGSVRKPHETFILSKYENVQAKSV 265 brasiliensis; 004271766.1 transferase SPFLLQTGERLRLLKGYENHSEGFDPRFETTRNNTVVSGNEQSARYFLPFEDQINREL Planctomyces family protein TLKPEVVDGLESVYPHVLESLRTPNSVCVHIRLGDYVSSGYDICGPEYYAKAISRLQQ brasiliensis DSM [Planctomyces LHGELRAFVFSDTPQAASRFLPADIDAQIMSEEPEVRDAARSLTVERSTIRDYFLMQQ 5305 brasiliensis CRHEVIPNSSFSYWAALLSSSDGDVIYPNRWYIDIDTSPRDLGLAPAEWTPIPLT DSM 5305] Butyrivibrio sp. WP_ 551028648 glycosyl 22.36 MIILQIAGGLGNQMQQYALYRKLLKCGKTVKLDLSWEGPEIQKNMLAPREFELVISKD 266 AE2015 022772730.1 transferase LPFEICTKEEKDALIKQNLFQKIAGKVSQKLGKSASSNAKVEVETKMYHEEIFDLDDV [Butyrivibrio YITGYFACQYYYDDVMAELQDLEVEPSHSIPELDQRNAVLASKMEKENSVSVHIRRGD sp. YLSPENVGILGNIASDKYYESAMNYFLEKDENTHEYIFTNDHEYAREHYSDESRYTII AE2015] DWNTGKNSLQDLMLMSHCKGNICANSTESFWGARLNKRPDRELVRTLKMRNNQEAQPE IMHEYWKNWILIDENGVIV Roseovarius WP_ 497499658 alpha-1,2- 22.34 MIDTPPPSQVITSRLFGGAGNQLFQYAAGRALADRLGCDLMIDARYVAGSRDRGDCFT 267 nubinhibens 009813856.1 fucosyl- HEAKARLRRDVALPPAKSDGPLRYALWRKFGRSPREHRERGLGVDPEFFNLPRGTYLH ISM; Roseovarius transferase, GYWQSEQYFGPDTDALRRDLTLTTALDAPNAAMAAQIDAAPCPVSFHVRRGDYIAAGA nubinhibens [Roseovarius YAACTPDYYRAAADHLATTLGKPLICEIFSNDPAWARDNLDLGQDQVIVDLNDEATGH nubinhibens] EDMALMARCAHHVIANSTFSWWGAWLNPDPDKLVVAPRNWFATQALHNPDLIPEQWHR L Eubacterium sp. WP_ 548315094 protein 22.33 MIEVNIVGQLGNQMFEYACARQLQKKYGGEIVLNTYEMRKETPNEKLSILDYKLSENV 268 CAG:581 022505071.1 [Eubacterium KIISDKPLSSANANNYLVKIMRQYFPNWYENFMAKRGTFVWKSARKYKELPELNEQLS sp. CAG:581] KHIVLNGYWQCDKYENDVVDTIREDFTPKYPLKAENEQLLEKIKSTESVCVTIRRGDF MNEKNKDIFYICDDDYENKALSKIKELCPDCTFFGESDDVEWIKKNVNFPGEVYFESG NDPVWEKLRLMSACKHEVLSNSSFSWWAQYLSDNNNKIVVAPDIWYKTGDPKKTALYQ DGWNLIHIGD Providencia AFH02807.1 383289327 glycosyl- 22.26 MKINGKESSMKIKQKKIISHLIGGLGNQLFQYATSYALAKENNAKIVIDDRLFKKYKL 269 alcalifaciens transferase HGGYRLDKLNIIGEKISSIDKLLFPLILCKLSQKENFIFKSTKKFILEKKTSSFKYLT [Providencia FSDKEHTKMLIGYWQNAIYFQKYFSELKEMFVPLDISQEQLDLSIQIHAQQSVALHVR alcalifaciens] RGDYISNKNALAMHGICSIDYYKNSIQHINAKLEKPFFYIFSNDKLWCEENLTPLEDG NFHIVENNSQEIDLWLISQCQHHIIANSTFSWWGAWLANSDSQIVITPDPWENKEIDI PSPVLSHWLKLKK Salmonella AFW04804.1 411146173 glycosyl- 22.26 MFSCLSGGLGNQMFQYSAAYILKKNICHAQLIIDDSYFYCQPQKDTPRNFEINQFNIV 270 enterica transferase FDRVITDEEKRAISKLRKFKKIPLPISKSNVITEFLFGKSLLTDEDFYKVLKKNQFTV [Salmonella KMNACLFSLYQDSSLINKYRDLILPLFTINDELLQVCQQLDSYGFICEHTNITSLHIR enterica] RGDYVINPHAAKFHGTLSMNYYSQAMNYVDHKLGKQLFIIFSDDVQWAAEKFGGRSDC YIVNNVNCQFSAIDMYLMSLCNNNIIANSTYSWWGAWLNKSEEKLVIAPRKWFAEDKE SLLAVNDWISI Sulfurospirillum YP_ 268680398 protein 22.18 MIIIKIMGGLASQLHKYSVGRALSLKYNTELKLDIFWFDNISGSDTIREYHLDKYNVV 271 deleyianum; 003304829.1 Sdel_1779 AKIATEQEIKQFKPNKYLLKINNLFQKFTNWKINYRNYCNESFISLENFNLLPDNIYV Sulfurospirillum [Sulfuro- EGEWSGDRYFSHIKEILQKELTLKSEYMDSTNHFLAKQSSDFAHDDNASKLHCICSLE deleyianum spirillum YYKKALQYISKNLLKMKLLIFSDDLDWLKPNENFLDNVEFEFVEGFQDYEEFHLMTLS DSM 6946 deleyianum KHNIIANSGFSLFFAWLNINHNKIIISLSEWVFEEKLNKYIIDNIKDKNILFLENLE DSM 6946] Pseudovibrio sp. YP_ 374329930 alpha-1,2- 22.15 MSVASQVRISGAARRRKLKPTLIVRIRGGIGNQLFQYALGRKIALETGMKLRFDRSEY 272 FO- 005080114.1 fucosyl- DQYFNRSYCLNISKTQGLSATESEMSAVLWPAQSFGQTVKLCRKFYPFYQRRYIREDE BEG1 transferase LLQDSETPVLKQSAYLDGYWQTWEIPFSIMEQLRDEITLKKPMVLERLKLLQRIKSGP [Pseudovibrio SAALHVRYGDYSQAHNLQNFGLCSAGYYKGAMDFLTERVPGLTFYVFSDSPERAREVV sp. FO-BEG1] PQQENVYFSDPMQDGKDHEDLMVMSSCDHIVTANSTFSWWAAFLNGNEDKHVIAPLKW FKNPNLDDSLIVPPHWQRL Prevotella  WP_ 496529942 alpha-1,2- 22.11 MKIVCIKGGLGNQLFEYCRYHGLLRQHNNHGVYLHYDRRRTKQHGGVWLDKAFLITLP 273 sp. oral 009236633.1 fucosyl- TEPWRVKLMVMALKMLRKLHLFKRLYREDDPRAVLIDDYSQHKQFITNAAEILNFRPF taxon 472 str. transferase AQLDYVDEITSEPFAVSVHVRRGDYLLPANKANFGVCSVHYYLSAAVAVRERHPDARF F0295; [Prevotella FVFSDDIEWAKMNLNLPNCVFVEHAQPQPDHADLYLMSLCKGHIIANSTFSFWGAYLS Prevotella sp. sp. oral taxon MGSSAIAIYPKQWFAEPTWNAPDIFLGHWIAL oral taxon 472 472] Butyrivibrio WP_ 551008155 glycosyl 22.08 MLIIRVAGGLGNQMQQYAMYRKLKSLGKEVKLDLSWFDVENQEGQLAPRKCELKYFDG 274 fibrisolvens 022752732.1 transferase VDFEECTDAERAYFTKRSILTKALNKVFPATCKIFEETEMFHPEIYSFKDKYLEGYFL [Butyrivibrio CNKYYDDILPFIQNEIVFPKHSDPKMQKRNEELMERMDGWHTASIHLRRGDYITEPQN fibrisolvens] EALFGNIATDAYYDAAIRYVLDKDYQTHFYIFSNDPEYAREHYSDESRYTIVIGNDGD NSLLDMELMSHCRYNICANSTFSFWGARLNKRSDKEMIRTFKMRNNQEVTAREMTDYW KDWILIDEKGNRIF Lewinella persica WP_ 522059857 protein 22.04 MVISRLFISGLGNQMFQYAFARRIQLQLNVKLRIDLSILLDSRPPDGYIKREYDLDIF 275 020571066.1 [Lewinella KLSPAYHCNPTSLRILYAPGKYRWSQVVRDLARKGYPVYMEKSFSVDNILLDSPPDNV persica] IYQGYWCISERYFSEVANTIRKDFAFQHSIQPQSESLAREIRKEDSVCLNIRRKDYLA SPTHNVTDETYYENCIQQMRERFSGARFFLESDDLVWCREFFADFHDVVIVGHDHAGP KEGNYLCILMAQCHFIVIIPNSTFAWWAAWLGERTGSVIMAPERWEGTDEFDYRDVVP ERWLKVPN

OTHER EMBODIMENTS

While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. Genbank and NCBI submissions indicated by accession number cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. 

1. A method for producing a fucosylated oligosaccharide in a bacterium comprising providing bacterium comprising an exogenous lactose-utilizing α(1,2) fucosyltransferase enzyme, wherein said α(1,2) fucosyltransferase enzyme has at least 90% sequence identity to amino acid sequence SEQ ID NO: 17; and culturing said bacterium in the presence of lactose.
 2. (canceled)
 3. The method of claim 1, wherein said α(1,2) fucosyltransferase enzyme comprises Prevotellaa sp. FutW , or a functional variant or fragment thereof.
 4. (canceled)
 5. The method of claim 1, further comprising retrieving the fucosylated oligosaccharide from said bacterium or from a culture supernatant of said bacterium.
 6. The method of claim 1, wherein said fucosylated oligosaccharide comprises 2′-fucosyllactose (2′-FL), lactodifucotetraose (LDFT), or lacto-N-difucohexaose I (LDFH I).
 7. The method of claim 1, wherein the bacterium further comprises an exogenous lactose-utilizing α(1,3) fucosyltransferase enzyme and/or an exogenous lactose-utilizing α(1,4) fucosyltransferase enzyme, or wherein said bacterium further comprises a reduced level of β-galactosidase activity, a defective colanic acid synthesis pathway, an inactivated adenosine-5′-triphosphate (ATP)-dependent intracellular protease, or an inactivated endogenous lacA gene, or any combination thereof.
 8. The method of claim 7, wherein the exogenous lactose-utilizing α(1,3) fucosyltransferase enzyme comprises a Helicobacter pylori 26695 futA gene.
 9. The method of claim 7, wherein the exogenous lactose-utilizing α(1,4) fucosyltransferase enzyme comprises a Helicobacter pylori UA948 FucTa gene or a Helicobacter pylori strain DMS6709 FucT III gene.
 10. (canceled)
 11. The method of claim 10, wherein said method further comprises culturing said bacterium in the presence of tryptophan and in the absence of thymidine.
 12. The method of claim 10, wherein said reduced level of β-galactosidase activity comprises a deleted or inactivated endogenous lacZ gene and/or a deleted or inactivated endogenous lacI gene of said bacterium.
 13. The method of claim 12, wherein said reduced level of β-galactosidase activity further comprises an exogenous lacZ gene or variant thereof, wherein said exogenous lacZ gene or variant thereof comprises an β-galactosidase activity level less than wild-type bacterium.
 14. The method of claim 10, wherein said reduced level of β-galactosidase activity comprises an activity level less than wild-type bacterium.
 15. The method of claim 14, wherein said reduced level of β-galactosidase activity comprises less than 6,000 units of β-galactosidase activity.
 16. The method of claim 14, wherein said reduced level of β-galactosidase activity comprises less than 1,000 units of β-galactosidase activity.
 17. The method of claim 10, wherein said bacterium comprises a lacIq gene promoter immediately upstream of a lacY gene, or wherein said bacterium further comprises a functional lactose permease gene, or wherein said bacterium comprises E. coli lacY, or wherein said bacterium further comprises an exogenous E. coli rcsA or E. coli rcsB gene, or wherein said bacterium further comprises a mutation in a thyA gene, or wherein said bacterium accumulates intracellular lactose in the presence of exogenous lactose, or wherein said bacterium accumulates intracellular GDP-fucose.
 18. The method of claim 10, wherein said defective colanic acid synthesis pathway comprises an inactivation of a wcaJ gene of said bacterium.
 19. The method of claim 10, wherein said inactivated ATP-dependent intracellular protease is a null mutation, inactivating mutation, or deletion of an endogenous Ion gene.
 20. The method of claim 19, wherein said inactivating mutation of an endogenous Ion gene comprises the insertion of a functional E. coli lacZ⁺ gene. 21.-26. (canceled)
 27. The method of claim 1, wherein said bacterium is E. coli.
 28. The method of claim 1, wherein said production strain is a member of the Bacillus, Pantoea, Lactobacillus, Lactococcus, Streptococcus, Proprionibacterium, Enterococcus, Bifidobacterium, Sporolactobacillus, Micromomospora, Micrococcus, Rhodococcus, or Pseudomonas genus.
 29. The method of claim 1, wherein said production strain is selected from the group consisting of Bacillus licheniformis, Bacillus subtilis, Bacillus coagulans, Bacillus thermophiles, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, and Bacillus circulans, Erwinia herbicola (Pantoea agglomerans), Citrobacter freundii, Pantoea citrea, Pectobacterium carotovorum, Xanthomonas campestris Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus jensenii, Lactococcus lactis, Streptococcus thermophiles, Proprionibacterium freudenreichii, Enterococcus faecium, Enterococcus thermophiles), Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium bifidum, Pseudomonas fluorescens and Pseudomonas aeruginosa.
 30. The method of claim 1, wherein said bacterium comprises a nucleic acid construct comprising an isolated nucleic acid encoding said α(1,2) fucosyltransferase enzyme.
 31. The method of claim 30, wherein said nucleic acid is operably linked to one or more heterologous control sequences that direct the production of the enzyme in the bacterium.
 32. The method of claim 31, wherein said heterologous control sequence comprises a bacterial promoter and operator, a bacterial ribosome binding site, a bacterial transcriptional terminator, or a plasmid selectable marker. 33.-47. (canceled)
 48. The method of claim 1, wherein the amino acid sequence of said enzyme comprises the amino acid sequence of FutW (SEQ ID NO: 17). 